<html lang="en"><head>
	<!-- Required meta tags -->
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
	<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

	<!-- Favicon -->
	<!-- cpcommit -->
	<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

	<script>
		(function () {
			var hostName = window.location.hostname;

			var browserAccepted = function () {

				var ua = window.navigator.userAgent;
				var trident = ua.indexOf('Trident/'); //IE 11;
				var msie = ua.indexOf('MSIE '); // IE 10 or older
				if (msie > 0) {
					return false;
				}
				return true;
			}();

			var pathToLibs = './js';
			var pathToError = './';
			// uncomment following lines only when running ix symlink to ix.xhtml on *.sec.gov
			/* commented out for running ix redirector script
			if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
				pathToLibs = './ixviewer/js';
				pathToError = '/ixviewer/';
			}
			*/
			if (browserAccepted) {

				// css
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

				// js
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.7.1.slim.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

				var date = new Date();
				var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
				document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
			} else {
				// user us on a browser that we do not support
				var currentUrl = window.location.href.split('?')[0];
				var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
				browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
				window.location.href = browserError;
			}
		})();
	</script><link rel="stylesheet" href="./js/css/custom-bootstrap.css"><link rel="stylesheet" href="./js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="./js/css/app.css"><script type="text/javascript" src="./js/lib/jquery-3.7.1.slim.min.js"></script><script type="text/javascript" src="./js/lib/popper.min.js"></script><script type="text/javascript" src="./js/lib/bootstrap.min.js"></script><script type="text/javascript" src="./js/lib/moment.js"></script><script type="text/javascript" src="./js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="./js/lib/he.js"></script><script type="text/javascript" defer="true" src="./js/production.min.js?d=22-4-2024"></script>
	<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} #dynamic-xbrl-form .text-block-indicator-left{border-left:.75rem solid ##003768;} #dynamic-xbrl-form .text-block-indicator-right{border-right:.75rem solid ##003768;} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>

<body>
	<noscript>This application relies heavily on JavaScript, you
		will need to allow JavaScript to use this application.</noscript>
	<nav class="reboot navbar navbar-expand-md navbar-dark navbar-height bg-sec fixed-top w-100 pl-0">
		<button class="reboot navbar-toggler ml-1" type="button" data-test="" data-toggle="collapse" data-target="#main-navbar" aria-controls="main-navbar" aria-expanded="false" aria-label="Toggle navigation">Inline Viewer</button>
		<div class="reboot navbar-height collapse navbar-collapse bg-sec w-100" data-test="main-navbar" id="main-navbar">
			<ul class="reboot navbar-nav mr-auto bg-inherit">
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a id="menu-dropdown-link" data-test="menu-dropdown-link" class="reboot nav-link dropdown-toggle click disabled" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="1" accesskey="1">
						<i class="reboot nav-loading fas fa-bars" title="Menu"></i>
						<span class="reboot d-md-none d-lg-inline">Menu</span>
						<span class="reboot sr-only sr-only-focusable">Menu</span>
					</a>
					<div class="reboot dropdown-menu">
						<a id="menu-dropdown-information" data-test="menu-dropdown-information" class="reboot dropdown-item click text-body" tabindex="1">Information</a>
						<a id="form-information-instance" data-test="form-information-instance" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL
							Instance</a>
						<a id="form-information-zip" data-test="form-information-zip" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL Zip
							File</a>
						<a id="form-information-html" data-test="form-information-html" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Open as HTML</a>
						<a id="menu-dropdown-settings" data-test="menu-dropdown-settings" class="reboot dropdown-item click text-body" tabindex="1">Settings</a>
						<a id="form-information-help" data-test="form-information-help" class="reboot dropdown-item click text-body" tabindex="1">Help</a>
						<span id="form-information-version" class="reboot dropdown-item-text text-body" tabindex="1"></span>
					</div>
				</li>
				<li class="reboot nav-item my-auto ml-1">
					<a id="sections-dropdown-link" data-test="sections-dropdown-link" class="reboot nav-link click disabled meta-required" tabindex="2" accesskey="2">
						<i class="reboot fas fa-layer-group" title="Sections"></i>
						<span class="reboot d-md-none d-lg-inline">Sections</span>
						<span class="reboot sr-only sr-only-focusable">Sections</span>
					</a>
				</li>
				<li class="reboot nav-item my-auto ml-1 mr-1">
					<form id="global-search-form" data-test="global-search-form" class="reboot my-2 my-lg-0 input-group disabled" novalidate="">
						<div class="reboot input-group-prepend">
							<button data-name="global-search-options" class="reboot dropdown btn btn-outline-light disabled" type="button" data-toggle="dropdown" tabindex="3">
								<i class="reboot nav-loading fas fa-cog" title="Additional Search Options">
									<span class="reboot sr-only sr-only-focusable">Additional
										Search Options</span>
								</i>
							</button>
							<div class="reboot dropdown-menu px-2">
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="1" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Name</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="2" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Content</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="3" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Labels</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="4" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Definitions</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="5" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Dimensions</span>
									</label>
								</div>
								<div class="reboot bg-light border p-1">
									<span class="reboot dropdown-item-text">Reference
										Options</span>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="6" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="7" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Sub-Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="8" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Paragraph</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="9" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Publisher</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="10" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="disabled">Include Section</span>
										</label>
									</div>
								</div>
								<div class="reboot form-check">
									<input class="reboot form-check-input" type="checkbox" name="search-options" value="11" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Match Case</span>
									</label>
								</div>
							</div>
						</div>
						<input type="text" class="reboot form-control disabled" id="global-search" data-test="global-search" placeholder="Search Facts" disabled="" aria-label="Search all Facts and highlight them accordingly." tabindex="4">
						<div class="reboot input-group-append">
							<button id="search-btn-clear" data-name="global-search-clear" class="reboot btn btn-outline-light disabled" type="button" tabindex="5">
								<i class="reboot nav-loading fas fa-times-circle" title="Clear Search"></i>
								<span class="reboot sr-only sr-only-focusable">Clear
									Search</span>
							</button>
							<button class="reboot btn btn-outline-light disabled" type="submit" tabindex="6">
								<i class="reboot nav-loading fas fa-search" title="Submit Search"></i>
								<span class="reboot sr-only sr-only-focusable">Submit
									Search</span>
							</button>
						</div>
					</form>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-data" data-test="nav-filter-data" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="7" accesskey="3">
						<i class="reboot nav-loading fas fa-list-alt" title="Data"></i>
						<span class="reboot d-md-none d-lg-inline">Data</span>
						<span class="reboot sr-only sr-only-focusable">Data</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-dropdown" data-name="data-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="0" checked="" tabindex="7">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="1" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Amounts Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="2" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Text Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="data-radios" value="3" disabled="" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Calculations Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="4" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Negatives Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="5" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Additional Items Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-tags" data-test="nav-filter-tags" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="8" accesskey="4">
						<i class="reboot nav-loading fas fa-tags" title="Tags"></i>
						<span class="reboot d-md-none d-lg-inline">Tags</span>
						<span class="reboot sr-only sr-only-focusable">Tags</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-tags-dropdown" data-name="tags-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="0" aria-label="Radio Button for All Tag Types" checked="" tabindex="8">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="1" aria-label="Radio Button for Standard Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span>Standard Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="tags-radios" value="2" disabled="" aria-label="Radio Button for Custom Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="Facts whose tags are outside the realm of DEI, US-GAAP, etc." class="reboot far fa-question-circle"></i>
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Custom Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-more" data-test="nav-filter-more" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="9" accesskey="5">
						<i id="loading-more-filters" class="reboot nav-loading fas fa-filter" title="More Filters"></i>
						<span class="reboot d-md-none d-lg-inline">More Filters</span>
						<span class="reboot sr-only sr-only-focusable">More Filters</span>
						<span title="Total active filters." class="reboot badge badge-warning"></span>
					</a>
					<div class="reboot dropdown-menu dropdown-menu-width">
						<label class="reboot dropdown-item-text d-none performance-concern">
							Selecting any of the below will take a few moments.</label>
						<div class="reboot accordion" id="more-filters-accordion">
							<form class="reboot" data-test="more-filters-form">
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Period" data-target="#user-filters-periods" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Periods</span>
											<span data-test="Period-count" id="filters-periods-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-periods" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Measures" data-target="#user-filters-measures" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Measures</span>
											<span data-test="Measures-count" id="filters-measures-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-measures" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot  px-0 py-0">
										<a href="#" data-test="Axis" data-target="#user-filters-axis" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Axis</span>
											<span data-test="Axis-count" id="filters-axis-count" class="reboot badge badge-secondary">
												<i class="fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-axis" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Members" data-target="#user-filters-members" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Members</span>
											<span data-test="Members-count" id="filters-members-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-members" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Scale" data-target="#user-filters-scales" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Scale</span>
											<span data-test="Scale-count" id="filters-scales-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-scales" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Balance" data-target="#user-filters-balances" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Balance</span>
											<span data-test="Balance-count" id="filters-balances-count" class="reboot badge badge-secondary">2</span>
										</a>
									</div>
									<div id="user-filters-balances" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-debit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Debit</label>
											</div>
										</div>
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-credit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Credit</label>
											</div>
										</div>
									</div>
								</div>
							</form>
						</div>
					</div>
				</li>
				<li id="current-filters-reset" data-test="current-filters-reset" class="reboot nav-item d-none my-auto ml-1">
					<a href="#" id="current-filters-reset-all" data-name="current-filters-reset" class="reboot nav-link dropdown-toggle text-danger disabled click" tabindex="11" accesskey="7">
						<i class="reboot nav-loading fas fa-redo"></i>
						<span class="reboot d-md-none d-lg-inline">Reset All
							Filters</span>
					</a>
				</li>
				<li id="links-dropdown" data-test="links-dropdown" class="reboot nav-item dropdown d-none my-auto ml-1">
					<a href="#" id="additional-links-dropdown" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="12" accesskey="8">
						<i class="reboot nav-loading fas fa-link"></i>
						<span class="reboot d-md-none d-lg-inline">Links</span>
					</a>
					<div id="links-dropdown-content" class="reboot dropdown-menu dropdown-menu-width w-auto"></div>
				</li>
			</ul>
			<ul class="reboot navbar-nav pull-right bg-inherit">
				<li class="reboot nav-item my-auto ml-1">
					<a id="facts-menu" data-test="facts-menu" class="reboot nav-link click" tabindex="13" accesskey="9">
						Facts
						<span class="reboot taxonomy-total-count badge badge-light"><i class="fas fa-spinner fa-spin"></i></span>
					</a>
				</li>
			</ul>
		</div>
	</nav>
	<div class="reboot main-container">
		<div id="error-container" data-test="error-container" class="reboot px-0"></div>
		<div id="xbrl-form-loading" data-test="xbrl-form-loading" class="reboot jumbotron h-100 d-none">
			<h2 class="reboot display-4 text-center">
				<i class="reboot fas fa-spinner fa-spin"></i>
				Loading Inline Form.
			</h2>
		</div>
		<div id="sections-menu" data-test="sections-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">
			<div class="reboot mb-2">
				<span class="reboot lead">Tagged Sections</span>
				<a id="sections-menu-toggle" class="reboot float-right click color-inherit" tabindex="2">
					<i class="reboot fas fa-times-circle mt-2 text-dark"></i>
				</a>
			</div>
			<form id="sections-menu-search-submit" data-name="sections-menu-search" class="reboot my-2 my-lg-0 input-group" novalidate="">
				<div id="sections-search-additional" class="reboot input-group-prepend d-none">
					<button class="reboot dropdown btn btn-sec" type="button" data-toggle="dropdown" tabindex="2">
						<i class="reboot nav-loading fas fa-cog"></i>
					</button>
					<div class="reboot dropdown-menu px-2">
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="1" checked="" tabindex="2">
							<label class="reboot form-check-label">Search in All.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="2" tabindex="2">
							<label class="reboot form-check-label">Search in Internal
								Sections Only.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="3" tabindex="2">
							<label class="reboot form-check-label">Search in External
								Sections Only.</label>
						</div>
					</div>
				</div>
				<input type="text" class="reboot form-control" id="sections-search" data-test="sections-search" placeholder="Search Sections" aria-label="Search all Sections by their associated label." name="search-sections" tabindex="2" required="">
				<div class="reboot input-group-append">
					<button id="section-menu-search-btn-clear" data-name="sections-menu-search-clear" class="reboot btn btn-sec" type="button" tabindex="2">
						<i class="nav-loading fas fa-times-circle" title="Clear Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Clear
							Sections Search</span>
					</button>
					<button class="reboot btn btn-sec" type="submit" tabindex="2">
						<i class="reboot nav-loading fas fa-search" title="Submit Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Submit
							Sections Search</span>
					</button>
				</div>
			</form>
			<hr>

			<div class="reboot accordion" id="tagged-sections">
				<!-- Below is populated dynamically VIA JS -->
			</div>
		</div>



		<div id="help-menu" data-test="help-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">

			<div class="reboot mb-2">
				<span class="reboot lead">Help</span> <a id="help-menu-close" data-test="help-menu-close" class="reboot float-right click"> <i class="reboot fas fa-times-circle mt-2"></i>
				</a>
			</div>
			<div class="reboot accordion" id="help-sections">
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-getting-started">
								<span class="reboot font-size-1 ">Getting Started</span>
							</button>
						</h5>
					</div>
					<div id="help-getting-started" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Inline XBRL viewer allows a user
							to quickly and easily review details of the tagged information in
							an Inline document by automatically placing a top and bottom
							highlight border around each tagged numeric fact and left and
							right border for each block tagged fact. Hovering over a tagged
							fact will highlight (shade) all content related to the tagged
							fact, and clicking on a tagged fact will reveal its tagging
							details in the Fact Review Window. Navigation, search and filter
							options are also provided to easily refine and identify specific
							types of tagged information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-fact-review-window">
								<span class="reboot font-size-1">Fact Review Window</span>
							</button>
						</h5>
					</div>
					<div id="help-fact-review-window" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Fact Review Window shows the tagging
							details for the currently selected fact, which is highlighted
							with a solid blue border. There are four categories of fact detail
							which can be viewed; an "N/A" value indicates there is no
							available information for the item within the given category:</p>
						<ul class="reboot">
							<li class="reboot">Attributes - All primary information (as
								applicable) describing the tagged fact including period, sign,
								decimals, dimensional detail (axes and members), scale, measure
								and data type.</li>
							<li class="reboot">Labels - Detailed documentation
								(definition) for the tag used, and other labels.</li>
							<li class="reboot">References - Authoritative reference
								information (as applicable) for the selected tag.</li>
							<li class="reboot">Calculation - Balance and calculation
								hierarchy details (numeric non-dimensioned items only).</li>
						</ul>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-search">
								<span class="reboot font-size-1">Searching</span>
							</button>
						</h5>
					</div>
					<div id="help-search" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">There are two ways to search the
							document: FACTS AND SECTIONS. To search information, enter a
							keyword in a search box and select the magnifying glass icon to
							return matching results. Search operators "and" (via "AND" or
							"&amp;") and "or" (via "OR" or "|") are available to further refine a
							search.</p>
						<p class="reboot m-2">
							<strong>FACTS</strong>
						</p>
						<p class="reboot m-2">The Search Facts box can be used to find
							tagged facts matching entered keywords. By default, tag name, tag
							labels, and tagged content are included in Search. Tagged facts
							matching the search criteria are shown with a yellow-colored
							(default) shading on the page and appear in the Facts List.
							Select the "X" button to the left of the magnifying glass icon to
							clear the search.</p>
						<p class="reboot m-2">The content included in Search can be increased to
							included tag definitions, dimensions, and authoritative
							references by selecting the cog / wheel icon to the left of the
							search box. See Settings for more information.</p>

						<p class="reboot m-2">
							<strong>SECTIONS</strong>
						</p>
						<p class="reboot m-2">The Search Sections box can be used to
							filter the tagged sections of the financial statements.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-filter">
								<span class="reboot font-size-1">Filters</span>
							</button>
						</h5>
					</div>
					<div id="help-filter" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">Filters change the number of highlighted
							facts and items in the fact list by providing several ways to
							review and pinpoint certain tagged information. Multiple filters
							can be used at once.</p>
						<p class="reboot m-2">
							<strong>DATA FILTERS</strong>
						</p>
						<p class="reboot m-2">These filter options allow the user to
							refine the highlighted tagged facts by data type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Amounts Only - Numeric facts only</li>
							<li class="reboot">Text Only - Textual facts only</li>
							<li class="reboot">Calculations Only - Numeric facts
								participating in a calculation only</li>
							<li class="reboot">Negatives Only - Negative Numeric amounts
								only</li>
							<li class="reboot">Additional Items Only - Tagged facts
								without a corresponding HTML presentation (i.e., hidden facts)
								only</li>
						</ul>
						<p class="reboot m-2">
							<strong>TAGS FILTER</strong>
						</p>
						<p class="reboot m-2">These filters allow the user to refine
							the highlighted facts by tag type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Standard Only- Facts with standard tags
								from a common taxonomy (e.g., US_GAAP, IFRS, DEI).</li>
							<li class="reboot">Custom Only - Facts with extension
								"custom" tags unique to the entity's document.</li>
						</ul>
						<p class="reboot m-2">
							<strong>MORE FILTERS</strong>
						</p>
						<p class="reboot m-2">Additional filters that allow user to
							further refine the highlighted facts:</p>
						<ul class="reboot">
							<li class="reboot">Periods - List of all used context years
								and reporting periods</li>
							<li class="reboot">Measures - List of all used units of
								measure (e.g., US Dollars); as applicable</li>
							<li class="reboot">Axis - List of all used axis
								(dimensions); as applicable (dimensions); as applicable</li>
							<li class="reboot">Scale - List of all used scaled options
								(e.g., thousands, millions); as applicable</li>
							<li class="reboot">Balance - Debit, credit; as applicable</li>
						</ul>
						<p class="reboot m-2">Multiple filters work in conjunction
							with each other. For example, selecting the "Amounts Only" Data
							filter and "Custom Only" Tags filter will highlight only numeric
							tagged facts using custom tags and list them in the fact list.
							Active filters are displayed in the Filter toolbar as they are
							selected. Active filters can be removed individually by
							unchecking or selecting ALL option for each filter, or all at
							once via the "Reset All Filters" option.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-facts-results-list">
								<span class="reboot font-size-1">Facts List (Results)</span>
							</button>
						</h5>
					</div>
					<div id="help-facts-results-list" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">On the toolbar, select the "count" to
							the right of the word Facts (e.g., Facts 234) to reveal the Facts
							List results - a navigable listing of all currently highlighted
							tagged facts. The count represents the current number of facts.</p>
						<p class="reboot m-2">By default, all tagged facts are
							displayed in the Fact List Results. The list content and count
							reflects the currently highlighted facts (i.e., both Filters and
							Search criteria refine the list to match the highlighted tagged
							facts). Navigation controls are available to move through the
							list as well as move the current view to the corresponding
							highlighted fact location automatically. When a fact in the Facts
							Results List is selected, it will reveal the Fact Review Window.</p>
						<p class="reboot m-2">Certain letters may appear to the right
							of an item in the Fact Result list to indicate a certain
							property. If the letter "A" appears for a fact, it indicates the
							fact is additional data (i.e., hidden with potentially no
							corresponding HTML presentation). If the letter "C" appears, the
							fact is tagged with a custom tag. If the letter "D" appears, the
							fact is tagged with dimensional information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-sections">
								<span class="reboot font-size-1">Sections</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-sections" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The SECTIONS toolbar item provides a
							listing of the tagged sections of the Inline document. Sections
							are divided into three groups:</p>
						<ul class="reboot">
							<li class="reboot">Document &amp; Entity Information</li>
							<li class="reboot">Financial Statements</li>
							<li class="reboot">Notes to the Financial Statements</li>
						</ul>
						<p class="reboot m-2">By expanding a group and selecting a
							section item in the listing, Inline XBRL viewer will navigate to that section.
							When the Tagged Sections feature is open, the Search Sections box
							will additionally filter the list of sections to only those
							sections that match the entered criteria.</p>
					</div>
				</div>

				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-menu">
								<span class="reboot font-size-1">Menu</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-menu" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">
							<strong>Information</strong>
						</p>
						<p class="reboot m-2">The Information menu item provides
							additional detail about the current Inline document and
							customizable viewer settings.</p>
						<ul class="reboot">
							<li class="reboot">Company and Document - Basic company and document
								information</li>
							<li class="reboot">Tags - Fact and tag (standard and custom)
								information</li>
							<li class="reboot">Files - Files used</li>
							<li class="reboot">Additional Items - Additional hidden data
								that's been tagged but potentially does not have a corresponding
								location in the HTML</li>
						</ul>
						<p class="reboot m-2">
							<strong>Save XBRL Instance</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Instance menu item allows
							an XBRL instance document (*.xml) that is extracted from the
							Inline document to be saved locally for use by software
							supporting the XBRL format.</p>
						<p class="reboot m-2">
							<strong>Save XBRL Zip</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Zip menu item allows a zip
							file (*.zip) that contains the as-provided XBRL instance document
							and related custom taxonomy files to be saved locally.</p>
						<p class="reboot m-2">
							<strong>Settings</strong>
						</p>
						<p class="reboot m-2">The Settings menu item provides the
							ability to customize Viewer features.</p>
						<p class="reboot m-2">
							<strong>Tagged Fact Hover</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">On - Displays the hover fact review
								window for any tagged fact*</li>
							<li class="reboot">Off - Hides the hover fact review window
								for any tagged fact (default)</li>
						</ul>
						<p class="reboot m-2">* May impact performance with certain
							web browsers.</p>
						<p class="reboot m-2">
							<strong>Auto Scrolling Position </strong>(This setting will have
							no effect on IE 10 or Safari)
						</p>
						<ul class="reboot">
							<li class="reboot">Top - Selecting a fact from the Sections
								Menu or the Fact Menu will automatically scroll that element to
								the Top of the Inline XBRL viewer window (default)</li>
							<li class="reboot">Center - Selecting a fact from the
								Sections Menu or the Fact Menu will automatically scroll that
								element to the middle of the Inline XBRL viewer window</li>
						</ul>
						<p class="reboot m-2">
							<strong>Highlight Colors</strong> (Use the save and reset buttons
							to save the selected setting or reset to default)
						</p>
						<ul class="reboot">
							<li class="reboot">Tagged Data - Change the highlight color
								of the tagged fact border</li>
							<li class="reboot">Search Results - Change the background
								color of tagged items matching the Search results</li>
							<li class="reboot">Selected Fact - Change the color of
								highlight border used to identify the currently selected fact</li>
							<li class="reboot">Tag Shading (hover) - Change the color of
								the shading applied to tagged data on hover</li>
						</ul>
						<p class="reboot m-2">
							<strong>Search Options</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">Match Case - Matches the specific case of
								the entered Search keyword</li>
							<li class="reboot">Include Labels - Extends Search to
								include tag labels</li>
							<li class="reboot">Include Definitions - Extends Search to
								include tag definitions</li>
							<li class="reboot">Include Dimensions - Extends Search to
								include dimensional detail</li>
							<li class="reboot">Include References - Extends Search to
								include authoritative reference information. Optionally specify
								the reference parts to include in the search (e.g., topic,
								subtopic, section)</li>
						</ul>
						<p class="reboot m-2">
							<strong>Help</strong>(this content)
						</p>
						<p class="reboot m-2">
							<strong>Version</strong>
						</p>
						<p class="reboot m-2">Indicates the current build of the Inline XBRL viewer
							application.</p>
					</div>
				</div>

			</div>
		</div>



		<div data-test="taxonomies-menu" id="taxonomies-menu" class="reboot right-sidenav col-sm-3 bg-light invisible">
			<div class="reboot d-flex flex-column flex-fill h-100">
				<div class="reboot mb-2">
					<span class="reboot lead">Facts</span>
					<a id="taxonomy-menu-secondary-toggle" data-test="taxonomy-secondary-toggle" class="reboot float-right click">
						<i class="reboot fas fa-times-circle mt-2"></i>
					</a>
				</div>
				<div id="taxonomies-menu-list-pagination" class="reboot d-flex flex-column flex-fill h-100 w-100">
					<div class="reboot pagination"></div>
					<div class="reboot form-group">
						<select id="taxonomies-menu-page-select" class="reboot form-control" aria-label="Quickly jump to a page in the Fact Menu." tabindex="13">
							<option class="reboot">Select Page</option>
						</select>
					</div>
					<div class="reboot list-group list-group-flush overflow-x-auto w-100"><span class="text-center py-5">Loading.</span></div>
				</div>
			</div>
		</div>
		<div id="back-to-top" class="reboot d-none">
			<button id="back-to-top-btn" type="button" class="btn btn-sm btn-primary">
				<i class="reboot fas fa-arrow-up"></i>
			</button>
		</div>

		<div id="dynamic-xbrl-form" class="position-relative"><!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:f17f1926-1a01-4baa-a406-054ce45079f2,g:c6b1c5ce-74aa-44b6-956b-90e243d128be,d:3ccccf37677d43f88002f8d995e2fd3c--><meta http-equiv="Content-Type" content="text/html">


<title>mrk-20230331</title><div style="display:none"><ix:header><ix:hidden><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV8zLTEtMS0xLTEzMTYxOA_94f05150-b88c-4ff4-8cf1-abf185b903a9">FALSE</ix:nonnumeric><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV80LTEtMS0xLTEzMTYxOA_0cd28e01-cb5b-450b-aa36-533d28feb38d">2023</ix:nonnumeric><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV81LTEtMS0xLTEzMTYxOA_c83e06f5-8eac-446a-97f6-959481ba41d2">Q1</ix:nonnumeric><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV82LTEtMS0xLTEzMTYxOA_f5002049-7d3b-417a-bc70-5f00636437ad">0000310158</ix:nonnumeric><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV83LTEtMS0xLTEzMTYxOA_1b036b4b-2009-4f50-b3d1-dee18ebbdf1d">12/31</ix:nonnumeric><ix:nonnumeric contextref="ifbdf486ae9934cc9a2a5283fa0638116_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonnumeric><ix:nonnumeric contextref="i548bda88a4fe4bd5bffaa38757444dad_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonnumeric><ix:nonnumeric contextref="i548bda88a4fe4bd5bffaa38757444dad_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="ifbdf486ae9934cc9a2a5283fa0638116_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="ifaac2668425b4eb4bfaea2c9834fd061_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonnumeric><ix:nonnumeric contextref="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonnumeric><ix:nonnumeric contextref="i03be4f41b99a4232bdc4d5da0449f285_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="i50b43bd94e56461888fca904c9a7ca24_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonnumeric><ix:nonnumeric contextref="i143c9f2549384565bcdcfdd243771159_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonnumeric><ix:nonnumeric contextref="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="ice27572fdfbf445cabdf5a62a7d76022_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="iac10665025d84f23872225d16c92ffed_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonnumeric><ix:nonnumeric contextref="i45afba88d4004605825fe82844d7a4a7_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonnumeric><ix:nonnumeric contextref="i5a23903b67354e33a6fc1a8676a4b984_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="i3a542fc8b3854857bda9666e66bd056e_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonnumeric><ix:nonnumeric contextref="if4fad0e8da324f249b5dc3a9f01637f7_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonnumeric><ix:nonnumeric contextref="ie091883aa8d84ebf868769397c540276_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric contextref="ib057b0780b1b420d824cb8350acd5ba2_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="mrk-20230331.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i59b625119501404d81b378dc2da40e6e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6f9aa917fb244d03ab52c4fcb13190ea_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5c3c68968d5a49b98049b259f527466f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff3b595ae954906bf225b8a7cc58b69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1302ee97335a4b8a864d880d15a75ffd_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">mrk:PrometheusBiosciencesIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c03ed79efac404d85fb217647f60f9e_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">mrk:PrometheusBiosciencesIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-04-01</xbrli:startdate><xbrli:enddate>2023-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id017497421574c008e33bacea591637e_D20230701-20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">mrk:PrometheusBiosciencesIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-07-01</xbrli:startdate><xbrli:enddate>2023-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1e8e4ea1abaf40778222b2bb6dcfb639_D20230201-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-02-01</xbrli:startdate><xbrli:enddate>2023-02-28</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib9dedd741503427183ecc62df92f5085_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c175c60a55e4c3eb9ac840966e13ebf_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609e1582535d4dfb834b95904e849c27_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8f3adb7e1a4d42dd925db11dbf71eac5_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58a876d3681e4986805915e1bac18ff1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3c3d2c4bb8cc45efb4e93d046dd6a753_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a91adde5a68413fbc1cfab655dbcbe6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i350e44c40f67467ba477b370f98d41fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6b1412b32dd45bf9b2dc2c9740d6c6f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71ce1d5e1bd141539620a96cb8b2ec10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf9cd10c9efe4059a13ad6f64f232a85_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i654e8b5924d8442fa9eb55859bbc8647_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib681c644ca864f3286e965d6d7324aa4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ide79c33fd45c49b19bce108416c71788_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i525916f3d1464ab9b6f291401c761233_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6e95ebf7c1884a0396c7c91a0e223ee6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2c6d877e0a5147208fe56690fbb929b0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4cdf23392f5642ba818b20d852b014a9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46e9161a43a44a2fa59e52960034468a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i71ffa17774c44d2287fe9111206866c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iba6c247720a049d28349afa51cec42a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id22834ff470f4f1aa7da131a94ad1d29_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6500964c8d3f4d06b28f3f23cada56e5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifc2de578164e434980f14d63a2153220_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5973fb4a5d684bcca7a62270623ac406_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9ff33d56484784be92a715ee774c2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife24131bdfa1419d8d2708d8b616e5b9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaae108da197453bb8b3b58a2cd21d7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492255c072c74c9f8a70fdd6212cfe65_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie92cc5b201cf42e9a6a395bf77ad597c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00731f51ddd64c099bf1f3a866d6e0ff_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia8a01e007c934b3285178dc642a890ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf5abe1e04c438f81048ecae5f02ed4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i364cafd01c114c558bf6c571df9b34b1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2d145059533c4960b5fc110813a1fdbf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ief58ac433ad9415a802f0001cc903fa8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifde6e88a8c324b84b8e1ac90ed088a69_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e956d6285d1456abb720e32551e7288_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3779054dfc7a4a51b4e90d43a5ac3684_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib7eff0028e2f4952bfe2bb459510ff9f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia56fd7048ad14abf96162c372b142909_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iace54ff30d73465189a461975d7b6b99_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if1e72c11f4d449889cefb13617918cd0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4d825d4c2aa44c79bf5a2366a7a86a9b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6c9458bb97f476b867db620d779e5fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie01022120e7d4f7cb61fb037b2355db5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if29e83faad31423b801afdcfcba98e44_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a73485be36248258f5601b826d7bfed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d20b318541f4dd2831d35fd11a17b0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3399af7b61814371b4415a2165606deb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i80a8ac9e73b64ff18bab741a42d8fdcd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i260c8037bbf543e0aa66e359ab18b50f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea6ddc3ada9445c95b033d7e07dd561_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idaa0511b79e949c7a6547505b9ae5551_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8e52ba3989df4480ab8a8c4136af64aa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i68f851c07e23480aa9ff233e42d37d7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6191c4207cdc459d90d7c79d3e4e64e5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icbe1869e706149f48a2091f4b9534dd9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5ef0c87d5feb45e381dc0a07c2d16382_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i63cb28ee8d6845b3bc89ee74ee01ff67_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i58e10bfa620942c4bcb811e0f171d36b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7e3019b3c61c4b70a15610624c8a4983_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i650127b972c04c1cbed3bec6d5fdfa9b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib2ae3db4c9364ff8843c87c364bab42b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9056f175eca54119943d05559433e20d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66da4be09b7447ab23b1c1811b5724d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36c8f57b20ce4f26a522df11b2be6320_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644d973253b54d3e94a4aa3644bbe995_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a085dfeaeb40a083f13e8a59287e8c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5173a42466784ad9a8ffe86302cb3b87_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iebdfd787169843bcaba790e915fc305b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifd3bb7ee67904313b2975cfef294c50b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ice904109d2ef48fd8e8ed1324f5c2c59_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic51d50d985d84a3f8f588fda28be3ce3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i25207351676d4c9e9e6961bf25936afd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4d5dff37e3ab4823ab8be6c8611cc6d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2404a6eca015453d8c2bb0e08613ae7b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec1c506714374a9baa8471e96e643d5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc4d047e87e6460984a1241620741fc2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i386e5b3e2b1d4771ae602c8544c7de85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i402d58f25e9e45a68055eb38b7d1d4ab_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0175444d0549416fb305c38749b41b24_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i245cacaf455e42329f9ae587d1a10cad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2dba74425a51433497fa7e5529627e25_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9cff7fdd9228489e9a08ae8b3a149a6e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id17be879320f41af82dedebba088c13f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie3d1e57b1dd24ae193bd71c6385b8769_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-02</xbrli:startdate><xbrli:enddate>2021-06-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if4eb1aad4f8349af99fa7c51391e5966_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-02</xbrli:startdate><xbrli:enddate>2021-06-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie7ee924f05bc48c787f3fd1d8f6303b6_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-02</xbrli:startdate><xbrli:enddate>2021-06-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1fd80dbdbfb341a2a9372748079c59e5_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-02</xbrli:startdate><xbrli:enddate>2021-06-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i185eb227b4104468b3c29dc49352d43a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i60b11c4ee8724493ae377bee597f7db8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i834db89c47b44369b713641fdff58447_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7966ec436ac148489c841a585ea76477_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870f46cf31cd4dd99b24227fb3adf06f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibde26f5431b54da79586ebd96e74a36d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6616b6afece4195a3a8c81945ca5296_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i111e37e345c242418c65ff71f8df4aa4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia85fb7ebe86e48688eaa6cca6140b251_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia7968694bdd844dcb91cdee1fa81b0c2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c124834ee87435999488308f1f35177_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie333238530bd43c2ac7bdbedf60929b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i39ffed41bf6448378d17f953bc0cc54b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if8831ff53ddb4e9384dd1c730f73c0d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i92816509cf8240d2ab4f3e2c2a61c6b0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idfa73697ee0a454c9ad0fdef7eff7f65_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i620edf85a16d4e4880ceb84b22f3cfab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3bc8fc361d904fbeb6492f5e521452f8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0bf782824e144ac698d3c52441494fa9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie23cb3149ce14b15a9a4f74c76232a80_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idb61832d74f44b15bb6f7e1e80aefe10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibd263f21d9824f4d88448a933573382e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7916bd167a5949cf9496c5497260c4da_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i59bdd8e429324f6985da2aa4f9cee50f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia26db14d5dfb4db6936c0133c122c21a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifb9eb1916f044d189f47e32c6cf11a65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6bd41c6996df44f5ad0c156034845a9e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i45f7c7de6a3b4eb69f814c83aa49e79c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2f8fc3f059d944d8ad12e7fed7bcc36b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i53768e8ff51d41dabfcdf8423e6ee2fa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46e4f372c2f54684954722f000f9b4fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i72738ef779d443e9ae3f451aa08e9bd5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1dbe9c123ccc49ce80d7ee4225c7c4d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i09b391351ac84dc89ccba17bcc925ec9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i80771ba562bd4e098155333659c919c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i735d6ae1f2044389b4cd1ff056ef3646_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cce1bf91c214333b3b50c15e3d7461c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40da318aa247452bac9b3018762feece_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993831891ccf428592c3e2f850548d44_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5739c18be2b4077ac27f27ef7c6e9f6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb4e20bd4ba34d448a2f3a3397c0d521_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e6cc36740bb4d71a793d4cb817b4486_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i44fa00da50de4c2abe7a97b20631529f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i313438c53a3745f5a9c308e10580003d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13663e430fa9440c8b9b613386d03310_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3459fac4643e42e29a49394546d2d3b7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib9f85f59e99b4ea189c2a085734df397_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c1922ae96df4166a7397fffeb3375e7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b9f469b4df444f7b96723d7a5c8b223_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>mrk:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="i336c99147cdf41e191d86c13d2a751dc_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7029fd7c7a6f43aca68f42e012aec70b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f9d19ca7854b0288a0454768961670_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbdf486ae9934cc9a2a5283fa0638116_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548bda88a4fe4bd5bffaa38757444dad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdddb9610a348a48e757c57cc1a2387_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic70cbdc57c9f458abe55135c7b061c1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425bb66138fc4a51933c6b6df28796a6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294f553218424e8cb257f3d9f97e01a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaac2668425b4eb4bfaea2c9834fd061_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03be4f41b99a4232bdc4d5da0449f285_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b43bd94e56461888fca904c9a7ca24_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143c9f2549384565bcdcfdd243771159_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice27572fdfbf445cabdf5a62a7d76022_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a06f418da43474f9f2f260add8790b3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf11d32e52ad425f979acb12dcd9aaac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac10665025d84f23872225d16c92ffed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45afba88d4004605825fe82844d7a4a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a23903b67354e33a6fc1a8676a4b984_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a542fc8b3854857bda9666e66bd056e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4fad0e8da324f249b5dc3a9f01637f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie091883aa8d84ebf868769397c540276_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib057b0780b1b420d824cb8350acd5ba2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaadad87b63f48448ddf5360530646a9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b17d802f304918b52da353344f6ac4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i028e5b27f0e04f339d7c2f519b8ae259_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib9ff469b241a4cd5972223863bfda226_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i96b677da60364882b5bc1b825a50fabe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i330867f88a774fb08f247e81d478866e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8118cf7c392f4ea598bfcb18b7bbd4d2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b6b9e2b940749269dcc355aa0ed57d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibc7fb1fb9fd543aba08f396008a05eb0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic3fb850e1f5f434f8e8a95228021a73d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i776fb83d7a1241a0826d11f6ebe76e81_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a3f219a7d404a31bf65ab7515e23942_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a140256baa4686a25015671d14aa5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93df6ced8a7748a4abd5d6c32906498c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa6408da9024f3ea458c3189fa1916d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f2bc401a074570afe7c168856f7ee2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85028f8c5acd441497714b4e936b0ece_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17a0e0f674094afda5f097dcbf70b93d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0cda95f4db4a4d1e892c7b8b8c2bdd34_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i020b0ff9857f4f16af9e432e1869c1f7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07c700750162434c9390aee0f12c47d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47442341eb14e6e97a2cc3f6b5bba11_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bffc0a6380440728c91dc8b47e0f31e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a8f3e37e4904159af4dd090e1bc5731_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a49b37db2544c739f3f57a6c315a232_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66cafb3d313644a3b3ba17dc3c1b05da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a99f61d5d9c4df5b63c5274b8898116_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9e79091e5045c68d0f830e6ac4c990_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2795fcc4916b4738ba959e843ff69ec3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96de2214f40e4ba59e7b629d43ba4d91_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451160fbee604ab990070211ebeba8de_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d67fffc7944fb8af71441dc67f9462_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8445329cbd40e38c431a9cab4cb4d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3beec2a915ab4328b794d0b11fbc0788_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814823701512438f9446387df4b6adcf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d93e6ac796f4cc0a31cd2625e3240a0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef3c5cc57074bf7bab4f63f14c711d4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia38b8466a7354dcfb672c615593eeffb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743f68c0230549c8bfbd0ad0a8901f37_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d3fb0c5d5a24db099308a75d6d48348_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4232e5688d9417880fdb23acd1671dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5ea1c804e54b9da2cfa1e35191be79_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c000934f3b49b4a1049b7c5825c3d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i012d7bd208a247b4b543d54583a218ef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07338fb5662b49d5bc2528a3307c626b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic115d2d37fd44d80b15e651843a0417f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d827d1b17a45afbc3e288430a5dc82_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb17c88faa0435c933b88267089cb0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04f9b00c03c4e4ea6423dcfad58d6b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie908803a7baf418983f47014731e40ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db38063fdeb45aaa60b2e97a4474133_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idebf467c560c4d1d9245b765b6e590d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89142ce181ae48e3a2d77a9f72861963_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ae55075eed47cdb14839b87c57acd5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f4032436bb84e00a3478c08a4a4bac8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bd81adc1667472a96ce3692b39fdda2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871a358ebbbd48f496202064b0918f47_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e90f41ec72b4d99ab066bfbad83afec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a48a4589b004511be5ec5ad70c7e2da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c30409b333846a0b003f5261f708353_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1c02180ad34f3e83fbb3df043ae3f5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6288684e9335426a899ee4586882280c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i305ac9c4908a4bffa1b9ce0a56239183_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eaafa1e0ba64836a551188797cd7c7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic36ef238f34c4ab180d3b3a52624eb9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib784c86ce67446f7940a517458674fd1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004682e5e94d4b12b9f2913eefd3a7fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34260a2a17d947768f68d2798eb0f8c1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b068359fb3948a182327c67ab308fb4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8f7806f9be14762977b7e08e79e4daf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2e484401b24c479443887a01bf805c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1b40aabc7a4eedbc4ba7ac12424d0c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5265c6f93c7f46d1ab829156c30fdf74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic497e29b39d04693be035586e02049ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i970e6180f53c4baeb53fdd14d90061da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075080b8fa0045b6adf42ad9d680a586_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if826811b47d7448eb6e1f3d6c36b5841_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96e781b662154001934e50bb59beb7cd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibffb1c0f1856491795524f9ede8241fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba1c7342bdd4e82a5d14645ae050399_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294603384e1e48b1b1962054c70f8781_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2707a83a0684b81b3f82c21c1a7d1e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia524db85b9fb4e5faaed403cdac7f778_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4b65ea8a7a94fb5acbe089d34abecfd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe9381ed615477a8d395b385d4bfc96_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2a2a2cde214dcf9145e7fed863dfaf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0fdebb01cd44ff4b7dd90a3757e19a8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b2724f66144388bc9d877014d99971_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402e5d3ff33d4949b0046490210e38a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a496ea51974c41968d7d7ece436a35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e31d8852884bf89e5bcb8b4f124896_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcc8586471c42e6a0ee92dda4a6bd01_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f39864d8e8e466da61d331c664f14db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae2044462124fec8e736b9c160ff048_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fbdfdee6afe4e74be18dd0c62050372_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idf5ff6cbdf22489b9efa70ffb318b8aa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fc780817394ba39db27d26c677ae95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49dd486feefe4b749fbe2cca62e80318_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e717c1f26e14e87978e3de102e7c698_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie81327a316a94b36974954a7e8642bc5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>mrk:case</xbrli:measure></xbrli:unit><xbrli:context id="ide0712a78628418ab61bbe9bb313aae7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7358a61460544d15a70b0957807efa73_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674ee2f2e244467391945b56813ef740_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="direct_purchaser"><xbrli:measure>mrk:direct_purchaser</xbrli:measure></xbrli:unit><xbrli:context id="i486acde0965b4e4fa567b783874fdd1b_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-06-30</xbrli:startdate><xbrli:enddate>2022-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>mrk:claim</xbrli:measure></xbrli:unit><xbrli:context id="i07e39fac74fc4d08a501e1e14a991816_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i88f1868d275a4b89ac8e4f956b24ddc5_I20230303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:RotaTeqAntitrustLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>mrk:state</xbrli:measure></xbrli:unit><xbrli:context id="i4305661e65274f559b5b59766d3c5cc3_D20221219-20221219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-12-19</xbrli:startdate><xbrli:enddate>2022-12-19</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4bd3fe27e3bf4036897cd39ae0448f14_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="company"><xbrli:measure>mrk:company</xbrli:measure></xbrli:unit><xbrli:context id="i79aeb0bcc641443b80308ef30bbad1d3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8407355ea334e558a58d39cf813e848_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaAndJanumetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i270837c6ca8b41c49574b8b379172454_D20230413-20230413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:ComplaintAgainstTheJohnsHopkinsUniversityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-04-13</xbrli:startdate><xbrli:enddate>2023-04-13</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>mrk:patent</xbrli:measure></xbrli:unit><xbrli:context id="i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica1e472338aa4a5298e4b867322ded49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75c3b66a14446a7b7855544f19742bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6bdceaee0c415785e978b1546e824f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9c7cab12f84742bc529ca888140834_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c01235f9a47471bbfd246c179b8ec70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa0666b9b0854af18214a4de1da949d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957a5e7283804544961eeffd229d90ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba2932606cf4136b76cf64715d17f5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifce529878ee94fbc97ff3cdc8e49ccb4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i918170e5b2fc416bb5213a74ad72646f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6faee1c09a204c63baa2f8635ef78da4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4725be788d3c4f1f966fba475c841405_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6e2497db5f4b4eda93858dd1c188cfb5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08889407a4ca4fa69735b8332945794b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc9c8d75d064da9855b8d3b37c02b10_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42da78b36e31450dab3194041180b0ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id895bb14f7154486a761071e11a287ca_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4350e7d8d13e45848709eed82cdba738_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d6c8aebc384e4b973cac8799704239_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb5a854388ff4957836b5593bd4f37e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b73a7dc82c4055afd7242f0e94f662_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b21fb880d134a06abed66e7d998914f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796d55aed90341e6a68727c28ffcab70_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc10dff04eb494ba85791126e4db053_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87e04afadbc24d00bf0c906ad452972e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibe63a010ec0a40ed91fe4b6b16e51a63_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ied44c0afd9384c30953e94941daa0cb0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i65afee1f42ae486f84514163f3843f68_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1742aab8c35467db6f531e481322561_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3b6bd9f9044238b1478ab578648204_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18372378d12a4968ac3f82433fa9ffdd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e7a6142fec4b32aa305b679a0d9a87_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4437cb5ce2e4c6cb15d052910fc825b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa514bfad3f4f6883b1d3d93683f530_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i041db7ac9be74d218c0c23a960fc9a27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33af4ad78921440a981af5aa4715c88a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad527aecfb724bf3b4777b628fefa6b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia2319d946cd342759a8f984524b58ad8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95a7d6e4f3b642ac849cb5b1af84aca1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a93158890945a9aa15c60a05506723_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f76fe0b880480684d05d01c6f398ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b83eed87b2d41c1a8c610f98765bba3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d63d8c8b08843008160820a9757c059_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ife1d684ce4c949b38894572598414983_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7af996fcfb0942ebab3aa1e8cea2e1a4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e5c54f51e5440dd9db7d51479f49629_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44331becfc824debbd8e96c96c590f56_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mrk:segment</xbrli:measure></xbrli:unit><xbrli:context id="i8df183ec48194fc4a2c6f8e8d986193f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaf2b65d0efcd4588b8eaf74e00590ea7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie772b761081d4a3f88dd5b139a18cde5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id23605aa21764c15b522d6ea781638b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8b1fe39c7ec246f0a53097e0b00b0803_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7caeaf606112447a8aa0d87b20c8f163_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if193ecf6603e436e9bc55f3e4f86a576_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4b3b69956cc9411da3f54f428aeeeb42_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4ef00ecad3374cfaa1259915898dc915_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id0d6b8513dcd4021a200090641fe0bff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0666b87a008d48918f71fa4e40a3259d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ied5a517f75814ffdacb6613032349a19_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3bdd7b02457a4826aeec0e25dbfa4df0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i373f00d87cd7457d9b079c9415e0c4ad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic416d710ef924adc9df8131effd1c200_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i421974800c0844798343dd8cfc3f3a20_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i26f185cbe1da4f4e89a1e2093171e27b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia7706e3163ae4d58a5f8660cb640d5ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaf21fc9f03d342bbbd66be0123de6225_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i943ebcf31d20440ea90b753cb238fe02_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia13e94e1a90043bcaea2ffba6d27061a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3f73d3370a5348dda651da8166f72bfc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie40a08ab45e2491eaad9788d31bc031d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i98d5687c5bca4aa0ae8be180444502a5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i148665041c5d4969a1b7468fc0b3306f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i245f27c3d3884d16886e2a02a3bea2be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i683c95eda6cc4e83a3f200cd8c1ae979_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iabc5de1d9ad9496abbed9093f2560c7e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6d15bac232384d3d9b567829ed8b4e4c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0eb110c2888a401a99ce08584a59ae29_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0622fda057824fe2acccd535fdedb1c4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1317f96f8242416cb217168b296ac180_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i15590b4a502a4441b2031cb5e67c164c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0272e13e3911432484c3574c4d88dea4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie1dd61290d2e4c28bdc142b28449b630_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0676bda79d3444beb30669ea1761cefa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i92cf8249b51045fc9f74f556cbb77945_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idd868d1665e843e8ba8e68820863660a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i85dada8cd49f441ca2211b4790538075_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9e7b43ab9aca461cbd07c3408576229d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i502537b5bd3244cba8148fdcded195c1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idd1279562a9049789bcf67e36e1345e6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if12d006ccf6947e59b7e26e27405537e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2caa7eb6734e47f694c35387f0b24c5e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iefe80ade170b452d810ea857bfb36486_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i168a16270ba04bf5bd0a98c57f6e7453_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i38f3c51ed3c142088d512d3cf86a4e85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5facb3a2afd54e37a08fcb30616f2d40_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i71c307b84c814567af562b778b4c1b53_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie8a9542dc59a4777a668cd31211b6c7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaa6e384e748d4e74833d7c8bd58e5051_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3a9cd1b2796b45cd823635c3a4ca1ec1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icc1f221331e847f78e9890ad89af8d80_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iced6646c844d4419a1591abce5241bc1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d46a1bed5b64222a563d18e9091ab03_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iee7d83d494044d17ac974c40323b8bfa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaf3bf82a5181435e9e26d6dfe9ccb7a1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i83f5ca79492e42dba088722bf7ae9575_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i556f1c52ae734ae6910cf6d6b9d26d16_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie70b1f6ac9824c5c9604f2e6cda7b721_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13c7df0a730141689941ffc740882c67_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie19b5dd8e1da4e7ca8d5114cd25d465e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8845bbae207945c29f58ed0faa7c916d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9ce84ce5bc4d4fd09f2f2edef567c63f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id3307d951777433f9183e38cea7b0eee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie514f725ab204576a9d82e520a0747cc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic3c351d397e549f08a5550b64c7bd217_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia85cef5855f74b3aa28b80d7e773c5e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7d745b43d42740a2a636f93305a10162_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idffa9ebb25b04dc3ab346d0e2525d0f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i81842dbc49284aeb8c307b130fc51daf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9ae5e82b75cb428f864e7695e7ca9c03_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5c5c36e08c35436d890e3cc5e49a26b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i63dd5e6b38074752a8397afebca2f449_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6a6d9596af343fe9fbfaadc1d8d3d34_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6cb822f6f0d24e56b21b1ba8cf3c5144_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie1a2a61f6cc34473ab9936b7066ad51b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6b9400d903e47749af467e683ebf4b8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5e28d66cb4d143f5b15da4ce16a7ff80_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i83dc7aa4430a4932893b4dc1505dc632_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibd11a9dea94b46ed9112ffcc77e533a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifa49ff54d4904fb783f4f755bf9c4739_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i16385f11510546058467040c76602eda_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i97cacd287b274b7283ca51aef88bed26_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ied566206459a4f21bda9d764fbd67597_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8c13b48a7232487dade4344d3bd6fef4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i36f1883cf7ee41de9a38e097ff1eebdc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1f696b0a7e848ffa8cd28bc5f62be74_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i33013fc5c1544b508c1f023d7e114799_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8189ab3ff1aa4b3fac07ab4d084ef309_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0934dfe57f25400aabf7629e013bf2d9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia482068e1c6841608dd3a6fc8530cff5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i36f337569e6e4b90b6c49162eccc9245_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i370790356a1f4d0f910d0150c46829ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic3ad548049e7437392c37716ac4a83fb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3025f3862fa34281bb1ddc0c23288056_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iadcf254d19a94241a8a193b57dc553f7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1be1a7ec6a2548d4861b2e925582acb3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9ece7f9fc39047fbaf47a27cce6b32ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9c4d7a0899854fe795ccaec1a0161a84_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i01970431619244f9a83fb73990c5cf14_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i958da05d9055499a88d25a539d74f6b9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i82a61880f039405d9d8e1832fd26a2d0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i06d3dc01e4cd4880b999376bd99d6191_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7414168e369644d7a58d58414fbde705_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8d7e8ff816e241f199e0011935427e7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iad4d2d0ea13747a1b99b669cf7ce5f36_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i01c8b28beea44e9998a1034bce51e508_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifc25085e4f3246fcbff1828176d06cb2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i42b4b84e15304e879f573aebe7198888_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1abbf56d966442aea56ac371531ef7d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46444b1898a945a692f90d2a907898a2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i745ba7617eb74e15ad18bf9b1bb5709e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2d35a8760f2f49e89952d761b1399baf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i185e17abc9a24ea38c9ca4921fa60212_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i69279d4f3a814a78996b4c54c84aba07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if658e80c557842d4a20c5570140db4b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if0feca83d79141c7aa9f2bbb6f89ece9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id9ab213a9fd74c98afcb44eb19dbc18a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7b3ad2cd408f4af38f724dabed4a97ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5d330794d9a24933add16f9c3e14c0e6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i90f3bbf8132048e7a806ef1c700bcb02_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c033c7782a84654914962664067c0b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic44db3f3e64b400fbb66bf36b4d59948_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia0f47191ae984e44a0ea39f24de59ca8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ica88e8e09cf5471f8ec81237bf2424e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icf3db16464a242348f5f5ec6b303e8e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic5dcef3812b24f21b01ed1f074b5e48e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie078fe8aa4b049019f87a49fe7163a94_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic81d4335a8564f6893a52c09eee896bb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i38f8338e607f4961b4e06e5ad59f06d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i481c25e1dc4042e583fd9ae56af1ea83_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5ab42425f0e84d0fa9cc1faa24e50ad9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f1f69903f024330aa3cd5f89dfe4aef_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4f18afff1f924a87aca15181db888f45_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7f2b65669412421487fc5a293c2d0226_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i252bf97a988d4ca089b4880ef38b9f6f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8ac3b496e9b7497bbd0a8568c2c05058_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0ba905ef97ef4ea2a2b74f044e828215_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i341c1828f974489ca631fd2f6fd5de33_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i91767bfb04eb4bad8b4c74cc699c4f11_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i078db72152b7433b892f65578b578811_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3d3ed97dcb1048b9b00df266e47fef85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idf7f29b275f343aeb93a10d0bc96a43a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1c5a4e651d8048d0bb7be915788d3451_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idfe3cd40147f4e2bbdcc6daea5c4f648_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idc375c5fb83442ce960061c4c1e7d3d2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1068453fd58a43ed853c52e49d369635_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2a170523e4784bd68826594b94740470_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icd460b0376004e6c9a2f91d187784dc9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib5c0d77138754544a2110eafaf9ef1de_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie30c6b82c81544b2a213a66f88a666e6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i944297bc97294b85b64026a5234105db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6714caf41ce2406282b4c22d36869265_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib880b79c41404a7f9ccb683284f4a657_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7242924d01844781882444c559d8edd7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0b5149a7a9724ba099430ae94f3eb7f9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3f44546bfba04d3182b566c995d1d6a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iea28f75c29f9495d97b2490ad495e473_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1c30e990884c453a8e86bf31356441ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib1de53f2d14549978ff86137b26acfdf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iea0edbdebc194dbda6f583be24a5f5be_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iff180f6730404c2fb6244e53cad88916_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idc67e8a229ad434b9d2759887e18dcff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3ecc10254bda49bf803e6b76575554b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia58fab4c69fb453394fb53a0a9cb3d93_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i08f54d2fb7c74345a43dd8eb5652ccb9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia99f107296c340309c3405bc2810419c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ied991033c3cc4ae8b1774bcbdfbc6a61_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i48ac0207dbb24fba961de45411f8f863_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i83d344caa1af4fadaeddfdde40462eb2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8c73bc1480c5460787fa096cbca3e186_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4136a4c6588c473b8dbc29bd43446a8c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if77a7432ec784877b792884b4331e9ee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id486cc4b73964a048598ee4145a36f51_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i260d3e7cbd5a4346b6de45c5013de1eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2913a3930e88428aacc1ff729877e753_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if553fafbad26405cad25ce4550638d3f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i660405fd34d447fbac3495f01c37c868_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic90971f816384ed793878fbed1daf9b9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i904e8e179a1a49698833ce1b0110d5b4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0a26625eb0434b3aa7c78f6443da31d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib7dcf8dd27b941e6a6224761d29aa39d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i83fa1e7afed046c4a90965eb45e55ef4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i296f4d5ae9ac48818a1c814d83edd6c5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i541f7bde3cb144d6a1a06f324c128077_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2171622cc8164fae9f90806cca105ee4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0201d118d8574b6db54cf6f7f5bb5c3e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icc177dc034fa4f9ca0cad6e36eb33f5d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icfa83b7726804a0da22e28fcde9c5ed2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i70a11b67918c44d3bfc01126c08b9fc2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icf8c3545f0134eebae2941403b2e022b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3f24746bebef41f9a462c02b830d6110_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i307318101eaf48d785d4b776c386341a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if69fe081e83e44b89e1642cb41b84015_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5e9cb136461a4e8aa85239cb391d845b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7a97503f4be84d46bdeff57349e01c23_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i809f9ceab45b4cc88ceaa644a4ed41d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic58118074eba4189a105e403b1233b58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i679d69340bf54bb4a090a15b7ce9076e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4067fe86262c405cb2919284c7e1f31c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib86ae90471ee4ab18226e2683b749444_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7b6b67a7073245c79ad8b17846729383_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iee1279d9656246229165b6071a908fe4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie1eaefd10a6d4f75bc5b01e6fd6e7612_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ice769ebe11cd4873b0e7fae638d4de55_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i77d9b85158ec4e37be193731477b820f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i83848e68f3b04891aad523922cca52c7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic9bae06748084a678545ae2a472fc025_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i49396c3fa3284569b4be0611825c2214_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i492a23d281624d04895b84c347c42464_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:219.75pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk2_a9e6369c-c0b8-4841-a5ee-7c14e8dd6782">10-Q</ix:nonnumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:219.75pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:3pt;text-align:center"><span><br></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:396.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:center"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MDMzMjlmNDhhYmRkNDA3NzlmNjA4MmI2NWEwZmZhN2UvdGFibGVyYW5nZTowMzMyOWY0OGFiZGQ0MDc3OWY2MDgyYjY1YTBmZmE3ZV8wLTAtMS0xLTEzMTYxOA_0ef2aa1d-3429-466e-8929-bae9e29f2bb7">☒</ix:nonnumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></tbody></table></div><div style="margin-top:6pt;padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xNDA_6902a18f-1936-4fec-aebd-32023db37c09">March 31, 2023</ix:nonnumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:396.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:center"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6N2RiYzZmMTY4MWRmNDk2ZjgyZjY1OTcxMWM4ODFlYzAvdGFibGVyYW5nZTo3ZGJjNmYxNjgxZGY0OTZmODJmNjU5NzExYzg4MWVjMF8wLTAtMS0xLTEzMTYxOA_9af3a534-f334-4a7b-b454-43742bae66d1">☐</ix:nonnumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the transition period from ______ to ______</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File No.&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk3_dd294642-03ce-4af2-8918-b34a07f25457">1-6571</ix:nonnumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODkw_dc1063ad-9eec-447d-823c-ae774448e00f">Merck&nbsp;&amp; Co., Inc.</ix:nonnumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.545%"><tbody><tr><td style="width:1.0%"></td><td style="width:41.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl8wLTAtMS0xLTEzMTYxOA_9bb8fa4e-1002-45db-a077-cccf42037241">New Jersey</ix:nonnumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl8wLTEtMS0xLTEzMTYxOA_9f7f5728-1bb4-430c-af20-07b38d74e7af">22-1918501</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl8zLTAtMS0xLTEzMTYxOA_3f5e467f-2196-45a5-8801-7d2c70f7f450">126 East Lincoln Avenue</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl80LTAtMS0xLTEzMTYxOA_429e5483-903d-4535-b74c-4061620deaf4">Rahway</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl80LTEtMS0xLTEzMTYxOA_5aacc37d-44a6-44c1-b167-8b7d85b4d95e">New Jersey</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl80LTItMS0xLTEzMTYxOA_1d1bc586-43b1-40c6-8229-d3cbbab81031">07065</ix:nonnumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Address of principal executive offices) (zip code)</span></td></tr></tbody></table></div><div style="margin-bottom:2pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Registrant’s telephone number, including area code)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> <ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODkx_74fcea6c-72d1-4893-9a90-52788148ab69">(908)</ix:nonnumeric>&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODky_8e211ce9-d277-4cb2-9f22-437ed660eab7">740-4000</ix:nonnumeric> </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tbody><tr><td style="width:1.0%"></td><td style="width:20.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Not Applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Former name, former address and former fiscal year, if changed since last report.)</span></td></tr></tbody></table></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tbody><tr><td style="width:1.0%"></td><td style="width:35.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Securities Registered pursuant to Section&nbsp;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8yLTAtMS0xLTEzMTYxOA_d86ab289-5682-4ffd-9727-c903224b6c36">Common Stock ($0.50&nbsp;par value)</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8yLTEtMS0xLTEzMTYxOA_cb529e27-e822-4f40-9a67-0df5922dd889">MRK</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8yLTItMS0xLTEzMTYxOA_915a08cf-0363-472b-9dac-0542e7996f24">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8zLTAtMS0xLTEzMTYxOA_ebbedc1f-6993-4f83-ab14-e95e629529ff">0.500% Notes due 2024</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8zLTEtMS0xLTEzMTYxOA_56bb0e3e-0444-4162-8be4-1c7109b59cf0">MRK 24</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8zLTItMS0xLTEzMTYxOA_ea5e4e7d-270b-4a9b-b9a9-73deeed066f5">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF80LTAtMS0xLTEzMTYxOA_6d86a2a0-32e6-448f-a0c3-b4fc636b4f63">1.875% Notes due 2026</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF80LTEtMS0xLTEzMTYxOA_beab5f44-7c3d-4a1f-a36b-0d0bd8642fce">MRK/26</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF80LTItMS0xLTEzMTYxOA_162bc9cc-debd-4b7b-bdf1-c27dddd141f7">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i59b625119501404d81b378dc2da40e6e_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF81LTAtMS0xLTEzMTYxOA_f098378b-1e96-480a-b131-48c625e0dfe4">2.500% Notes due 2034</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i59b625119501404d81b378dc2da40e6e_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF81LTEtMS0xLTEzMTYxOA_92b385d4-56d2-4911-b640-8a9f1955a841">MRK/34</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i59b625119501404d81b378dc2da40e6e_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF81LTItMS0xLTEzMTYxOA_e720995f-3865-48f1-952f-28f02cc7a222">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF82LTAtMS0xLTEzMTYxOA_a40291b0-c7b2-4a39-8a5a-b26d611d5a23">1.375% Notes due 2036</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF82LTEtMS0xLTEzMTYxOA_147790df-f046-41f1-93d7-65cb2f92f1b3">MRK 36A</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF82LTItMS0xLTEzMTYxOA_83d99553-a0ce-41ea-b684-09cdc75ae00d">New York Stock Exchange</ix:nonnumeric></span></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODkz_b1c24cde-b7b0-4fbc-97f0-841c8f340cb4">Yes</ix:nonnumeric>&nbsp;&nbsp;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">☒</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">☐</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required&nbsp;to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk0_67742bb5-0278-4da9-8e98-562369793366">Yes</ix:nonnumeric>&nbsp;&nbsp;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">☒</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">☐</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tbody><tr><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MjgzMTAwZjAyMTE0NDc2NTg4NmQxZDBkMjkwZGQyYzMvdGFibGVyYW5nZToyODMxMDBmMDIxMTQ0NzY1ODg2ZDFkMGQyOTBkZDJjM18wLTAtMS0xLTEzMTYxOA_23cc4da8-c656-4389-ab13-fa260094c00e">Large accelerated filer</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">☒</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">☐</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">☐ </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MjgzMTAwZjAyMTE0NDc2NTg4NmQxZDBkMjkwZGQyYzMvdGFibGVyYW5nZToyODMxMDBmMDIxMTQ0NzY1ODg2ZDFkMGQyOTBkZDJjM18yLTMtMS0xLTEzMTYxOA_3803a375-2884-4e3c-885f-a8d6276073ed">☐</ix:nonnumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MjgzMTAwZjAyMTE0NDc2NTg4NmQxZDBkMjkwZGQyYzMvdGFibGVyYW5nZToyODMxMDBmMDIxMTQ0NzY1ODg2ZDFkMGQyOTBkZDJjM180LTMtMS0xLTEzMTYxOA_eadaf207-a492-4b84-85ce-c008f43988a1">☐</ix:nonnumeric></span></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">☐</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&nbsp;&nbsp;No&nbsp;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk1_b1dd325d-1306-4e45-bead-28f343ff608e">☒</ix:nonnumeric></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of the close of business on April&nbsp;30, 2023: <ix:nonfraction unitref="shares" contextref="i6f9aa917fb244d03ab52c4fcb13190ea_I20230430" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODg3_be69b0d3-66c6-439c-b4a8-5f68956b99c4">2,537,435,954</ix:nonfraction></span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:3pt;text-align:center"><span><br></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tbody><tr><td style="width:1.0%"></td><td style="width:9.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_16">Condensed Consolidated Statement of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_19">Condensed Consolidated Statement of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_22">Condensed Consolidated Balance Sheet</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_25">Condensed Consolidated Statement of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_31">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_82">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_82">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_115">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_115">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_118">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_121">Cautionary Factors That May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_121">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_124">OTHER INFORMATION </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_124">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_127">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_133">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_136">41</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_139">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_139">42</a></span></div></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Part I - Financial Information</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_13"></div><div style="margin-top:5pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&nbsp;1. Financial Statements</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_16"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:77.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMi0xLTEtMS0xMzE2MTg_22a948dc-764f-4b1e-bd35-1d8c5714fc99">14,487</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMi0zLTEtMS0xMzE2MTg_bce1380b-87c8-407a-9c79-f8ebd0e11ede">15,901</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNC0xLTEtMS0xMzE2MTg_0188d0d0-f266-40a6-aa92-9c61754cf8cd">3,926</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNC0zLTEtMS0xMzE2MTg_2180f02d-8ce8-437f-a4ea-95b8792af6fa">5,380</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNS0xLTEtMS0xMzE2MTg_a4ac50f0-1dea-41f4-b71a-2a24673df9a2">2,479</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNS0zLTEtMS0xMzE2MTg_d408b7de-2761-4d61-ad78-59cbcefdfb94">2,323</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNi0xLTEtMS0xMzE2MTg_9f820cd5-8bcf-49cc-97b7-b6385fd4b003">4,276</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNi0zLTEtMS0xMzE2MTg_756f3780-1e8c-4b78-885d-84bda4f33475">2,576</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNy0xLTEtMS0xMzE2MTg_44827c4c-7eba-4264-80bc-1dd8dfe84c88">67</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNy0zLTEtMS0xMzE2MTg_6b97c534-fe69-4c7d-aa8f-84c89af6340e">53</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOC0xLTEtMS0xMzE2MTg_179cbe9b-cbaf-4611-ab53-9332ca253bc5">89</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOC0zLTEtMS0xMzE2MTg_1b228471-d719-454e-9351-e1fae4b738aa">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOS0xLTEtMS0xMzE2MTg_c5123e2e-a3c4-40cf-8372-89e9fbab2ae2">10,837</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOS0zLTEtMS0xMzE2MTg_0fac0ed5-3cb8-4d9a-8ba9-8bfc51189375">11,040</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTAtMS0xLTEtMTMxNjE4_c02f2f04-f0c9-4239-95ea-5a79557a3f84">3,650</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTAtMy0xLTEtMTMxNjE4_371e37d2-281a-4235-a5a7-2f9333970a21">4,861</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes on Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTEtMS0xLTEtMTMxNjE4_a240005f-5659-4544-bfbf-fb2bb8f88da4">825</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTEtMy0xLTEtMTMxNjE4_af2b2bd1-b7c0-43cd-bb39-01398ec1029f">554</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTItMS0xLTEtMTMxNjE4_6ca2d321-3ded-41ea-9897-2efa2c811ccb">2,825</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTItMy0xLTEtMTMxNjE4_e0f721ab-c987-4e71-a1aa-486327058661">4,307</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net Income (Loss) Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTMtMS0xLTEtMTMxNjE4_1649114a-5201-4188-8214-62f6970413b9">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTMtMy0xLTEtMTMxNjE4_7fad438f-474a-456b-a99b-7c86a6265a87">3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTYtMS0xLTEtMTMxNjE4_43492766-3d70-4de9-80c0-fe2e21a3502c">2,821</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTYtMy0xLTEtMTMxNjE4_56c8a1aa-d900-49af-892d-b9852e0de55b">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjAtMS0xLTEtMTMxNjE4_e06ecac2-0828-4ce4-9b20-1e44c477d8fc">1.11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjAtMy0xLTEtMTMxNjE4_2fd6ca77-c5f7-4bb2-a4e8-670358fdd45e">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjQtMS0xLTEtMTMxNjE4_0ba68e04-477d-4410-a877-9e2049b1916b">1.11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjQtMy0xLTEtMTMxNjE4_613a5df7-687d-42a0-974e-e501b8140487">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:78.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.769%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfMi0xLTEtMS0xMzE2MTg_9d53d2c2-5134-41e9-9d8d-821d9fe93af3">2,821</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfMi0zLTEtMS0xMzE2MTg_6e1f75f4-5afd-48c6-af9c-cbf68de94662">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive (Loss) Income Net of Taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on derivatives, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNC0xLTEtMS0xMzE2MTg_5a7677b3-7232-48b9-a7f4-08a44a47e840">133</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNC0zLTEtMS0xMzE2MTg_9a51891c-672a-4ff0-be38-247e3c6c0521">63</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNS0xLTEtMS0xMzE2MTg_8afa93a5-1374-4939-aac2-b70a3df0387a">50</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNS0zLTEtMS0xMzE2MTg_2fb4cc0c-9b00-4f76-bec4-0de35149ff75">32</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNi0xLTEtMS0xMzE2MTg_68db319a-f0ba-4a40-bd7d-b928d5f6b5c1">68</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNi0zLTEtMS0xMzE2MTg_cb304264-9240-44f2-90ec-ed5bec455ceb">35</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNy0xLTEtMS0xMzE2MTg_bd932dc9-79a6-48a5-8035-e1ec438564a5">115</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNy0zLTEtMS0xMzE2MTg_7861fdb2-ca43-4fc1-b735-949b79991b43">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive Income Attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfOC0xLTEtMS0xMzE2MTg_dc01a782-40da-4aa7-8075-ee8dfa630e14">2,706</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfOC0zLTEtMS0xMzE2MTg_f20970f2-647b-4a21-8e84-be3796791313">4,370</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 3 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEET</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMy0xLTEtMS0xMzE2MTg_967daee1-ff2a-4951-bc69-ef80e6c538bc">9,707</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMy0zLTEtMS0xMzE2MTg_cf16b07d-b043-475c-8128-383bd4d4a8d8">12,694</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNC0xLTEtMS0xMzE2MTg_222f313d-ef29-4b3c-96cc-9f6b9a4a4310">680</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNC0zLTEtMS0xMzE2MTg_6b79232d-6853-4540-a628-11657f6e55d1">498</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable (net of allowance for doubtful accounts of $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjo0OGFhZGQxM2Y1YWY0YTdiOTY2NGU4M2M5MDYxODI2NF82Nw_822fc7ba-dbd7-4ca1-9492-6374e8145232">76</ix:nonfraction> in 2023</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;and $<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjo0OGFhZGQxM2Y1YWY0YTdiOTY2NGU4M2M5MDYxODI2NF84MQ_6f908c8f-6c0a-48ea-9592-adb4ff628a9f">72</ix:nonfraction> in 2022) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0xLTEtMS0xMzE2MTg_1222faae-5699-4374-906d-dbbcd43c9e18">10,415</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0zLTEtMS0xMzE2MTg_2632de83-4d07-44bb-b75e-8cc7340640b2">9,450</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories (excludes inventories of $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjowY2FmNDMwOTI0YzM0ZmZjOWFjMmVhMjcyNWRkNGE5M180Mg_c907277a-5910-4e63-8412-acc88ddbd2f2">3,284</ix:nonfraction> in 2023 and $<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjowY2FmNDMwOTI0YzM0ZmZjOWFjMmVhMjcyNWRkNGE5M181NQ_44add83a-9702-4bc1-9816-2f6bfc0a2114">2,938</ix:nonfraction> in 2022</span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">classified in Other assets - see Note&nbsp;7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0xLTEtMS0xMzE2MTg_3f76f305-e2cc-479b-8fb7-8cc02bdfac01">5,863</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0zLTEtMS0xMzE2MTg_3d3b9b26-6181-4b32-9195-a9aa050fd839">5,911</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNy0xLTEtMS0xMzE2MTg_68f303a5-a8cf-43f1-8d28-342523a8aead">6,737</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNy0zLTEtMS0xMzE2MTg_5b39bf45-6ea2-46c6-b9f1-3af22664561d">7,169</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOC0xLTEtMS0xMzE2MTg_1ca0e339-2d4b-47fe-b39d-6d57bf6bc74b">33,402</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOC0zLTEtMS0xMzE2MTg_88756b45-3286-4a3b-81e1-f3a360f3d9fc">35,722</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOS0xLTEtMS0xMzE2MTg_191b18c6-fc96-4880-8ded-9c835b314eb5">1,290</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOS0zLTEtMS0xMzE2MTg_b252f003-c2a5-48fd-87d8-75270eb6d5df">1,015</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, Plant and Equipment, at cost, net of accumulated depreciation of $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGNjNzRkM2RmNmMyNDVjMmEwOGYwODg5NmNmNjFkZWNfNzk_45b9288c-51fb-4214-8763-27e6779afff4">18,256</ix:nonfraction> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">in 2023 and $<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGNjNzRkM2RmNmMyNDVjMmEwOGYwODg5NmNmNjFkZWNfOTI_e9f6ca0c-9ee9-4abb-b0e1-9239835657f8">17,985</ix:nonfraction> in 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMS0xLTEtMTMxNjE4_1902832c-043f-456e-9b28-17abf435c562">21,758</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMy0xLTEtMTMxNjE4_b3f2922d-1a77-495f-bd89-b28214766485">21,422</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTEtMS0xLTEtMTMxNjE4_4562c099-5b86-4fc2-a7d5-d3f25188e55b">21,209</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTEtMy0xLTEtMTMxNjE4_3c100ee6-afa8-4491-ae7e-905b4718a6f1">21,204</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Intangibles, Net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTItMS0xLTEtMTMxNjE4_7787aa44-dccd-4963-95c4-6b8884765d64">19,857</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTItMy0xLTEtMTMxNjE4_9987f72b-9b7a-46b2-b5e6-3c6844a32e71">20,269</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTMtMS0xLTEtMTMxNjE4_e0cb0b02-4494-4513-bbb2-59c39256d635">10,280</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTMtMy0xLTEtMTMxNjE4_b41112bc-0d60-4e46-9eb8-9baefef41f5b">9,528</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTQtMS0xLTEtMTMxNjE4_0df0d197-c2c8-4ced-b066-1f734f6fd62d">107,796</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTQtMy0xLTEtMTMxNjE4_555c1f83-c6ba-4b93-bd57-2375723dd275">109,160</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTctMS0xLTEtMTMxNjE4_96023f21-9b9f-4413-a412-3cf6d8317a09">2,672</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTctMy0xLTEtMTMxNjE4_23570947-3333-4116-872a-27e71fb6fada">1,946</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTgtMS0xLTEtMTMxNjE4_30919281-ef34-4152-86a0-6130039359d2">3,680</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTgtMy0xLTEtMTMxNjE4_de982a18-bde9-4a2f-8703-5aa1e4467f8e">4,264</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTktMS0xLTEtMTMxNjE4_5c75670e-171d-4642-809e-b2629b0a969e">13,000</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTktMy0xLTEtMTMxNjE4_941ff79c-e2eb-44b7-98cd-aabe27fb1454">14,159</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjAtMS0xLTEtMTMxNjE4_8d3cb187-9ac4-4ea7-9401-18e573106cf0">1,872</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjAtMy0xLTEtMTMxNjE4_83596902-72c3-4b8a-9664-ac7d0752b626">1,986</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjEtMS0xLTEtMTMxNjE4_a730ca51-dd3b-4e99-960b-f32420625ed9">1,907</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjEtMy0xLTEtMTMxNjE4_bb244e75-0734-4718-a367-5934625c9927">1,884</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjItMS0xLTEtMTMxNjE4_3d9d8385-c265-4769-8757-ac8133ea94d5">23,131</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjItMy0xLTEtMTMxNjE4_b9c1605e-67f6-4b9d-9fbe-313dce0ab1be">24,239</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjMtMS0xLTEtMTMxNjE4_7e905a0e-7f44-487a-a3aa-fe584eacf25d">28,074</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjMtMy0xLTEtMTMxNjE4_f846fcd2-b793-4a77-9d0f-945e2daa5251">28,745</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjQtMS0xLTEtMTMxNjE4_e559db80-b288-453f-b0dd-14928d9eb67d">1,442</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjQtMy0xLTEtMTMxNjE4_da5652c4-91bd-4a1b-8b13-03f6c5c5f9ef">1,795</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjUtMS0xLTEtMTMxNjE4_759565f5-2ba5-4057-ac81-f8818f03e6d0">8,244</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjUtMy0xLTEtMTMxNjE4_246b808e-19fc-45ce-8028-70f9bc85e926">8,323</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck&nbsp;&amp; Co., Inc. Stockholders’ Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonfraction unitref="usdPerShare" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfMTk_128e47ea-16fc-48b1-a3d1-a39408894e0c"><ix:nonfraction unitref="usdPerShare" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfMTk_504cabe0-2ba9-4258-9d7f-3be08ef9fb82">0.50</ix:nonfraction></ix:nonfraction> par value</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Authorized - <ix:nonfraction unitref="shares" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNDU_5388a816-78d9-49f3-bcbb-4ece1514df88"><ix:nonfraction unitref="shares" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNDU_a3209d0f-d4dc-4731-b6a7-7268823b40b6">6,500,000,000</ix:nonfraction></ix:nonfraction> shares</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued - <ix:nonfraction unitref="shares" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNjQ_341472b4-707a-4453-ab41-60dfa82eaa9b"><ix:nonfraction unitref="shares" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNjQ_993b83ae-b115-4843-a85c-55f40f10efe8">3,577,103,522</ix:nonfraction></ix:nonfraction> shares in 2023 and 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMS0xLTEtMTMxNjE4_79fb7564-56ee-4d60-986f-f2042d770186">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMy0xLTEtMTMxNjE4_7b227f27-ff2b-469a-9e6d-18d2de2a2ec3">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjgtMS0xLTEtMTMxNjE4_da6468c1-42c2-46fa-99f8-5e51d9f1c397">44,467</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjgtMy0xLTEtMTMxNjE4_70bb3dbd-e09a-4850-88ea-f4844bd6a1d2">44,379</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjktMS0xLTEtMTMxNjE4_cca8165e-e648-4706-bbb1-f09f38f5a380">62,039</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjktMy0xLTEtMTMxNjE4_3bd92cbf-1e13-437b-a6bd-77c654470344">61,081</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzAtMS0xLTEtMTMxNjE4_b12dd89a-1d1c-47e7-ad14-8c5484cb4f6f">4,883</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzAtMy0xLTEtMTMxNjE4_aa72c78d-ec8d-4799-8c47-978ea8205ec5">4,768</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzEtMS0xLTEtMTMxNjE4_3d85a20a-fe4f-4877-adb6-379299a33c60">103,411</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzEtMy0xLTEtMTMxNjE4_66806729-0f43-42d4-9a45-d7ac807dbed8">102,480</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less treasury stock, at cost:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGQxMGIwNzYwNTM1NDlmMmFjZDZmNjgyMTEyODZkZTVfMzU_4156c5c2-2f3b-4715-8897-8ac783d34baf">1,039,651,210</ix:nonfraction> shares in 2023 and <ix:nonfraction unitref="shares" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGQxMGIwNzYwNTM1NDlmMmFjZDZmNjgyMTEyODZkZTVfNTU_b610ec30-f8ec-4c4f-9476-dbf7523bb992">1,039,269,638</ix:nonfraction> shares in 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMS0xLTEtMTMxNjE4_461a7221-c005-40d5-906e-a0ced02e8a6c">56,577</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMy0xLTEtMTMxNjE4_a783c954-4094-44da-afd5-b3063453d865">56,489</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Merck&nbsp;&amp; Co., Inc. stockholders’ equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzMtMS0xLTEtMTMxNjE4_5d07777d-2ea2-4207-81ce-86b701e6e164">46,834</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzMtMy0xLTEtMTMxNjE4_424582a5-e3c9-4ebf-9c9a-8325609abc41">45,991</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzQtMS0xLTEtMTMxNjE4_f8989083-de67-4ad3-bf49-2871f5d529e2">71</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzQtMy0xLTEtMTMxNjE4_859d6f87-7d8d-4a30-b9e1-e33e12ca7467">67</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzUtMS0xLTEtMTMxNjE4_09113873-7a8f-4863-868e-d7c1db560549">46,905</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzUtMy0xLTEtMTMxNjE4_fbdb4efa-b44f-467c-9479-6f8dc058ec69">46,058</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzYtMS0xLTEtMTMxNjE4_986ca522-42af-495a-8d5c-73ec54bd96fe">107,796</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzYtMy0xLTEtMTMxNjE4_0dd841fe-3632-4023-8da8-907dd5c192a4">109,160</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 4 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMy0xLTEtMS0xMzE2MTg_96df26bc-b065-421d-9b4b-f29e1526bc5e">2,825</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMy0zLTEtMS0xMzE2MTg_d973dad5-1be3-4ae4-976a-1698ee71f3ea">4,307</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNS0xLTEtMS0xMzE2MTg_d90c522f-6883-4fb5-bf24-932945d33689">543</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNS0zLTEtMS0xMzE2MTg_dec9ed94-267c-42fc-8d0e-ee1e62a82fc3">699</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNi0xLTEtMS0xMzE2MTg_b5531913-afe0-4a79-aaea-92497ee62209">448</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNi0zLTEtMS0xMzE2MTg_979a722b-8726-47dd-ae20-57e44456acf2">421</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOC0xLTEtMS0xMzE2MTg_f770899b-d54c-4209-9c23-6d6e75dccda4">450</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOC0zLTEtMS0xMzE2MTg_16542396-21c6-4733-a312-03bcbd4a33f1">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of Imago BioSciences, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOS0xLTEtMS0xMzE2MTg_bc25a7bf-4cea-43c8-8289-40019cf71366">1,192</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOS0zLTEtMS0xMzE2MTg_263abef6-bec6-41af-9959-6ace0ce88fcc">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTAtMS0xLTEtMTMxNjE4_0de064bb-1471-4c23-b18e-ea756677c8aa">277</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTAtMy0xLTEtMTMxNjE4_d5beb90c-dfa4-4c17-a15e-1cf6443250b7">338</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTEtMS0xLTEtMTMxNjE4_1696e982-58c0-41ab-a25d-8c5349da8e33">145</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTEtMy0xLTEtMTMxNjE4_f6ba5549-ebbc-4423-bd0b-c0b78a6431eb">120</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTItMS0xLTEtMTMxNjE4_6f34df55-0d21-410f-9940-256f6a21d765">197</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTItMy0xLTEtMTMxNjE4_124ca8e5-2693-42b6-bcdd-2688d99aedd2">143</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net changes in assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTMtMS0xLTEtMTMxNjE4_bd556e0f-f8b2-4c05-95af-01089814842a">2,890</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTMtMy0xLTEtMTMxNjE4_d4095305-7596-4cc2-9835-39d54c0ed506">1,299</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Cash Provided by Operating Activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTQtMS0xLTEtMTMxNjE4_d4fa6fde-1e10-4b5e-8a1f-81058bd4bc86">1,339</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTQtMy0xLTEtMTMxNjE4_bf1fd024-50c7-49e6-a734-16e6ac7ca85d">4,761</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTYtMS0xLTEtMTMxNjE4_d1497e77-af35-4705-a186-9a00da0399b9">1,007</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTYtMy0xLTEtMTMxNjE4_60dd1360-f35f-417f-aeb4-8f3cdf07fdbf">984</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of securities and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTctMS0xLTEtMTMxNjE4_485191f7-5ee4-4524-b344-fedabc168793">562</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTctMy0xLTEtMTMxNjE4_12420839-30b0-4a6f-885c-cfe8d9051c4f">372</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of securities and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTgtMS0xLTEtMTMxNjE4_621f6940-d559-4c6f-9c20-b5d0d60f38f5">500</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTgtMy0xLTEtMTMxNjE4_92e6b1fe-156e-49da-8aac-385142f90edc">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Imago BioSciences, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTktMS0xLTEtMTMxNjE4_a16e09fe-9bab-4028-b7f4-62014a0f001f">1,327</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTktMy0xLTEtMTMxNjE4_457175af-1125-4f41-ae7f-ffd55d717a9a">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjEtMS0xLTEtMTMxNjE4_9fcf7baf-941d-4861-86d5-fadb2ce37601">37</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjEtMy0xLTEtMTMxNjE4_042b8b62-02b2-4cab-8dac-173b990d06e5">182</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjItMS0xLTEtMTMxNjE4_dde27029-013a-4f21-9d1d-da96e9b5c8e2">2,359</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjItMy0xLTEtMTMxNjE4_3d3e0417-06f2-4516-a14e-3d98aede7085">1,173</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjUtMS0xLTEtMTMxNjE4_5aad0010-ef4c-45b6-8002-7e8c4d53da42">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjUtMy0xLTEtMTMxNjE4_78e76ae4-7af1-4a54-9154-39553da4bd71">1,250</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjctMS0xLTEtMTMxNjE4_34a99e25-8882-4dbb-99f4-0a118d022c7b">149</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjctMy0xLTEtMTMxNjE4_547ab818-36b8-46c6-8216-1f164b119103">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends paid to stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjgtMS0xLTEtMTMxNjE4_a9e81bee-bfbb-4c85-a95f-51adb653ac90">1,853</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjgtMy0xLTEtMTMxNjE4_887f60e0-ce30-4a24-9aa1-c194599fab6f">1,745</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjktMS0xLTEtMTMxNjE4_9fda3d61-3899-45cb-afdb-726d11db379a">30</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjktMy0xLTEtMTMxNjE4_ae6beb2f-1113-4127-974b-19e7718f0947">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzAtMS0xLTEtMTMxNjE4_84a0d387-1f44-49fd-a73b-1f3774e740f0">81</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzAtMy0xLTEtMTMxNjE4_6f818a21-e15d-4163-93dc-c948bf8acf5d">103</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Cash Used in Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzEtMS0xLTEtMTMxNjE4_a29a9e77-4dba-4e43-808d-2537b985aa5f">2,054</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzEtMy0xLTEtMTMxNjE4_a5a219d0-be6a-4d13-8306-9c72bfe5372d">3,086</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzctMS0xLTEtMTMxNjE4_cc1d4d3f-1239-48a6-9633-85cd7548fcc8">87</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzctMy0xLTEtMTMxNjE4_e5fd50f1-af3c-44b9-9ac2-f6863a65efdc">55</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzgtMS0xLTEtMTMxNjE4_6f769ff9-7bc0-4809-a8a1-cb9bd2cd4327">2,987</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzgtMy0xLTEtMTMxNjE4_b2fb9306-ccd7-4c95-8e12-84beb46b61dd">447</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZTQwNmNiNmMwNWZjNDI3Y2I0ODk3ZjkyMGI2ZDgxYTBfOTg_9415480a-1c90-4b11-a9f7-715a776bda3e">79</ix:nonfraction> and $<ix:nonfraction unitref="usd" contextref="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZTQwNmNiNmMwNWZjNDI3Y2I0ODk3ZjkyMGI2ZDgxYTBfMTA1_864b1408-ebf8-4800-a362-7266f39b0329">71</ix:nonfraction> at January 1, 2023 and 2022, respectively, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMS0xLTEtMTMxNjE4_c330c56f-4e92-499f-ab27-745afc28c960">12,773</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMy0xLTEtMTMxNjE4_e1bb938c-2e47-4577-9f92-528f4ad0ee01">8,167</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZDRjYjdjYjExZDRmNGEwYjllZWY0ZGNkNGFhZTQ3YTdfOTM_4136cb22-f5b0-48ae-9788-19eeb5a2ec2c">79</ix:nonfraction> </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and $<ix:nonfraction unitref="usd" contextref="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZDRjYjdjYjExZDRmNGEwYjllZWY0ZGNkNGFhZTQ3YTdfMTAx_b39ba864-55bf-43af-b36b-ee05f41e4d25">58</ix:nonfraction> at March&nbsp;31, 2023 and 2022, respectively, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMS0xLTEtMTMxNjE4_5e444c09-8ef4-47ec-a166-77e567aa8423">9,786</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMy0xLTEtMTMxNjE4_2f82e097-732a-4893-bc44-d945a285b65d">8,614</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 5 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><div style="text-align:justify"><span><br></span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_31"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1.    <ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfNTIzNA_c8ad131b-6693-448d-bbd5-b63555253a56" continuedat="i24e8f43604e34b07bbba9e8ea2dde53a" escape="true"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfNTIzNQ_be0e9094-f28a-4ad5-bc4b-deefad9b251e" continuedat="i1e30c1b455044ee5a97e3d654002065f" escape="true">Basis of Presentation</ix:nonnumeric></ix:nonnumeric></span></div><ix:continuation id="i1e30c1b455044ee5a97e3d654002065f" continuedat="i5a1ab3d0b4f64632935d15cd40f64de6"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i24e8f43604e34b07bbba9e8ea2dde53a" continuedat="iccc0a77790fa49f2998c53f9bcb8968a">The accompanying unaudited condensed consolidated financial statements of Merck&nbsp;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February&nbsp;24, 2023. </ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="iccc0a77790fa49f2998c53f9bcb8968a">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.</ix:continuation> <ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfMjc0ODc3OTA4NDAyOA_2b498c63-3def-40b4-ba4d-64960898e05f" escape="true">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</ix:nonnumeric></span></div><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfNTIzNw_c72c5834-99e5-4a52-a79f-874615827d46" continuedat="ifd0592ca47024d039cf9a6878e440cab" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standard</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard Not Yet Adopted</span></div></ix:nonnumeric></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i5a1ab3d0b4f64632935d15cd40f64de6"><ix:continuation id="ifd0592ca47024d039cf9a6878e440cab">In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption</ix:continuation></ix:continuation>. </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_40"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTA0ODY_07d1381a-5073-4c20-9340-d3077ff62e74" continuedat="i3fa3ce8621c7476e99a0489dad5c8030" escape="true">Acquisitions, Research Collaborations and Licensing Agreements</ix:nonnumeric></span></div><ix:continuation id="i3fa3ce8621c7476e99a0489dad5c8030" continuedat="i48fc4b45a466458f9160f80c0e908e8e"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus’ lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $<ix:nonfraction unitref="usdPerShare" contextref="i1302ee97335a4b8a864d880d15a75ffd_I20230430" decimals="2" name="mrk:AssetAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfNTQ5NzU1ODM4Mzg3_d4c63538-f831-47fe-97bf-4ae60d30ba4d">200</ix:nonfraction> per share in cash for a total equity value of approximately $<ix:nonfraction unitref="usd" contextref="i2c03ed79efac404d85fb217647f60f9e_D20230401-20230430" decimals="-8" name="us-gaap:AssetAcquisitionPriceOfAcquisitionExpected" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfNTQ5NzU1ODM4Mzc5_a5ddbb2e-e454-48d8-b02f-37b14b029855">10.8</ix:nonfraction> billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $<ix:nonfraction unitref="usd" contextref="id017497421574c008e33bacea591637e_D20230701-20230930" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfNTQ5NzU1ODM5MDQz_614062ba-076a-491b-a741-beef8d298826">10.3</ix:nonfraction>&nbsp;billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $<ix:nonfraction unitref="usd" contextref="i1e8e4ea1abaf40778222b2bb6dcfb639_D20230201-20230228" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDU2OA_ce532234-2516-49a3-a45c-3e4563d6c39f">175</ix:nonfraction> million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $<ix:nonfraction unitref="usd" contextref="ib9dedd741503427183ecc62df92f5085_I20230228" decimals="-8" name="mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDU4NA_7c1b2c89-c79e-43d3-8e94-a6e5875046db">1.0</ix:nonfraction> billion, $<ix:nonfraction unitref="usd" contextref="ib9dedd741503427183ecc62df92f5085_I20230228" decimals="-8" name="mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDYwMg_0f19d466-0cbe-4518-b989-72855a941e0a">2.8</ix:nonfraction> billion in regulatory milestones, and $<ix:nonfraction unitref="usd" contextref="ib9dedd741503427183ecc62df92f5085_I20230228" decimals="-8" name="mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDYxOA_6f4bc67c-fc4e-48bd-92f1-367c2868853f">5.5</ix:nonfraction> billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $<ix:nonfraction unitref="usd" contextref="i3c175c60a55e4c3eb9ac840966e13ebf_I20230131" decimals="-6" name="mrk:CollaborativeArrangementPreferredStockInvestmentInCounterparty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDYzNA_a4e29fb2-141c-487d-a9dc-93ba5790ad83">100</ix:nonfraction> million in Kelun-Biotech’s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $<ix:nonfraction unitref="usd" contextref="i609e1582535d4dfb834b95904e849c27_D20230101-20230131" decimals="-7" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY1MQ_5cbcd9f1-00c7-4a03-9f41-13945323aab5">1.35</ix:nonfraction> billion </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 6 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i48fc4b45a466458f9160f80c0e908e8e"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(including payments to settle share-based equity awards) and also incurred approximately $<ix:nonfraction unitref="usd" contextref="i609e1582535d4dfb834b95904e849c27_D20230101-20230131" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY4Nw_77edc5e1-884d-4bb6-ab2b-f1846940a192">60</ix:nonfraction>&nbsp;million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $<ix:nonfraction unitref="usd" contextref="i8f3adb7e1a4d42dd925db11dbf71eac5_I20230131" decimals="-6" name="mrk:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY4Mw_654d2a2e-1736-4ca5-9721-99373993720e">219</ix:nonfraction> million, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $<ix:nonfraction unitref="usd" contextref="i609e1582535d4dfb834b95904e849c27_D20230101-20230131" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY2Nw_9303e97a-c62b-475e-b1ff-9e4f0e3b2f10">1.2</ix:nonfraction> billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></ix:continuation></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_43"></div><div style="margin-top:15pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE2NDQ_1c37924b-3e7c-4c80-8b87-e898179b99e7" continuedat="i5fe098dab8694a46a5ee8f44afec41e9" escape="true">Collaborative Arrangements</ix:nonnumeric></span></div><ix:continuation id="i5fe098dab8694a46a5ee8f44afec41e9" continuedat="ica67ba0d241a433f932b911fe84143f5"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&nbsp;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&nbsp;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $<ix:nonfraction unitref="usd" contextref="i58a876d3681e4986805915e1bac18ff1_D20220101-20220331" decimals="-6" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjE3Mw_b56b74e0-0535-4054-9690-16a469ab5856">600</ix:nonfraction>&nbsp;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $<ix:nonfraction unitref="usd" contextref="i3c3d2c4bb8cc45efb4e93d046dd6a753_I20220331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjI2Mw_c9c8ddb2-95d1-46ef-9bf9-d3eda777afcb">600</ix:nonfraction>&nbsp;million liability (which remained accrued at March 31, 2023) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $<ix:nonfraction unitref="usd" contextref="i6a91adde5a68413fbc1cfab655dbcbe6_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjM3Mg_dce96547-b25d-4615-b1f8-f1ac4fd3a91e">250</ix:nonfraction>&nbsp;million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. Also in the first quarter of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $<ix:nonfraction unitref="usd" contextref="i350e44c40f67467ba477b370f98d41fc_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjYyNw_f41fe619-0e01-4c3b-a78c-60b89ae7a08c">400</ix:nonfraction>&nbsp;million. Potential future sales-based milestone payments of $<ix:nonfraction unitref="usd" contextref="id6b1412b32dd45bf9b2dc2c9740d6c6f_I20230331" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjc2MA_e59d6705-d747-42e9-86fa-6bbabcc85ac5">2.1</ix:nonfraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2023, Merck made a regulatory milestone payment to AstraZeneca (which had been previously accrued for) of $<ix:nonfraction unitref="usd" contextref="i71ce1d5e1bd141539620a96cb8b2ec10_I20221231" decimals="-6" name="mrk:CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzg0ODI5MDcxNjA5Ng_f445abb1-99a6-4c1c-8e73-b288eeef069a">105</ix:nonfraction>&nbsp;million. In 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $<ix:nonfraction unitref="usd" contextref="idf9cd10c9efe4059a13ad6f64f232a85_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjk3Mg_3f2815ff-b48a-427c-86a5-7933c1e6eb84">250</ix:nonfraction>&nbsp;million from Merck to AstraZeneca. Potential future regulatory milestone payments of $<ix:nonfraction unitref="usd" contextref="id6b1412b32dd45bf9b2dc2c9740d6c6f_I20230331" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsRegulatory" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzA1Mg_864b5908-03da-4517-8564-21624333da2e">1.1</ix:nonfraction> billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonfraction unitref="usd" contextref="i654e8b5924d8442fa9eb55859bbc8647_I20230331" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzIxMQ_e0014abc-695c-4555-b300-4c43a2adb0e5">1.5</ix:nonfraction> billion at March&nbsp;31, 2023 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 7 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ica67ba0d241a433f932b911fe84143f5" continuedat="id0cd72df7b02460784d57bb56560359d"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE2NTc_3c242269-2707-49af-af00-29a650ff88ce" continuedat="i7fd958410862453fb5c377626a03a601" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:82.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib681c644ca864f3286e965d6d7324aa4_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMi0xLTEtMS0xMzE2MTg_74799bc7-1ca0-4041-a9d1-784e79d4724a">275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide79c33fd45c49b19bce108416c71788_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMi0zLTEtMS0xMzE2MTg_2445dbff-4eb4-46d6-b22b-4a8bf9abe3c1">266</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i525916f3d1464ab9b6f291401c761233_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMy0xLTEtMS0xMzE2MTg_d0a05f97-6fd7-4ee2-8d43-c2faa2305371">23</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e95ebf7c1884a0396c7c91a0e223ee6_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMy0zLTEtMS0xMzE2MTg_6afd9307-c819-4227-a213-cdfe99dd151c">9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c6d877e0a5147208fe56690fbb929b0_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNC0xLTEtMS0xMzE2MTg_b2155d73-8814-4f50-bf37-8ed20429ee2e">298</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4cdf23392f5642ba818b20d852b014a9_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNC0zLTEtMS0xMzE2MTg_be895c9b-c589-47d8-914e-8187cb5166aa">275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46e9161a43a44a2fa59e52960034468a_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNi0xLTEtMS0xMzE2MTg_a68e8f3c-31d9-45e0-9bdd-7df16a360b50">70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i71ffa17774c44d2287fe9111206866c3_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNi0zLTEtMS0xMzE2MTg_2f37606e-2c17-448f-820a-d0d9575d6d07">299</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba6c247720a049d28349afa51cec42a7_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNy0xLTEtMS0xMzE2MTg_510db6bc-d4e3-4767-9ad1-0f39921b337d">47</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id22834ff470f4f1aa7da131a94ad1d29_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNy0zLTEtMS0xMzE2MTg_941eda5a-d0e6-4139-80a2-5e8d720047eb">44</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6500964c8d3f4d06b28f3f23cada56e5_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfOC0xLTEtMS0xMzE2MTg_ac61b060-8225-4634-a588-fa0168539d11">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifc2de578164e434980f14d63a2153220_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfOC0zLTEtMS0xMzE2MTg_e788dba8-1bd1-4ec6-9893-12a63f3d4f63">26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5973fb4a5d684bcca7a62270623ac406_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTEtMS0xLTEtMTM1MDU5_854b54f9-ca63-4780-8dfd-acdedb4a61e9">303</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb9ff33d56484784be92a715ee774c2d_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTEtMy0xLTEtMTM1MDU5_fbaf5877-e3f0-4f5a-ac6f-fc1171938592">303</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife24131bdfa1419d8d2708d8b616e5b9_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTItMS0xLTEtMTM1MDU5_c5b00a61-6e39-4056-add7-365bf9702589">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icaae108da197453bb8b3b58a2cd21d7c_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTItMy0xLTEtMTM1MDU5_6742257a-287b-4aca-92f9-3599893f8593">123</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i492255c072c74c9f8a70fdd6212cfe65_I20230331" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTMtMS0xLTEtMTM1MDU5_c8186b42-96de-4c6d-8a64-2e65cbc35478">600</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie92cc5b201cf42e9a6a395bf77ad597c_I20221231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTMtMy0xLTEtMTM1MDU5_e8fdc6fd-77eb-48b2-9a4f-25a04e1cd41a">600</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $<ix:nonfraction unitref="usd" contextref="i46e9161a43a44a2fa59e52960034468a_D20230101-20230331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzYwNQ_37b61bd6-0fe6-42cb-b27c-7f980b54667a">250</ix:nonfraction>&nbsp;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:nonnumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $<ix:nonfraction unitref="usd" contextref="i00731f51ddd64c099bf1f3a866d6e0ff_D20230101-20230331" decimals="-6" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDA4Nw_b29673ef-c363-4cab-8a66-34060a0c9421">125</ix:nonfraction>&nbsp;million sales-based milestone payment from Merck to Eisai. Accordingly, Merck recorded a $<ix:nonfraction unitref="usd" contextref="ia8a01e007c934b3285178dc642a890ea_I20230331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDEwMQ_e986925c-8b1f-43b7-b251-90b33e20d1b3">125</ix:nonfraction>&nbsp;million liability and a corresponding increase to the intangible asset related to Lenvima. Merck also recognized $<ix:nonfraction unitref="usd" contextref="ibcf5abe1e04c438f81048ecae5f02ed4_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDI2MQ_00156a08-5ef2-4cba-8d1f-d66362e0fc04">72</ix:nonfraction>&nbsp;million of cumulative amortization catch-up expense related to the recognition of this milestone. In 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $<ix:nonfraction unitref="usd" contextref="i364cafd01c114c558bf6c571df9b34b1_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTI1Ng_013770cb-4688-4be6-868d-9d2308d196ff">600</ix:nonfraction> million (of which $<ix:nonfraction unitref="usd" contextref="i2d145059533c4960b5fc110813a1fdbf_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzg0ODI5MDcxNjExMA_41529f8d-a1b5-4d86-850a-3113422a1d37">300</ix:nonfraction>&nbsp;million was paid in the first quarter of 2022). Potential future sales-based milestone payments of $<ix:nonfraction unitref="usd" contextref="ief58ac433ad9415a802f0001cc903fa8_I20230331" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTMxMQ_07a0f1e3-df84-4466-b4a2-795fe78eb01e">2.4</ix:nonfraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $<ix:nonfraction unitref="usd" contextref="i364cafd01c114c558bf6c571df9b34b1_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTUyMg_24f3de46-2e58-4eca-90c0-8a6a4db624ba">50</ix:nonfraction>&nbsp;million from Merck to Eisai (of which $<ix:nonfraction unitref="usd" contextref="i2d145059533c4960b5fc110813a1fdbf_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzg0ODI5MDcxNjEyNA_1f0e6b02-7acf-4fff-aafc-0b0fe0d4499f">25</ix:nonfraction>&nbsp;million was paid in the first quarter of 2022). There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonfraction unitref="usd" contextref="ifde6e88a8c324b84b8e1ac90ed088a69_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTc0Nw_aadc8296-443e-45d9-abc8-4b055cf6fc05">812</ix:nonfraction> million at March&nbsp;31, 2023 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 8 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="id0cd72df7b02460784d57bb56560359d" continuedat="i30bf41d5bf9d483fabf7abc80e674a5f"><ix:continuation id="i7fd958410862453fb5c377626a03a601" continuedat="i6a660a5e740143c88e7b0bad6f66f976"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.674%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e956d6285d1456abb720e32551e7288_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMi0xLTEtMS0xMzE2MTg_5704adaf-06bf-4c77-a032-5b6148ea4449">232</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3779054dfc7a4a51b4e90d43a5ac3684_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMi0zLTEtMS0xMzE2MTg_b4106292-b8b0-40bc-bbc4-9ca2f8ca4b31">227</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib7eff0028e2f4952bfe2bb459510ff9f_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNC0xLTEtMS0xMzE2MTg_4fba7867-22c0-4102-9fb4-22bb6a55f2f5">126</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia56fd7048ad14abf96162c372b142909_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNC0zLTEtMS0xMzE2MTg_c1927729-3453-42d1-b7b2-1c0d658d7e49">53</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iace54ff30d73465189a461975d7b6b99_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNS0xLTEtMS0xMzE2MTg_cf0131c2-2434-4c9f-b1d1-9bb902dce42f">51</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1e72c11f4d449889cefb13617918cd0_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNS0zLTEtMS0xMzE2MTg_b3620da4-3001-4e38-add8-957229556c9a">31</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d825d4c2aa44c79bf5a2366a7a86a9b_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNi0xLTEtMS0xMzE2MTg_1d608a63-360d-4e67-baf3-36d2d5ac8709">39</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6c9458bb97f476b867db620d779e5fb_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNi0zLTEtMS0xMzE2MTg_8f2be031-2a7b-4b31-9087-eadee4437a0a">57</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie01022120e7d4f7cb61fb037b2355db5_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfOS0xLTEtMS0xMzUwNzI_ebf8203c-9b93-4f0c-b124-e3c4d8cb08f0">244</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if29e83faad31423b801afdcfcba98e44_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfOS0zLTEtMS0xMzUwNzI_efd8494d-cbee-4cb1-969e-2786013d9dc2">214</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a73485be36248258f5601b826d7bfed_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMTAtMS0xLTEtMTM1MDcy_63caf6e9-fbe8-4a2f-8936-3ed71bc08231">125</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d20b318541f4dd2831d35fd11a17b0f_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMTAtMy0xLTEtMTM1MDcy_950c665c-6fe0-497f-a721-2429be7cbc57">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $<ix:nonfraction unitref="usd" contextref="ibcf5abe1e04c438f81048ecae5f02ed4_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDUyOA_605e6f9f-ddab-4fd3-a609-fb8f81ecce5a">72</ix:nonfraction>&nbsp;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S., the European Union (EU) and Japan in 2021, and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In the first quarter of 2022, Merck made the final $<ix:nonfraction unitref="usd" contextref="i3399af7b61814371b4415a2165606deb_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNzUwMQ_86568ae3-2a89-4b8f-a220-fe9f79af8dca">400</ix:nonfraction> million sales-based milestone payment under this collaboration to Bayer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $<ix:nonfraction unitref="usd" contextref="i80a8ac9e73b64ff18bab741a42d8fdcd_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNzg3MA_431359ce-6d67-4076-8b06-01b44e89df07">613</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i260c8037bbf543e0aa66e359ab18b50f_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNzg3Nw_dbb0fcf2-9914-4459-9f9e-0c340834576d">56</ix:nonfraction> million, respectively, at March&nbsp;31, 2023 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. </span></div><ix:continuation id="i6a660a5e740143c88e7b0bad6f66f976" continuedat="i01ac50b0494a41c3969c743d5b80e870"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ea6ddc3ada9445c95b033d7e07dd561_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMi0xLTEtMS0xMzE2MTg_bee6db62-be92-422b-8426-ff8cac6972d4">99</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idaa0511b79e949c7a6547505b9ae5551_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMi0zLTEtMS0xMzE2MTg_3861b94a-aa37-4fff-b524-d2f4bb8521a0">72</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8e52ba3989df4480ab8a8c4136af64aa_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMy0xLTEtMS0xMzE2MTg_fc0d7477-fe6b-4792-8abc-07b33daafeba">59</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i68f851c07e23480aa9ff233e42d37d7a_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMy0zLTEtMS0xMzE2MTg_ff653039-52c5-4302-8654-7717b393fbb9">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6191c4207cdc459d90d7c79d3e4e64e5_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNC0xLTEtMS0xMzE2MTg_04da46d6-2120-41d1-b059-ca09e33c2341">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icbe1869e706149f48a2091f4b9534dd9_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNC0zLTEtMS0xMzE2MTg_084b60d3-b978-487a-bf1b-40c2143d9508">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ea6ddc3ada9445c95b033d7e07dd561_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNS0xLTEtMS0xMzE2MTg_cf129a58-23ac-4ee9-8614-df5b63a53506">165</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idaa0511b79e949c7a6547505b9ae5551_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNS0zLTEtMS0xMzE2MTg_f9d25f4a-8836-467d-bf76-1dcf058258bb">136</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ef0c87d5feb45e381dc0a07c2d16382_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNy0xLTEtMS0xMzE2MTg_6c504c59-edb6-429f-b395-4b500f6e9560">57</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i63cb28ee8d6845b3bc89ee74ee01ff67_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNy0zLTEtMS0xMzE2MTg_ae266853-f516-4de1-9bbc-b7946cdd4760">50</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i58e10bfa620942c4bcb811e0f171d36b_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOC0xLTEtMS0xMzE2MTg_48b431af-91b6-46c3-8b7f-926ced1a0cad">33</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e3019b3c61c4b70a15610624c8a4983_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOC0zLTEtMS0xMzE2MTg_6f5cd3da-684a-434e-b53f-d0f2c213d7a3">23</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i650127b972c04c1cbed3bec6d5fdfa9b_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOS0xLTEtMS0xMzE2MTg_3e26c119-276d-40f4-9a44-b046efc7a254">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib2ae3db4c9364ff8843c87c364bab42b_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOS0zLTEtMS0xMzE2MTg_09db9b21-8a8b-4c8d-810e-1d2f92316943">17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9056f175eca54119943d05559433e20d_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTEtMS0xLTEtMTM1MDkw_565df713-1d25-4420-b05c-4af6f3a39e85">142</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib66da4be09b7447ab23b1c1811b5724d_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTEtMy0xLTEtMTM1MDkw_6de8499f-c9bf-4d75-b520-7100e5db6bba">143</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i36c8f57b20ce4f26a522df11b2be6320_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTItMS0xLTEtMTM1MDkw_5d84ed63-e6e7-4fba-b06a-66279c3afc44">68</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i644d973253b54d3e94a4aa3644bbe995_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTItMy0xLTEtMTM1MDkw_e27df872-02ba-4cda-98e5-10f393e99d9c">80</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. </span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 9 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i30bf41d5bf9d483fabf7abc80e674a5f"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><ix:continuation id="i01ac50b0494a41c3969c743d5b80e870"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie2a085dfeaeb40a083f13e8a59287e8c_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfMi0xLTEtMS0xMzE2MTg_67a5aab8-5077-4e5f-88fa-025487baace4">392</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5173a42466784ad9a8ffe86302cb3b87_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfMi0zLTEtMS0xMzE2MTg_9056897f-e7c4-4892-a7a1-facb86398168">3,247</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iebdfd787169843bcaba790e915fc305b_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNC0xLTEtMS0xMzE2MTg_2473cf88-0755-486e-9e2b-48342ce2077f">221</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd3bb7ee67904313b2975cfef294c50b_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNC0zLTEtMS0xMzE2MTg_1bec1812-312a-4d69-8255-c92dc59a04aa">1,726</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice904109d2ef48fd8e8ed1324f5c2c59_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNS0xLTEtMS0xMzE2MTg_22b3e4c4-e28a-478a-9fca-aafba988135a">27</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic51d50d985d84a3f8f588fda28be3ce3_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNS0zLTEtMS0xMzE2MTg_9862c8c0-3a0e-4e86-905a-e6006d1189a5">35</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i25207351676d4c9e9e6961bf25936afd_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNi0xLTEtMS0xMzE2MTg_425e7ca2-e1d0-4e0f-b08b-a454303317c5">16</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d5dff37e3ab4823ab8be6c8611cc6d4_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNi0zLTEtMS0xMzE2MTg_c5a0a898-96ee-4e25-a5e2-4cec541e804d">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2404a6eca015453d8c2bb0e08613ae7b_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfOS0xLTEtMS0xMzUxMjE_8e2b2622-60c6-4834-8027-b1eece7661b2">191</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iec1c506714374a9baa8471e96e643d5b_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfOS0zLTEtMS0xMzUxMjE_100467b4-2fdd-4b1d-a49b-643cf66bcef9">348</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a <ix:nonfraction unitref="number" contextref="idc4d047e87e6460984a1241620741fc2_D20230101-20230331" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEwMDQ_fe59036a-22cd-47d6-bd25-cbf115e3d0d3">20</ix:nonfraction>% sales royalty from BMS which could increase to a maximum of <ix:nonfraction unitref="number" contextref="i386e5b3e2b1d4771ae602c8544c7de85_D20230101-20230331" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEwNjc_1ca41360-8f30-4a1d-b874-e65cdef8801a">24</ix:nonfraction>% based on sales levels. This royalty will be reduced by <ix:nonfraction unitref="number" contextref="i402d58f25e9e45a68055eb38b7d1d4ab_D20230101-20230331" decimals="2" name="mrk:RoyaltyRateDeductionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTExMjU_b2a05f76-a071-45be-b934-0a18a3078515">50</ix:nonfraction>% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $<ix:nonfraction unitref="usd" contextref="i0175444d0549416fb305c38749b41b24_D20230101-20230331" decimals="-6" name="mrk:ContingentProceedsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEzMzM_fd6c5905-a32e-468d-a322-c8beec1f7a47">80</ix:nonfraction>&nbsp;million. Merck recorded alliance revenue related to this collaboration within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> of $<ix:nonfraction unitref="usd" contextref="i245cacaf455e42329f9ae587d1a10cad_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEzNzI_5ac0347c-c6aa-4452-b4ea-1238bcadc98f">43</ix:nonfraction> million in the first quarter of 2023 (consisting of royalties) compared with $<ix:nonfraction unitref="usd" contextref="i2dba74425a51433497fa7e5529627e25_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTQ5NzU1ODMxOTE4_d2de489b-6e5b-416d-916d-149a5274be6e">52</ix:nonfraction> million in the first quarter of 2022 (consisting of royalties of $<ix:nonfraction unitref="usd" contextref="i9cff7fdd9228489e9a08ae8b3a149a6e_D20220101-20220331" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE1Njk_4e146289-a74f-4594-9d6c-f3e1f5079f44">32</ix:nonfraction>&nbsp;million and the receipt of a regulatory approval milestone payment of $<ix:nonfraction unitref="usd" contextref="id17be879320f41af82dedebba088c13f_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE2NDI_052a299e-edac-420a-a3f3-f166108216fd">20</ix:nonfraction>&nbsp;million).</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_34"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4.     <ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfNDg0MQ_b5a23f81-a507-423d-8706-1fcfa30e2f3b" continuedat="if4b8220d835f42d5bd564e25245eae36" escape="true">Spin-Off of Organon &amp; Co. </ix:nonnumeric></span></div><ix:continuation id="if4b8220d835f42d5bd564e25245eae36" continuedat="i64f812861e1b4999b82bcb6a39652095"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within <ix:nonnumeric contextref="ie3d1e57b1dd24ae193bd71c6385b8769_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMTUxMg_aac2e37f-a343-4c72-afc8-bb397287c7f9">25</ix:nonnumeric> months following the spin-off; however, the provision of certain services has been extended to <ix:nonnumeric contextref="if4eb1aad4f8349af99fa7c51391e5966_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMTYwMw_5b6e89e7-82a9-411c-8518-8e624a6d6d2a">35</ix:nonnumeric> months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from <ix:nonnumeric contextref="ie7ee924f05bc48c787f3fd1d8f6303b6_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMjk1NQ_90e85114-8b2b-4494-832f-45932804432f">four years</ix:nonnumeric> to <ix:nonnumeric contextref="i1fd80dbdbfb341a2a9372748079c59e5_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMjk2MQ_563a61c3-4bc3-44ac-8272-fbe62a6349d7">ten years</ix:nonnumeric>. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $<ix:nonfraction unitref="usd" contextref="iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzA3Mw_2a79e7ae-c051-4dc9-bca1-d38df893f1c2">94</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i185eb227b4104468b3c29dc49352d43a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzA4MA_e17d3db0-edd5-42cd-8f6b-33c990b5c880">99</ix:nonfraction>&nbsp;million and related cost of sales of $<ix:nonfraction unitref="usd" contextref="iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzExMg_eba6c3e0-d041-4cec-a37f-9e2acdd983c6">107</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i185eb227b4104468b3c29dc49352d43a_D20220101-20220331" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzExOQ_163f4501-f901-4427-8ea4-8ac3494dea99">105</ix:nonfraction>&nbsp;million for the first quarter of 2023 and 2022, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 10 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i64f812861e1b4999b82bcb6a39652095"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">respectively. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for both the first quarter of 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts due from Organon under all of the above agreements were $<ix:nonfraction unitref="usd" contextref="i60b11c4ee8724493ae377bee597f7db8_I20230331" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzQ5Mg_08229b35-c1d3-42ba-a466-5d781af56091">473</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i834db89c47b44369b713641fdff58447_I20221231" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzQ5OQ_b4666865-911d-4add-a4f4-c28e32c9af6a">511</ix:nonfraction>&nbsp;million at March&nbsp;31, 2023 and December&nbsp;31, 2022, respectively, and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $<ix:nonfraction unitref="usd" contextref="i60b11c4ee8724493ae377bee597f7db8_I20230331" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzYyOA_7467b4b9-7bd7-4b1a-8d8e-eead26f7c4a3">229</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i834db89c47b44369b713641fdff58447_I20221231" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzYzNQ_5dcf5beb-98d1-48cd-a595-cb00c82453e4">345</ix:nonfraction>&nbsp;million at March&nbsp;31, 2023 and December&nbsp;31, 2022, respectively, and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_46"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMzM1MQ_1e02db7c-e14c-4516-9136-6df3038e5a2b" continuedat="i774d7d39ad90454d9c7b6f7c5a26f484" escape="true">Restructuring</ix:nonnumeric></span></div><ix:continuation id="i774d7d39ad90454d9c7b6f7c5a26f484" continuedat="i05ce9cd238ab46cd829db61779679284"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, Merck&nbsp;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint.&nbsp;The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfNjE5_d1022dea-a367-4f63-a2e1-45a406210bbf">3.7</ix:nonfraction> billion. The Company estimates that approximately <ix:nonfraction unitref="number" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfNjY0_a746e296-63ef-4ebb-a029-d7bf219d8394">70</ix:nonfraction>% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately <ix:nonfraction unitref="number" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfODIw_27019124-db5f-4dec-ac7b-54c7f3a8de7d">30</ix:nonfraction>% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTAwNw_ee23e170-d0db-4e22-822b-21f8988ead88">97</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTAxNA_4f021e93-9e6d-4db2-90ee-ad854f55aa0c">127</ix:nonfraction> million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March&nbsp;31, 2023, Merck has recorded total pretax accumulated costs of approximately $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTMwMg_293ebde1-b892-4487-bc89-ef8ee5a5f249">3.4</ix:nonfraction> billion. For the full year of 2023, the Company expects to record charges of approximately $<ix:nonfraction unitref="usd" contextref="i7966ec436ac148489c841a585ea76477_I20231231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTM4Ng_4a45ee3e-51e4-4d53-925c-07198671e920">400</ix:nonfraction> million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMzM0OQ_1c377b1c-7694-47ec-b7eb-7632e83f3320" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i870f46cf31cd4dd99b24227fb3adf06f_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi0xLTEtMS0xMzE2MTg_4a251308-c167-4b29-8fe8-461fe78e61d2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibde26f5431b54da79586ebd96e74a36d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi0zLTEtMS0xMzE2MTg_2395dd4d-2ce0-4681-ab97-a60a91c5dde1">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id6616b6afece4195a3a8c81945ca5296_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi01LTEtMS0xMzE2MTg_5058d124-6a72-400d-bf95-6bd11f4c00f0">8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i111e37e345c242418c65ff71f8df4aa4_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi03LTEtMS0xMzE2MTg_6a6305bb-f574-432d-9882-271d7725a466">29</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia85fb7ebe86e48688eaa6cca6140b251_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy0xLTEtMS0xMzE2MTg_9fcfdf77-13da-4ca1-9584-5457e8cc0332">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7968694bdd844dcb91cdee1fa81b0c2_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy0zLTEtMS0xMzE2MTg_95bafa5e-a430-4fc6-a802-0aec5c5e0220">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c124834ee87435999488308f1f35177_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy01LTEtMS0xMzE2MTg_cf7ae6ce-c484-4b9e-827a-0e7cae20ab92">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie333238530bd43c2ac7bdbedf60929b5_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy03LTEtMS0xMzE2MTg_b812dee7-97fb-4b7b-a2de-bf71eef6a619">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39ffed41bf6448378d17f953bc0cc54b_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS0xLTEtMS0xMzE2MTg_f4d7d166-18e4-495a-91bf-55603ee2b242">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if8831ff53ddb4e9384dd1c730f73c0d1_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS0zLTEtMS0xMzE2MTg_1f26925d-456a-4f98-aa2f-e6ebf1183f50">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92816509cf8240d2ab4f3e2c2a61c6b0_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS01LTEtMS0xMzE2MTg_cda6bde9-3780-4b1b-b0fd-e5b59e22bdb2">26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idfa73697ee0a454c9ad0fdef7eff7f65_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS03LTEtMS0xMzE2MTg_c65a8966-412b-4ac1-a612-a0d2ad49edf7">67</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi0xLTEtMS0xMzE2MTg_d7b785a0-0061-4ad0-ab49-4f6146b6d364">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi0zLTEtMS0xMzE2MTg_09de9cbc-62dc-4b24-ab8e-f701f3170f0e">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi01LTEtMS0xMzE2MTg_a76f26cb-16ee-4657-8a77-527132e0f727">35</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi03LTEtMS0xMzE2MTg_a4187f63-7784-418f-b73b-d6c01aceee92">97</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i620edf85a16d4e4880ceb84b22f3cfab_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi0xLTEtMS0xMzE2MTg_e8b87523-455b-46f9-a71b-5290e11305b9">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bc8fc361d904fbeb6492f5e521452f8_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi0zLTEtMS0xMzE2MTg_86a9681c-7543-4563-9066-7b8d8cb54fda">18</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0bf782824e144ac698d3c52441494fa9_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi01LTEtMS0xMzE2MTg_80941371-5ecc-48c2-9ee8-8f64bb3bb234">28</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie23cb3149ce14b15a9a4f74c76232a80_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi03LTEtMS0xMzE2MTg_2d205baf-6619-4a8e-af1f-ce78a6c45bd9">46</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idb61832d74f44b15bb6f7e1e80aefe10_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy0xLTEtMS0xMzE2MTg_17e107e1-c573-4a67-8ae9-2f6a7c73e660">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd263f21d9824f4d88448a933573382e_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy0zLTEtMS0xMzE2MTg_0f04cb32-1412-4388-b8d7-bba5c07a66f1">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7916bd167a5949cf9496c5497260c4da_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy01LTEtMS0xMzE2MTg_7f77a7c6-0af0-47ba-ba71-6aa4d5af4c58">17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59bdd8e429324f6985da2aa4f9cee50f_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy03LTEtMS0xMzE2MTg_c5d89087-b149-4fbe-abd7-5330cf2f779d">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia26db14d5dfb4db6936c0133c122c21a_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC0xLTEtMS0xMzE2MTg_4ffb78c2-848a-4cf4-bb72-e298d67c4b5b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifb9eb1916f044d189f47e32c6cf11a65_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC0zLTEtMS0xMzE2MTg_5eb49cf0-334b-4d55-9a0b-18d41ccb05fc">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6bd41c6996df44f5ad0c156034845a9e_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC01LTEtMS0xMzE2MTg_3f35dc14-b85b-4a50-b77a-de2cf96c2640">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i45f7c7de6a3b4eb69f814c83aa49e79c_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC03LTEtMS0xMzE2MTg_608d6eac-f46b-40b3-87dc-ab7e1e82771f">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f8fc3f059d944d8ad12e7fed7bcc36b_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS0xLTEtMS0xMzE2MTg_1ede5b46-b774-4818-9522-c5ced7592c03">26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i53768e8ff51d41dabfcdf8423e6ee2fa_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS0zLTEtMS0xMzE2MTg_0ed644ee-6e32-41c4-8e46-a9257c65a89e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46e4f372c2f54684954722f000f9b4fb_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS01LTEtMS0xMzE2MTg_7247cabc-464b-4aa8-889b-9656841bdd4b">27</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i72738ef779d443e9ae3f451aa08e9bd5_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS03LTEtMS0xMzE2MTg_f499b2ed-5ee4-4cc3-8a45-7d4cd376e50f">53</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1dbe9c123ccc49ce80d7ee4225c7c4d8_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi0xLTEtMS0xMzE2MTg_5adb07b1-ca85-41e7-9ec6-5d4dcf4e1046">26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i09b391351ac84dc89ccba17bcc925ec9_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi0zLTEtMS0xMzE2MTg_c8c01545-83a4-4345-9eec-e8d2c2d51064">29</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i80771ba562bd4e098155333659c919c8_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi01LTEtMS0xMzE2MTg_143e66b4-e4e5-4ff0-8031-5d716e770f8c">72</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi03LTEtMS0xMzE2MTg_54b00390-2085-48c2-a043-6bffa0b72e98">127</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other activity in 2023 and 2022 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&nbsp;10) and share-based compensation.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 11 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i05ce9cd238ab46cd829db61779679284" continuedat="i41e45d7961c34b3095acef5e6e3fc3ff"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMzM0Nw_e70e3132-acf5-4b6d-b90b-d1e766b2fc0a" continuedat="ic31c53bb1c6e4a6ab53e18b6ea245c8e" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March&nbsp;31, 2023:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&nbsp;1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i735d6ae1f2044389b4cd1ff056ef3646_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS0xLTEtMS0xMzE2MTg_cb6cf49d-2d9e-4458-9517-cd2a0d9f9112">479</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3cce1bf91c214333b3b50c15e3d7461c_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS0zLTEtMS0xMzE2MTg_8a0be797-80a0-43e0-ab29-a5e2e4625193">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i40da318aa247452bac9b3018762feece_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS01LTEtMS0xMzE2MTg_aed67f0a-c975-4425-8315-95b55f90a0fd">34</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS03LTEtMS0xMzE2MTg_6bba8055-6d8b-4be1-a927-501c0718a7de">513</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi0xLTEtMS0xMzE2MTg_75f61ce1-ef48-4355-9c4f-97acad05698a">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi0zLTEtMS0xMzE2MTg_ce85565c-61cb-4cc4-80fc-41a7a91eb2e6">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi01LTEtMS0xMzE2MTg_456fd158-30b1-429d-bda9-ebc41e412fa3">35</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi03LTEtMS0xMzE2MTg_beb15f2e-c1f2-4912-9b61-30d94be7957f">97</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy0xLTEtMS0xMzE2MTg_7c7914b2-dbb7-4a5e-a3ee-c66511650972">47</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy0zLTEtMS0xMzE2MTg_6cd89a9c-30dc-4ee6-8511-f58b5d662548">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy01LTEtMS0xMzE2MTg_dfea054e-6596-45ed-aa6b-d0f84b213ce5">27</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy03LTEtMS0xMzE2MTg_e8a98298-8bb1-4a74-8299-53cd6e086d99">74</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC0xLTEtMS0xMzE2MTg_d389b604-ecda-4b40-a790-41625208270c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC0zLTEtMS0xMzE2MTg_2106c809-de45-469e-aea6-d9be2af9ee2a">21</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC01LTEtMS0xMzE2MTg_b9e78c78-6d00-4744-a0cf-85258aeee6f5">9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC03LTEtMS0xMzE2MTg_a9d10e8c-c90f-465f-8163-551d866b31ee">30</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves March&nbsp;31, 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i993831891ccf428592c3e2f850548d44_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS0xLTEtMS0xMzE2MTg_750a11c7-350e-4550-aa6b-db78757b1423">473</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic5739c18be2b4077ac27f27ef7c6e9f6_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS0zLTEtMS0xMzE2MTg_2cad3c1e-f71e-4142-91db-0843db847afc">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb4e20bd4ba34d448a2f3a3397c0d521_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS01LTEtMS0xMzE2MTg_7bbf4e47-7616-47aa-a0a7-1f431d67b69f">33</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS03LTEtMS0xMzE2MTg_4f54125c-4ed5-4c8f-bc48-a02df57368fc">506</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"><ix:continuation id="i41e45d7961c34b3095acef5e6e3fc3ff" continuedat="ie3fbd895d937437eb813de3752429394"><ix:continuation id="ic31c53bb1c6e4a6ab53e18b6ea245c8e" continuedat="i1833ce52b314418b8be9535aeec18e44">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.45pt"><ix:continuation id="ie3fbd895d937437eb813de3752429394"><ix:continuation id="i1833ce52b314418b8be9535aeec18e44">The remaining cash outlays are expected to be largely completed by the end of 2025.</ix:continuation></ix:continuation> </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_49"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5NTg_9664b5fd-2815-482e-ab6e-1acd36eab700" continuedat="i72dd6368c7264f47a92f483478e95258" escape="true">Financial Instruments</ix:nonnumeric></span></div><ix:continuation id="i72dd6368c7264f47a92f483478e95258" continuedat="i279048b7cdac4d16993ea98b81a84696"><div style="margin-top:5pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than <ix:nonnumeric contextref="i7e6cc36740bb4d71a793d4cb817b4486_D20230101-20230331" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQ2Ng_fb4b5cd1-943b-4df2-8adc-e5a587e8e26a">two years</ix:nonnumeric> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash&nbsp;flows from both designated and non-designated contracts are reported as operating activities&nbsp;in the Condensed Consolidated Statement of&nbsp;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than <ix:nonnumeric contextref="i44fa00da50de4c2abe7a97b20631529f_D20230101-20230331" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTA2Mg_45af942e-783a-4b0f-a194-91858dd76916">six months</ix:nonnumeric>. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 12 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i279048b7cdac4d16993ea98b81a84696" continuedat="i3b95c8167d444f11b36ba48c91fbd2b3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5NTE_4d780aad-70cf-4542-9884-2e315547e0ae" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC0xLTEtMS0xMzE2MTg_cbaa9f8d-c1ed-4b35-a63c-f34c2ffc193e">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC0zLTEtMS0xMzE2MTg_40ad9e37-c988-4b43-9d96-abfb9abcdd29">16</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i313438c53a3745f5a9c308e10580003d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC05LTEtMS0xMzE2MTg_9ce8243e-127e-4228-87f7-58158488bd1c">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i13663e430fa9440c8b9b613386d03310_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC0xMS0xLTEtMTMxNjE4_ec6b82a9-e19e-4dbd-9563-a1037ca3ae1a">1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3459fac4643e42e29a49394546d2d3b7_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS0xLTEtMS0xMzE2MTg_cc87d1a8-cfb9-46d5-97f5-52ec34b8fe3f">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib9f85f59e99b4ea189c2a085734df397_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS0zLTEtMS0xMzE2MTg_2fc0068c-85ec-47d2-8d5f-df4fe374df15">53</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c1922ae96df4166a7397fffeb3375e7_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS05LTEtMS0xMzE2MTg_3517fea1-6c70-4dce-9a2a-f23ac47e017b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b9f469b4df444f7b96723d7a5c8b223_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS0xMS0xLTEtMTMxNjE4_64671865-e101-4ddf-b81a-0e1bf4ab1062">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div></ix:nonnumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. In March 2023, the Company entered into <ix:nonfraction unitref="interest_rate_swap" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="0" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM4OTQz_dde3febc-0da7-4b23-b7a6-41b04e76643b">five</ix:nonfraction> forward starting swaps and in April 2023 entered into <ix:nonfraction unitref="interest_rate_swap" contextref="i336c99147cdf41e191d86c13d2a751dc_I20230430" decimals="0" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM5NDA2_34f70cf4-a002-438a-99ad-58ec8ffee05b">two</ix:nonfraction> additional forward starting swaps, each with a notional amount of $<ix:nonfraction unitref="usd" contextref="i7029fd7c7a6f43aca68f42e012aec70b_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM4OTQ3_23d8d92b-0d78-4b08-b738-32e64b745d3a"><ix:nonfraction unitref="usd" contextref="i95f9d19ca7854b0288a0454768961670_I20230430" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM4OTQ3_4d8435be-b8d0-4716-812c-aaaecb689bc7">100</ix:nonfraction></ix:nonfraction>&nbsp;million.</span></div><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5ODA_55be7146-6521-4eae-b448-5ea6359c9678" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair&nbsp;Value&nbsp;of&nbsp;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.&nbsp;Dollar<br>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair&nbsp;Value&nbsp;of&nbsp;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.&nbsp;Dollar<br>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8">Other Assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i548bda88a4fe4bd5bffaa38757444dad_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0yLTEtMS0xMzE2MTg_50a2c904-4c16-4a93-a288-3f287aca7d62">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bdddb9610a348a48e757c57cc1a2387_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC02LTEtMS0xMzE2MTg_21f0afa5-a11e-4f3a-a8ec-4a019f6f7a4a">300</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifbdf486ae9934cc9a2a5283fa0638116_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC04LTEtMS0xMzE2MTg_ed6c9da5-4ba0-433d-a263-18490c9bcb41">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic70cbdc57c9f458abe55135c7b061c1d_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xMi0xLTEtMTMxNjE4_f841f82a-303f-4d87-9bfa-d7225d0b9487">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i548bda88a4fe4bd5bffaa38757444dad_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS00LTEtMS0xNDMwOTA_18840083-892c-49b6-97a6-78494d07fcf1">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i425bb66138fc4a51933c6b6df28796a6_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS02LTEtMS0xNDMwOTA_a054f779-db89-4e8a-a1fb-b0d922f96892">200</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifbdf486ae9934cc9a2a5283fa0638116_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xMC0xLTEtMTQzMDkw_aecd975b-7bf3-4a61-9406-9fa9119e68a9">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i294f553218424e8cb257f3d9f97e01a5_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xMi0xLTEtMTQzMDkw_2f1bf1e8-05c4-4a3b-9861-e52acced7935">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c">Other current assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0yLTEtMS0xMzE2MTg_d2691c45-411b-4be9-beb2-e0575fe0ca39">104</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS02LTEtMS0xMzE2MTg_030715d4-bf1c-4933-a93c-0b3e414453cf">4,253</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifaac2668425b4eb4bfaea2c9834fd061_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS04LTEtMS0xMzE2MTg_e54cbddf-083f-4d5c-80d1-029f586b1e27">220</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifaac2668425b4eb4bfaea2c9834fd061_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xMi0xLTEtMTMxNjE4_a3ed3c28-263d-47b9-9f44-a16216111c9b">4,824</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0yLTEtMS0xMzE2MTg_f313614b-040a-4301-b5ef-d66777afb721">32</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi02LTEtMS0xMzE2MTg_e1124fa7-28bc-4cef-a7de-1f6c3cd58fd5">1,756</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i03be4f41b99a4232bdc4d5da0449f285_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi04LTEtMS0xMzE2MTg_64e192d2-d430-4c23-8618-3c76ecc8443d">27</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i03be4f41b99a4232bdc4d5da0449f285_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xMi0xLTEtMTMxNjE4_206c49a7-0bc2-4f0a-9a54-96169319ffd0">1,609</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i50b43bd94e56461888fca904c9a7ca24_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy00LTEtMS0xMzE2MTg_a4054cbb-da6a-4acf-bf95-3fd6183ce447">116</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i50b43bd94e56461888fca904c9a7ca24_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy02LTEtMS0xMzE2MTg_b8d632d6-a636-4a97-96e5-e014436314c5">3,444</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i143c9f2549384565bcdcfdd243771159_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xMC0xLTEtMTMxNjE4_381550ec-ae84-4a6b-8cfd-c04702f63f40">101</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i143c9f2549384565bcdcfdd243771159_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xMi0xLTEtMTMxNjE4_f7fca098-f954-48c9-825d-db0f82e20dd2">2,691</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC00LTEtMS0xMzE2MTg_89192b89-afdd-473c-b1cf-983403ceb15c">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC02LTEtMS0xMzE2MTg_2e598751-aa1f-442a-b425-f16522b0c50d">120</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice27572fdfbf445cabdf5a62a7d76022_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xMC0xLTEtMTMxNjE4_9bf90ced-8fec-4c64-a19e-7a2f605efefb">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice27572fdfbf445cabdf5a62a7d76022_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xMi0xLTEtMTMxNjE4_0be777f1-a5a1-4ec6-b0e6-ff59c6feb14a">91</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2a06f418da43474f9f2f260add8790b3_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS0yLTEtMS0xMzE2MTg_3fcbf349-b567-4e91-9e0c-46dca51c752e">137</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2a06f418da43474f9f2f260add8790b3_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS00LTEtMS0xMzE2MTg_13a208cc-4199-49e3-b92a-1a853251cfc4">119</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2a06f418da43474f9f2f260add8790b3_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS02LTEtMS0xMzE2MTg_52a1ad54-6986-4218-b10f-59d3b60e3b46">10,073</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf11d32e52ad425f979acb12dcd9aaac_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS04LTEtMS0xMzE2MTg_b1c7ea18-fbb7-409f-94b5-398c3c053779">247</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf11d32e52ad425f979acb12dcd9aaac_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS0xMC0xLTEtMTMxNjE4_75df709b-935a-457b-99ea-a5f3fd899fa0">102</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf11d32e52ad425f979acb12dcd9aaac_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS0xMi0xLTEtMTMxNjE4_57f78cee-525f-4109-937d-071952783e21">9,215</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iac10665025d84f23872225d16c92ffed_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMi0xLTEtMTMxNjE4_86edffdf-b6a2-486c-9ae5-f5354250882a">121</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iac10665025d84f23872225d16c92ffed_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtNi0xLTEtMTMxNjE4_bdb4b795-912c-47ef-8be2-7863d07933e0">9,507</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i45afba88d4004605825fe82844d7a4a7_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtOC0xLTEtMTMxNjE4_f84e4d3b-19a1-4620-bb3b-40a7a8d524e7">186</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i45afba88d4004605825fe82844d7a4a7_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMTItMS0xLTEzMTYxOA_53cdffa0-4b7f-44ba-8465-9f64f9646dd0">8,540</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMi0xLTEtMTQyNTQx_c6cc6fa1-1969-40df-8e42-6d42b9ed64f6">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtNi0xLTEtMTQyNTQx_4924fbff-1928-4a87-b397-2a7c30d530e8">65</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5a23903b67354e33a6fc1a8676a4b984_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtOC0xLTEtMTQyNTQx_b5a47de5-1eb9-4d35-9f8b-0883412bec1d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5a23903b67354e33a6fc1a8676a4b984_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMTItMS0xLTE0MjU0MQ_7dedba2e-068c-4459-979a-8c3e8b365653">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a542fc8b3854857bda9666e66bd056e_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItNC0xLTEtMTMxNjE4_69f37321-46fb-4389-8671-1136127008af">164</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a542fc8b3854857bda9666e66bd056e_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItNi0xLTEtMTMxNjE4_2d0806cb-1295-4aa7-afe1-c8c37686a706">10,592</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4fad0e8da324f249b5dc3a9f01637f7_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMTAtMS0xLTEzMTYxOA_db0536fb-8574-4554-9ed9-e5b96979e6ba">307</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4fad0e8da324f249b5dc3a9f01637f7_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMTItMS0xLTEzMTYxOA_42ac5322-fc22-404c-a467-b7c7904dd591">10,926</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie091883aa8d84ebf868769397c540276_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtNC0xLTEtMTQzMTAy_3bf77e6b-3339-402e-9e91-11d304209122">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie091883aa8d84ebf868769397c540276_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtNi0xLTEtMTQzMTAy_db72235a-32cd-4983-ae11-0046a19a1efb">124</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib057b0780b1b420d824cb8350acd5ba2_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMTAtMS0xLTE0MzEwMg_6046560d-992b-4a5c-b1c0-3461145925c1">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib057b0780b1b420d824cb8350acd5ba2_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMTItMS0xLTE0MzEwMg_3b179ff9-c812-436d-a5f3-0207d0dc51a6">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibaadad87b63f48448ddf5360530646a9_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMi0xLTEtMTMxNjE4_6e23a723-e2cf-4614-8922-054d5c03e151">122</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibaadad87b63f48448ddf5360530646a9_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtNC0xLTEtMTMxNjE4_858d4e90-e122-45e9-96a3-ddc132677cbb">165</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibaadad87b63f48448ddf5360530646a9_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtNi0xLTEtMTMxNjE4_d97a9276-f9dc-4299-ae70-82b99dfdc920">20,288</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtOC0xLTEtMTMxNjE4_d4fdbe62-6fe6-441d-b156-8502179cdcab">186</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMTAtMS0xLTEzMTYxOA_2b813906-7f95-44e1-a533-9c1abd8f82db">307</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMTItMS0xLTEzMTYxOA_ad1d41c9-5f8f-49f6-995f-714e54d2840b">19,466</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtMi0xLTEtMTMxNjE4_abbde945-b8ad-48b0-96a9-7e26a2d3652a">259</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtNC0xLTEtMTMxNjE4_e1414130-a896-4356-b90b-9a7e2e94051c">284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtNi0xLTEtMTMxNjE4_399a16b7-5043-49b0-a894-eedbc04640d0">30,361</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtOC0xLTEtMTMxNjE4_439859eb-bd4a-42e8-a23b-1263f01c21ec">433</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtMTAtMS0xLTEzMTYxOA_e5fdafd1-8bd9-4b88-a121-14249c9e871b">409</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtMTItMS0xLTEzMTYxOA_8e014bfc-64c6-405b-98ea-4d2f6e4ba46b">28,681</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 13 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i3b95c8167d444f11b36ba48c91fbd2b3" continuedat="i11a2e7c9e69f45f3a7c26739fe5c7338"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below). <ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="mrk:OffsettingAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MDg_1489cfad-b0d8-4a6c-9617-0c63dbc04c06" continuedat="i65a8d26977364441bb4ba47722745959" escape="true">The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</ix:nonnumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i65a8d26977364441bb4ba47722745959"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi0xLTEtMS0xMzE2MTg_9df851ad-05b0-4cb7-a118-8dcd34af6bb4">259</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi0zLTEtMS0xMzE2MTg_cf885fb0-f77a-48e2-880a-2a3f2232ce2c">284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi01LTEtMS0xMzE2MTg_95bfdd0c-fd01-44cc-8fcb-b7af0acbb9c5">433</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi03LTEtMS0xMzE2MTg_e20b1bd6-5591-426d-9d2b-c1668b77785f">409</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy0xLTEtMS0xMzE2MTg_7a18f736-2c52-4549-9689-4c27b80deaf8">148</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy0zLTEtMS0xMzE2MTg_968cd43a-1197-4975-b402-73bf4b0f752e">148</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy01LTEtMS0xMzE2MTg_51a1ca3b-19cb-4728-ab5e-1f686d3ff3f8">220</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy03LTEtMS0xMzE2MTg_cbe65719-231a-479d-9d29-c7a436bcc183">220</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC0xLTEtMS0xMzE2MTg_3d2e90e5-0268-4744-a79b-98331c0a1f59">13</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC0zLTEtMS0xMzE2MTg_70aa5d34-636f-47e9-9840-7ab920e6adc0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC01LTEtMS0xMzE2MTg_34435864-a062-484c-a0b7-eecd4406f5be">66</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC03LTEtMS0xMzE2MTg_057b96d1-06dd-463a-86c5-b86d743050ce">19</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS0xLTEtMS0xMzE2MTg_6ff7b00d-76fd-4681-b6d3-102be2e6e492">98</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS0zLTEtMS0xMzE2MTg_1b470521-5647-4f2f-84c5-e0fe577a1026">136</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS01LTEtMS0xMzE2MTg_6cd0b0ab-075c-440f-93aa-e969c056e979">147</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS03LTEtMS0xMzE2MTg_dcfc3945-172a-44ad-8388-083c6c353023">170</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></div><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MDM_4c32dc9a-ed6a-4369-8e71-7d8b8f02e82b" escape="true"><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Hedges are Recorded</span></div></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy0xLTEtMS0xMzE2MTg_22a948dc-764f-4b1e-bd35-1d8c5714fc99">14,487</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy0zLTEtMS0xMzE2MTg_bce1380b-87c8-407a-9c79-f8ebd0e11ede">15,901</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy01LTEtMS0xMzE2MTg_179cbe9b-cbaf-4611-ab53-9332ca253bc5">89</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy03LTEtMS0xMzE2MTg_1b228471-d719-454e-9351-e1fae4b738aa">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy05LTEtMS0xMzE2MTg_a155be89-531e-4713-8f68-5c9b4a90f298">115</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy0xMS0xLTEtMTMxNjE4_541f339b-0eed-442f-b7e5-fcb548e271b6">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i86b17d802f304918b52da353344f6ac4_D20230101-20230331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNi01LTEtMS0xMzE2MTg_e452a98b-c70d-41d7-a482-30f1838cc726">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i028e5b27f0e04f339d7c2f519b8ae259_D20220101-20220331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNi03LTEtMS0xMzE2MTg_16071167-afc5-4664-948f-741ee9249a4b">10</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i86b17d802f304918b52da353344f6ac4_D20230101-20230331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNy01LTEtMS0xMzE2MTg_c46d858e-ad70-4175-b211-ef3a8f53bfd4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i028e5b27f0e04f339d7c2f519b8ae259_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNy03LTEtMS0xMzE2MTg_d6ac96c8-7b59-42cf-a66c-7f0513662586">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTAtOS0xLTEtMTMxNjE4_c0b72b8a-70b7-4926-bcdb-721039df42d1">66</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTAtMTEtMS0xLTEzMTYxOA_7f52f705-25fc-46fe-898a-a2416c811c71">148</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib9ff469b241a4cd5972223863bfda226_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtMS0xLTEtMTMxNjE4_63ad98ab-1fb8-4feb-9763-9f0a72e303d1">101</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96b677da60364882b5bc1b825a50fabe_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtMy0xLTEtMTMxNjE4_6d2194a2-cff0-4fee-a90b-a8f77910b7c3">67</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtOS0xLTEtMTMxNjE4_e526cf4a-d599-4614-981f-ed23c3e2c0d4">101</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtMTEtMS0xLTEzMTYxOA_2804f17e-7256-4031-9d63-8fd5a771a8a9">67</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i330867f88a774fb08f247e81d478866e_D20230101-20230331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTMtNS0xLTEtMTMxNjE4_8bce689f-00d6-4a8e-96fe-978f0144a70e">1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8118cf7c392f4ea598bfcb18b7bbd4d2_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTMtNy0xLTEtMTMxNjE4_229d3661-b791-403b-ace3-ae50abdbca42">1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i330867f88a774fb08f247e81d478866e_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTQtOS0xLTEtMTMxNjE4_44fcba0c-30ee-49d3-bb0d-76ea24a4d7f8">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8118cf7c392f4ea598bfcb18b7bbd4d2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTQtMTEtMS0xLTEzMTYxOA_8447855c-5ef4-45cb-a2d1-bc3296421787">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div></ix:nonnumeric><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MTc_52cb4752-d5ed-47eb-9821-c6371bb02c13" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.359%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNC0zLTEtMS0xMzE2MTg_6d07b28c-4812-4146-81ea-f4a2fca3b9d0">13</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6b6b9e2b940749269dcc355aa0ed57d7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNC01LTEtMS0xMzE2MTg_34791cc4-bf9b-46f3-90f1-665d28024c67">28</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc7fb1fb9fd543aba08f396008a05eb0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNS0zLTEtMS0xMzE2MTg_e728eec8-5f0c-4f93-9d57-82d50a4c42d2">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic3fb850e1f5f434f8e8a95228021a73d_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNS01LTEtMS0xMzE2MTg_02f54c1c-197b-43ae-91dc-30cd1f2ffb14">2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts serve as economic hedges of forecasted transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March&nbsp;31, 2023, the Company estimates $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfOTgyOQ_fddfd25d-1e22-47d1-bbfe-f36c4ba9f792">71</ix:nonfraction> million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 14 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i11a2e7c9e69f45f3a7c26739fe5c7338" continuedat="id4ba55aae8404f9f9711fe5c98183e92"><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MTg_9432e5ed-20f3-4378-849b-4fa3d5b83c6e" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&nbsp;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&nbsp;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br>Value</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i776fb83d7a1241a0826d11f6ebe76e81_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xLTEtMS0xMzU4NDQ_ebb3f79e-28e4-4edf-a924-8fdd8e33daaf">663</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i776fb83d7a1241a0826d11f6ebe76e81_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0zLTEtMS0xMzU4NDQ_c50bcca5-2665-47dd-9a37-7a04ba0ac298">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i776fb83d7a1241a0826d11f6ebe76e81_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy01LTEtMS0xMzU4NDQ_62978d6b-f095-4383-b06a-c328926964c7">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i776fb83d7a1241a0826d11f6ebe76e81_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy03LTEtMS0xMzgyODg_95724fca-3830-4875-a860-9c1c21299590">663</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a3f219a7d404a31bf65ab7515e23942_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy05LTEtMS0xMzU4NDQ_609d66b2-1f18-4a58-ad09-df256f3ea0b0">498</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a3f219a7d404a31bf65ab7515e23942_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMS0xLTEtMTM1ODQ0_8e28da52-4455-40e0-8137-9dcfe8db9182">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a3f219a7d404a31bf65ab7515e23942_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMy0xLTEtMTM1ODQ0_881c0c90-3f1f-4580-82b3-53e4fc336028">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a3f219a7d404a31bf65ab7515e23942_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xNS0xLTEtMTM3MDI1_1317ee72-f6a4-4f57-ab7d-7ca5768baa3b">498</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xLTEtMS0xMzE2MTg_1c0a6358-3e8d-4355-b789-ff35995fb9f9">92</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0zLTEtMS0xMzE2MTg_e4f3191f-8505-4052-952e-8cce6662cc70">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy01LTEtMS0xMzE2MTg_17046ae1-855b-4652-ad2c-490e7ede0e87">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy03LTEtMS0xMzE2MTg_8e8bf003-394c-47c5-a608-560951f1289f">92</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92a140256baa4686a25015671d14aa5b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy05LTEtMS0xMzE2MTg_440cdd91-ac34-4899-b413-5b57c68da8b7">68</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92a140256baa4686a25015671d14aa5b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMS0xLTEtMTMxNjE4_c19d8c2a-b8db-4e5b-b64f-d78a3014c888">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92a140256baa4686a25015671d14aa5b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMy0xLTEtMTMxNjE4_ec604bca-89ef-46c2-a045-52f1e2a2289e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92a140256baa4686a25015671d14aa5b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xNS0xLTEtMTMxNjE4_da336add-720b-4c04-ba66-9de88b38852d">68</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93df6ced8a7748a4abd5d6c32906498c_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xLTEtMS0xMzE2MTg_9e10429e-a1f3-46b3-964e-6dfb201cf33f">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93df6ced8a7748a4abd5d6c32906498c_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0zLTEtMS0xMzE2MTg_a9c7cd83-64a8-4550-bba7-52f3aa32437d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93df6ced8a7748a4abd5d6c32906498c_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS01LTEtMS0xMzE2MTg_062e8e8c-9124-49f1-9295-1a7c0414a109">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93df6ced8a7748a4abd5d6c32906498c_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS03LTEtMS0xMzE2MTg_80243d15-5cbb-44a9-ab4d-3e6ab08f8e08">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5aa6408da9024f3ea458c3189fa1916d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS05LTEtMS0xMzE2MTg_47c5d10e-de64-4295-8fab-5a7e4d1d6c15">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5aa6408da9024f3ea458c3189fa1916d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xMS0xLTEtMTMxNjE4_6b5633d0-f8e7-4ba7-bac1-87b9e2ae8cfa">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5aa6408da9024f3ea458c3189fa1916d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xMy0xLTEtMTMxNjE4_c0cca5ce-fb86-4548-9bde-d904cc94ac08">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5aa6408da9024f3ea458c3189fa1916d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xNS0xLTEtMTMxNjE4_ac586d21-f44b-4a6d-bec1-49054b0701fa">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1f2bc401a074570afe7c168856f7ee2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xLTEtMS0xMzE2MTg_e37c5043-2f2a-4783-bb90-9fc3807a9cb8">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1f2bc401a074570afe7c168856f7ee2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0zLTEtMS0xMzE2MTg_43888fd8-aa07-4f41-9d84-f953c88ffd8b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1f2bc401a074570afe7c168856f7ee2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi01LTEtMS0xMzE2MTg_2bdd5689-59ff-4aaa-a11a-2693b6b00d88">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1f2bc401a074570afe7c168856f7ee2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi03LTEtMS0xMzE2MTg_b1341752-58cc-4e67-8a83-5ea253fc5603">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i85028f8c5acd441497714b4e936b0ece_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi05LTEtMS0xMzE2MTg_9760707e-49fb-47c5-b677-6b01c4a58a43">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i85028f8c5acd441497714b4e936b0ece_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xMS0xLTEtMTMxNjE4_fdf3ea92-14e9-436e-bd39-072624ab4ab0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i85028f8c5acd441497714b4e936b0ece_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xMy0xLTEtMTMxNjE4_0341e4c2-18a9-45a8-bf88-456ab3cdeb39">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i85028f8c5acd441497714b4e936b0ece_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xNS0xLTEtMTMxNjE4_a92132e2-5f8b-4d47-bcc1-1f3c3beb97fc">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xLTEtMS0xMzE2MTg_eca26d5e-0c5d-4a81-aada-dd3182c057e4">760</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0zLTEtMS0xMzE2MTg_47dec290-97f4-41f0-87e6-0aa6e194ffa2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy01LTEtMS0xMzE2MTg_3ff9fd31-4578-4ea8-bc11-34dee56af85c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy03LTEtMS0xMzE2MTg_5f904d27-87dd-4ead-826e-cfcad94392d9">760</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy05LTEtMS0xMzE2MTg_8f9fcbae-ebe5-4e48-b7dd-cfe150e2e2ba">569</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xMS0xLTEtMTMxNjE4_a7e1b47f-4469-4e68-9be9-ea2934fbe819">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xMy0xLTEtMTMxNjE4_efb397d7-4228-4663-b5b2-e9e01c28004a">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xNS0xLTEtMTMxNjE4_4a229de1-c21a-45a5-8243-e93e7befdcb8">569</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOC03LTEtMS0xMzE2MTg_cce764db-ff9e-45fa-ad78-e99c726545a1">1,585</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOC0xNS0xLTEtMTMxNjE4_db920bff-366b-4fc4-a49e-42206d6c385d">1,284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOS03LTEtMS0xMzE2MTg_a37b903a-f00d-4e98-a016-145a168486d5">2,345</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOS0xNS0xLTEtMTMxNjE4_23b11816-8ae4-407e-84c3-5a6ef8ee4d36">1,853</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net gains of $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTAzNDg_e8a02200-6507-4d0c-a5d2-b7286057cebb">338</ix:nonfraction>&nbsp;million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2023 on equity securities still held at March&nbsp;31, 2023. Unrealized net losses of $<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTA1MzQ_a8000f2a-ccb3-4531-80e8-0b58870ce2a6">225</ix:nonfraction> million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2022 on equity securities still held at March&nbsp;31, 2022.</span></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March&nbsp;31, 2023 and March&nbsp;31, 2022, the Company also had $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTA3MjI_a659a1b6-1257-4cdf-b474-b5ba6d0f1efc">942</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTA3Mjk_7819aab3-e59e-4f18-8c63-036852492128">643</ix:nonfraction> million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTEyMTc_51a9dc70-2c78-4a34-9674-9808fc360cdb">1</ix:nonfraction> million and unrealized losses of $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTEyNDk_d679b3be-650f-4c6e-9795-f99c84c84168">21</ix:nonfraction>&nbsp;million related to certain of these equity investments still held at March&nbsp;31, 2023. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTEzOTI_74087441-f2d2-45d0-a05a-2e00f3713822">14</ix:nonfraction>&nbsp;million related to certain of these investments still held at March&nbsp;31, 2022. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at March&nbsp;31, 2023 were $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE2Nzc_ccb6be9f-f29d-49e3-b207-2dd0148e3798">287</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE2ODQ_896b0127-dafc-4b24-bf8e-dafc5c2e3610">40</ix:nonfraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March&nbsp;31, 2023 and March&nbsp;31, 2022, the Company also had $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE3Mzg_707ed689-9e7e-41d7-b4c2-1ecf26a109d1">725</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-8" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE3NDU_5fd15a6e-0e70-4b43-8844-730c36416d88">1.2</ix:nonfraction>&nbsp;billion, respectively, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. (Gains) losses recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> relating to these investment funds were $(<ix:nonfraction unitref="usd" contextref="i17a0e0f674094afda5f097dcbf70b93d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE5NTk_d0a5bedc-df10-442d-b6f3-0be90a69b09e">132</ix:nonfraction>)&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i0cda95f4db4a4d1e892c7b8b8c2bdd34_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE5NjY_c4f6aadd-5e59-4935-a503-5822ab65e29e">509</ix:nonfraction>&nbsp;million for the first quarter of 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&nbsp;1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 15 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="id4ba55aae8404f9f9711fe5c98183e92" continuedat="i4aa981479cc240b99204444f93effa2b"><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5ODM_093e36d5-cacb-4300-a433-140a801df272" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i020b0ff9857f4f16af9e432e1869c1f7_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xLTEtMS0xMzE2MTg_0e54fa1c-6aee-4acd-afaa-e1c5986265b1">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07c700750162434c9390aee0f12c47d9_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0zLTEtMS0xMzE2MTg_9c68e298-88c0-43d6-a0da-ffe9c74ab8d0">663</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if47442341eb14e6e97a2cc3f6b5bba11_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS01LTEtMS0xMzE2MTg_efccf205-5d4b-45a5-b28a-e6a0f9b21ce3">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8bffc0a6380440728c91dc8b47e0f31e_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS03LTEtMS0xMzE2MTg_d58408ae-0aa1-4580-8160-e3a3785039be">663</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a8f3e37e4904159af4dd090e1bc5731_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS05LTEtMS0xMzE2MTg_0e3b5efe-4ae2-4279-a9c0-3d2fcb842c76">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2a49b37db2544c739f3f57a6c315a232_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xMS0xLTEtMTMxNjE4_2567dea2-5b34-4959-9afa-0aebc308d036">498</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i66cafb3d313644a3b3ba17dc3c1b05da_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xMy0xLTEtMTMxNjE4_6a3b23e8-737e-4e94-a723-b9edab0124d4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5a99f61d5d9c4df5b63c5274b8898116_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xNS0xLTEtMTMxNjE4_2daf049c-b11c-46b4-bea6-6d6092124d1c">498</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7f9e79091e5045c68d0f830e6ac4c990_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xLTEtMS0xNDI4MDU_aaa59637-fab3-4866-bae2-6f1af816ed4f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2795fcc4916b4738ba959e843ff69ec3_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0zLTEtMS0xNDI4MDU_3bdea0bc-5356-4ac3-83c4-02670e8f3cfe">22</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96de2214f40e4ba59e7b629d43ba4d91_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi01LTEtMS0xNDI4MDU_6e332e58-a88a-4104-91d8-b79cf7ec9891">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i451160fbee604ab990070211ebeba8de_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi03LTEtMS0xNDI4OTc_73ccbfd9-b77c-4f26-82e8-74a1dc481dad">22</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46d67fffc7944fb8af71441dc67f9462_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi05LTEtMS0xNDI4MTQ_56c2e6aa-9ae5-48e3-8a38-844f5394bde4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifb8445329cbd40e38c431a9cab4cb4d6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMS0xLTEtMTQyODE0_d9140173-e53b-454d-8a03-30994ddf7301">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3beec2a915ab4328b794d0b11fbc0788_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMy0xLTEtMTQyODE0_84b9095b-f1f2-47a2-8ffd-aa1517f0b3da">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i814823701512438f9446387df4b6adcf_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xNS0xLTEtMTQyODk3_ebaa5901-0aaa-4ca8-ad5a-741b7e77e61e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0d93e6ac796f4cc0a31cd2625e3240a0_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xLTEtMS0xMzE2MTg_884af47b-a529-4cc6-9685-b638d5df485d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idef3c5cc57074bf7bab4f63f14c711d4_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0zLTEtMS0xMzE2MTg_1fccf83e-484b-4e05-bba2-62d03e5eb4d1">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia38b8466a7354dcfb672c615593eeffb_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi01LTEtMS0xMzE2MTg_2f535a18-44ac-455f-a8db-c795d14bd486">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i743f68c0230549c8bfbd0ad0a8901f37_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi03LTEtMS0xMzE2MTg_78cf2b88-306a-4f88-b54f-d383655d2f69">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d3fb0c5d5a24db099308a75d6d48348_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi05LTEtMS0xMzE2MTg_ae698376-872f-46fc-b710-53b2468985f7">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic4232e5688d9417880fdb23acd1671dc_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMS0xLTEtMTMxNjE4_4475b2b7-02c6-46c5-aae9-97b6fac707cc">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4c5ea1c804e54b9da2cfa1e35191be79_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMy0xLTEtMTMxNjE4_fe1f1e39-6c59-4492-a54d-f6057804f23c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i31c000934f3b49b4a1049b7c5825c3d0_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xNS0xLTEtMTMxNjE4_e55660ab-f3d2-48b4-a76a-b60223b51e11">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i012d7bd208a247b4b543d54583a218ef_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xLTEtMS0xMzE2MTg_b26b196d-d28e-4b44-80d1-ae7a4000970f">1,284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07338fb5662b49d5bc2528a3307c626b_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0zLTEtMS0xMzE2MTg_767b5fb1-432c-4252-8b7f-b5a1c59bdbce">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic115d2d37fd44d80b15e651843a0417f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy01LTEtMS0xMzE2MTg_19ae8582-9021-47e0-ae04-3bf16d691cb0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8d827d1b17a45afbc3e288430a5dc82_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy03LTEtMS0xMzE2MTg_035fdb1c-cf4d-41d1-b7c4-e3c11a1af9d2">1,284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6bb17c88faa0435c933b88267089cb0f_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy05LTEtMS0xMzE2MTg_fcd82b47-bbc0-4c85-a37b-631874a80b4a">1,015</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib04f9b00c03c4e4ea6423dcfad58d6b3_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xMS0xLTEtMTMxNjE4_7efdc7f9-72d3-4b34-9816-0d9d31a1e50b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie908803a7baf418983f47014731e40ea_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xMy0xLTEtMTMxNjE4_1f84d769-2780-471a-89c0-f9076e0a54b1">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1db38063fdeb45aaa60b2e97a4474133_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xNS0xLTEtMTMxNjE4_21988a98-02bb-41b5-a30d-e1dc03b4c60f">1,015</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xLTEtMS0xMzE2MTg_4e4e971f-a4b0-41c0-890c-e274b7e2923d">1,284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0zLTEtMS0xMzE2MTg_f6e2f1a6-d2b2-4586-8abe-6e4bde4e8b74">686</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC01LTEtMS0xMzE2MTg_a8f16158-84ce-4260-bf3e-1a2b77537f23">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC03LTEtMS0xMzE2MTg_4c724860-a9a6-401b-b051-7756ecc7b7c6">1,970</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC05LTEtMS0xMzE2MTg_2e52ab60-a4d3-4acc-9d80-ead68654c649">1,015</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xMS0xLTEtMTMxNjE4_b0794eec-ed80-419b-b140-9eb616a79d80">498</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xMy0xLTEtMTMxNjE4_80c26481-74a1-4d11-83d1-231c47605b71">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xNS0xLTEtMTMxNjE4_0e575ddb-093d-4dce-a701-a729e92740f4">1,513</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7f9e79091e5045c68d0f830e6ac4c990_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMS0xLTEtMTMxNjE4_b7c1774b-3226-4605-88f3-ffd02dbb5576">70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2795fcc4916b4738ba959e843ff69ec3_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMy0xLTEtMTMxNjE4_d80dfe03-f2c8-46d3-8d9d-ae292b277c45">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96de2214f40e4ba59e7b629d43ba4d91_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtNS0xLTEtMTMxNjE4_5696dfda-858a-44f8-aa3f-0f1de3e51b31">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i451160fbee604ab990070211ebeba8de_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtNy0xLTEtMTMxNjE4_96f45da5-f6a7-428b-9c26-420e3f43d14e">70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46d67fffc7944fb8af71441dc67f9462_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtOS0xLTEtMTMxNjE4_c4c7ec95-902b-44e1-9a72-0cc089655c01">68</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifb8445329cbd40e38c431a9cab4cb4d6_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMTEtMS0xLTEzMTYxOA_8e6882df-69cc-43b6-92c5-6b02032038bc">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3beec2a915ab4328b794d0b11fbc0788_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMTMtMS0xLTEzMTYxOA_f478da74-6cfe-494e-9c7c-d312ae56e06b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i814823701512438f9446387df4b6adcf_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMTUtMS0xLTEzMTYxOA_e0dbc358-8f5c-4477-adb7-e1f332799b80">68</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c30409b333846a0b003f5261f708353_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMS0xLTEtMTMxNjE4_5f566187-2eb1-48c2-97f7-2c159c59ea87">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d1c02180ad34f3e83fbb3df043ae3f5_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMy0xLTEtMTMxNjE4_7c5c3aa8-c0b3-4a1f-8d99-d5b536f050c8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6288684e9335426a899ee4586882280c_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtNS0xLTEtMTMxNjE4_26355afe-92f3-46f1-ba80-d9110584de78">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i305ac9c4908a4bffa1b9ce0a56239183_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtNy0xLTEtMTMxNjE4_b4bd97eb-c6c3-4491-b71f-d23814cf4375">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3eaafa1e0ba64836a551188797cd7c7c_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtOS0xLTEtMTMxNjE4_5a24c76e-6057-4665-8584-a8e8f721fc56">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic36ef238f34c4ab180d3b3a52624eb9d_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMTEtMS0xLTEzMTYxOA_3a8192b4-d20e-4fa4-88ad-fe6c85e7ed87">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib784c86ce67446f7940a517458674fd1_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMTMtMS0xLTEzMTYxOA_ca1d9860-b54f-460d-9830-bf60df710d8b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i004682e5e94d4b12b9f2913eefd3a7fb_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMTUtMS0xLTEzMTYxOA_c53c81dd-ecab-4af7-accf-670d4d759793">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i012d7bd208a247b4b543d54583a218ef_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMS0xLTEtMTMxNjE4_0c5b3078-6b13-4fa4-867c-93f3112b530f">301</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07338fb5662b49d5bc2528a3307c626b_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMy0xLTEtMTMxNjE4_dd65fcb2-a6bd-4fb6-bc1d-10911ad2ef40">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic115d2d37fd44d80b15e651843a0417f_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItNS0xLTEtMTMxNjE4_84b98074-1b42-42c2-823d-5feee64de00e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8d827d1b17a45afbc3e288430a5dc82_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItNy0xLTEtMTMxNjE4_01172adc-e976-43c7-b190-2dc1de853e05">301</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6bb17c88faa0435c933b88267089cb0f_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItOS0xLTEtMTMxNjE4_d8e922eb-e03c-4a4b-a32b-c7854d522014">269</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib04f9b00c03c4e4ea6423dcfad58d6b3_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMTEtMS0xLTEzMTYxOA_cc97dd16-0871-4d57-ac48-cac4203bccfb">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie908803a7baf418983f47014731e40ea_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMTMtMS0xLTEzMTYxOA_de47a288-b36d-44b8-97d1-b01f8b3b73bd">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1db38063fdeb45aaa60b2e97a4474133_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMTUtMS0xLTEzMTYxOA_7b34bd22-cd04-4cbd-91e1-7a917f7e7eaf">269</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMS0xLTEtMTMxNjE4_292d338b-e4a7-46ab-b976-e6e4607c57f3">375</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMy0xLTEtMTMxNjE4_4825e079-11ba-4dea-80d4-9e0817058aec">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtNS0xLTEtMTMxNjE4_0ab20310-6b48-4e18-9499-a4d6eea90eb3">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtNy0xLTEtMTMxNjE4_9783e758-1216-4218-b674-8ab5f9ee62c1">375</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtOS0xLTEtMTMxNjE4_fcd41c03-7b67-4fce-8ca4-3317b93b11e5">340</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMTEtMS0xLTEzMTYxOA_5d8904c2-de85-4a36-809a-a1c1f6ae4b82">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMTMtMS0xLTEzMTYxOA_d3fe0a7c-5618-490a-95b7-9982c5fe7220">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMTUtMS0xLTEzMTYxOA_29f75233-134b-465e-b19b-49dfb159de7c">340</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34260a2a17d947768f68d2798eb0f8c1_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMS0xLTEtMTMxNjE4_ca36872b-5bfe-42b2-93b4-a0b8b968576a">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0b068359fb3948a182327c67ab308fb4_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMy0xLTEtMTMxNjE4_b0cd73d8-2b57-4754-be46-a5fd56f17be3">139</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia8f7806f9be14762977b7e08e79e4daf_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtNS0xLTEtMTMxNjE4_3546d76f-fdfb-41cb-903a-68bb4d765c65">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a2e484401b24c479443887a01bf805c_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtNy0xLTEtMTMxNjE4_dfa00044-779f-41b4-a83f-12d03be91fe4">139</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2b1b40aabc7a4eedbc4ba7ac12424d0c_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtOS0xLTEtMTMxNjE4_df1f3877-2282-48e1-b140-7768875f1dbf">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5265c6f93c7f46d1ab829156c30fdf74_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMTEtMS0xLTEzMTYxOA_2fe12f6d-57a4-4776-a315-8d550fb49a97">215</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic497e29b39d04693be035586e02049ba_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMTMtMS0xLTEzMTYxOA_3bc604fd-c461-4663-af44-8be75b1e76c3">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i970e6180f53c4baeb53fdd14d90061da_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMTUtMS0xLTEzMTYxOA_b28c6326-6031-44db-9fdd-bd862903f773">215</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i075080b8fa0045b6adf42ad9d680a586_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMS0xLTEtMTQyNzM5_0c24c1b0-0975-465c-9422-c5059618e9ba">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if826811b47d7448eb6e1f3d6c36b5841_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMy0xLTEtMTQyNzM5_b9066cb5-337e-4246-9d51-c2408a0ea254">119</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96e781b662154001934e50bb59beb7cd_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctNS0xLTEtMTQyNzM5_d24738f0-8879-4bac-84e6-699c957684ae">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibffb1c0f1856491795524f9ede8241fc_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctNy0xLTEtMTQyNzM5_f9ceb638-bc1a-49ae-8c1a-31e382cdddb8">119</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ba1c7342bdd4e82a5d14645ae050399_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctOS0xLTEtMTQyNzM5_bfd9b65a-26e5-49bd-ad0b-8392d0378711">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i294603384e1e48b1b1962054c70f8781_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMTEtMS0xLTE0MjczOQ_0d7ae1eb-e839-4658-bdd8-3a60b50c9151">218</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie2707a83a0684b81b3f82c21c1a7d1e9_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMTMtMS0xLTE0MjczOQ_95ea9c4a-7172-4401-b15d-5eb65d8b05f2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia524db85b9fb4e5faaed403cdac7f778_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMTUtMS0xLTE0MjczOQ_749b4f51-5f97-4cf5-9ff1-8d9b6ce4f5f4">218</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id4b65ea8a7a94fb5acbe089d34abecfd_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMS0xLTEtMTQyNjM5_359fe91c-b543-42a8-846f-a49881989970">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iefe9381ed615477a8d395b385d4bfc96_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMy0xLTEtMTQyNjM5_add84cbf-83a4-4e47-9505-f779aa30b8ba">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iec2a2a2cde214dcf9145e7fed863dfaf_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNS0xLTEtMTQyNjM5_a98df310-7cd0-4565-9a0a-dd4677e59b62">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie0fdebb01cd44ff4b7dd90a3757e19a8_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNy0xLTEtMTQyOTAw_1935a71d-f60f-42c0-b621-d68401600e44">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92b2724f66144388bc9d877014d99971_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtOS0xLTEtMTQyNjM5_4a9e2ed3-83ef-49ec-a881-f2d27ce14dba">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i402e5d3ff33d4949b0046490210e38a1_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTEtMS0xLTE0MjYzOQ_17f6df11-b755-4b6f-8c28-622c23fe9c63">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia4a496ea51974c41968d7d7ece436a35_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTMtMS0xLTE0MjYzOQ_4e142787-e72f-4516-8e1a-15d8679c2fc1">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i04e31d8852884bf89e5bcb8b4f124896_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTUtMS0xLTE0MjkwMA_410446bf-d1af-4dcf-906a-f57c822644ec">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMS0xLTEtMTMxNjE4_9b24cb78-a48f-4a20-91f2-b2cc52391c8d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMy0xLTEtMTMxNjE4_53abf6f3-62df-4e76-9697-be441d83fb49">259</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNS0xLTEtMTMxNjE4_4e7d2486-4293-46dc-8206-1f6d8d93321d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNy0xLTEtMTMxNjE4_8ed6e4b1-9fbf-44d5-b2ad-4671b6263c58">259</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtOS0xLTEtMTMxNjE4_5d074d82-04a0-4fe5-b072-81bf95f40d1c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTEtMS0xLTEzMTYxOA_cc2a570a-97b1-44ce-af07-5f0c1a640cb7">433</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTMtMS0xLTEzMTYxOA_8ae18f96-6d3b-43ed-ba57-67240c0dfd12">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTUtMS0xLTEzMTYxOA_284f4954-e0c9-43b7-9bf0-10fa07c5e1b1">433</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMS0xLTEtMTMxNjE4_58916fb2-9d1b-40e8-9f85-0d1c3c679c51">1,659</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMy0xLTEtMTMxNjE4_5f3bf00a-64cc-4917-a293-bfdbcef934c9">945</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktNS0xLTEtMTMxNjE4_b655d779-28b5-4cd1-8d8b-5fc9761830d8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktNy0xLTEtMTMxNjE4_6b4d4136-85e1-4f14-b3b9-9e3fa023da9f">2,604</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktOS0xLTEtMTMxNjE4_f2cf04e7-a236-4643-bcb8-2eed165c7855">1,355</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMTEtMS0xLTEzMTYxOA_76cedcc4-4a6b-4536-8477-c41e9d972482">931</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMTMtMS0xLTEzMTYxOA_4960d5cd-0675-4292-b1f8-eafce8616e9b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMTUtMS0xLTEzMTYxOA_a8330c04-4d6c-417b-b9c7-123fa114b6db">2,286</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMS0xLTEtMTMxNjE4_483e8c09-8fd3-4704-b97d-002e40b38d10">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMy0xLTEtMTMxNjE4_8d1fbb4d-d276-4025-80cb-7537cc352a36">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItNS0xLTEtMTMxNjE4_9a72a642-8e82-4e99-b714-adb309aa9824">353</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItNy0xLTEtMTMxNjE4_d25bf528-9231-4ba8-9aec-b1bbc9947029">353</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItOS0xLTEtMTMxNjE4_88da0802-966b-4747-a7d3-89fc8d1761f4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMTEtMS0xLTEzMTYxOA_67dc2411-5000-4474-b67a-7c69401f7c52">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMTMtMS0xLTEzMTYxOA_19d25332-f73b-4c80-ac60-db5e4d1d038b">456</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMTUtMS0xLTEzMTYxOA_84bfb37e-b89d-48e0-a3f3-08164eb33d77">456</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i075080b8fa0045b6adf42ad9d680a586_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMS0xLTEtMTMxNjE4_7fb4b891-f36b-4b58-93ee-1865502b2ff1">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if826811b47d7448eb6e1f3d6c36b5841_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMy0xLTEtMTMxNjE4_849178a0-9960-4c32-bbdf-897b019c2a76">276</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96e781b662154001934e50bb59beb7cd_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtNS0xLTEtMTMxNjE4_30447676-6124-476e-84e4-6e98b6c6496e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibffb1c0f1856491795524f9ede8241fc_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtNy0xLTEtMTMxNjE4_db589160-61c7-41fd-94b5-e1b0c9c35dfa">276</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ba1c7342bdd4e82a5d14645ae050399_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtOS0xLTEtMTMxNjE4_2cecf214-d3fe-4d3b-b75d-dbf3dbb49a68">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i294603384e1e48b1b1962054c70f8781_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMTEtMS0xLTEzMTYxOA_2c5212ca-19aa-4b55-acd7-24f2d0b1691e">402</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie2707a83a0684b81b3f82c21c1a7d1e9_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMTMtMS0xLTEzMTYxOA_97006aaa-a6f2-4c7c-a096-bfd142a55687">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia524db85b9fb4e5faaed403cdac7f778_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMTUtMS0xLTEzMTYxOA_9b23a4de-9f1f-4733-893a-f2c6bd10d8f6">402</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34260a2a17d947768f68d2798eb0f8c1_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMS0xLTEtMTMxNjE4_eba8a516-d7d5-413d-8f4c-2538153b6e7e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0b068359fb3948a182327c67ab308fb4_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMy0xLTEtMTMxNjE4_0cfb45d0-81a5-425b-9a07-f2b8b369f752">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia8f7806f9be14762977b7e08e79e4daf_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtNS0xLTEtMTMxNjE4_b533cf8b-13ee-4517-ace8-a52379956989">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a2e484401b24c479443887a01bf805c_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtNy0xLTEtMTMxNjE4_3dd0ac8c-acb4-4e00-ac7a-10d0f9a6c305">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2b1b40aabc7a4eedbc4ba7ac12424d0c_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtOS0xLTEtMTMxNjE4_05325343-7ff4-4597-b6a5-a8b6dc33f8a5">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5265c6f93c7f46d1ab829156c30fdf74_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMTEtMS0xLTEzMTYxOA_762439c4-93ca-4fc0-91c3-1854b6061e9a">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic497e29b39d04693be035586e02049ba_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMTMtMS0xLTEzMTYxOA_4f213633-9202-409e-8c29-923e8db35773">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i970e6180f53c4baeb53fdd14d90061da_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMTUtMS0xLTEzMTYxOA_6a1cb643-070f-4b60-a5e0-0f20fbe6eae3">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id4b65ea8a7a94fb5acbe089d34abecfd_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMS0xLTEtMTQyNjYy_024ffe50-d376-4c95-bce6-99e121e627fb">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iefe9381ed615477a8d395b385d4bfc96_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMy0xLTEtMTQyNjYy_fca214be-cfa6-4cef-84fe-cc43d44ab8d0">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iec2a2a2cde214dcf9145e7fed863dfaf_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNS0xLTEtMTQyNjYy_51aa7166-3ebe-4ee0-87ba-fbbb12541b7e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie0fdebb01cd44ff4b7dd90a3757e19a8_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNy0xLTEtMTQyOTA1_d40c5be6-44a8-41c9-bd2f-aa6dd24efd34">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92b2724f66144388bc9d877014d99971_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctOS0xLTEtMTQyNjYy_495c74db-3a49-4c66-8949-318bc67356bf">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i402e5d3ff33d4949b0046490210e38a1_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTEtMS0xLTE0MjY2Mg_269bf6d4-76e1-47dd-be52-efb7022fefea">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia4a496ea51974c41968d7d7ece436a35_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTMtMS0xLTE0MjY2Mg_6df333ce-8880-4bd8-a301-c400065f1764">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i04e31d8852884bf89e5bcb8b4f124896_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTUtMS0xLTE0MjkwNQ_4d7d9ef9-ca6c-4d6f-8128-1a8750b46d18">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMS0xLTEtMTMxNjE4_b857af57-9d2e-4eb5-9dd5-1f34bf374b7f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMy0xLTEtMTMxNjE4_5535b5e1-3f27-403e-a8ef-1bc6a00ccd1a">284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtNS0xLTEtMTMxNjE4_bcca3703-a77d-4d28-9c9f-ef89a99462b2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtNy0xLTEtMTMxNjE4_fd46a7fd-f447-45bf-8841-88f4e7c8d3dd">284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtOS0xLTEtMTMxNjE4_dee273a3-9619-4474-96b8-49885d93ac42">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMTEtMS0xLTEzMTYxOA_ecaddc40-f9eb-4e29-9dfa-e2cec2451f9e">409</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMTMtMS0xLTEzMTYxOA_d0af7ed3-95ce-4a5d-9629-e463ec23d3e4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMTUtMS0xLTEzMTYxOA_473cf8ad-74c1-4db0-9ec0-5b2db273d472">409</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMS0xLTEtMTMxNjE4_0c86ec9e-e6fd-42b1-82ce-8d4cbc61cb18">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMy0xLTEtMTMxNjE4_820c292d-a492-40f2-ae40-217bfcf5d286">284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNS0xLTEtMTMxNjE4_229c5749-4671-4364-985a-21d5f134e1d7">353</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNy0xLTEtMTMxNjE4_9152b670-9b27-4261-be56-a76cbb6c1ad0">637</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctOS0xLTEtMTMxNjE4_3cef6eb2-da16-40ac-a2d3-c8696cf3e143">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTEtMS0xLTEzMTYxOA_5979c81c-86d2-4e6c-8da4-ad307b8cc0b9">409</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTMtMS0xLTEzMTYxOA_4843c7b6-5dde-4aa6-a5c3-005f3e625252">456</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTUtMS0xLTEzMTYxOA_6853952c-b498-47a2-b79c-07d82b45501c">865</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2023 and December&nbsp;31, 2022, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included $<ix:nonfraction unitref="usd" contextref="i8dcc8586471c42e6a0ee92dda4a6bd01_I20230331" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQyMzE_756d628a-d2cf-4408-96d7-4b7016dc49da">8.8</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="i8f39864d8e8e466da61d331c664f14db_I20221231" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQyMzg_569481a9-ffb8-4b27-bad8-0e5c06ddb3a7">11.3</ix:nonfraction> billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5Nzk_77d6f099-347e-4ded-9d4d-8c753d5a96ab" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMS0xLTEtMS0xMzE2MTg_144665d5-ea1c-43c1-9aef-5f5684399d89">456</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMS0zLTEtMS0xMzE2MTg_f44b2f37-b77f-411d-977f-63b293cb5d5a">777</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMi0xLTEtMS0xMzE2MTg_3eebe763-44f1-4be7-85bd-478614d9db0c">14</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMi0zLTEtMS0xMzE2MTg_a2cfc153-5828-4ebf-97fb-c3ee10feb3b6">84</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMy0xLTEtMS0xMzE2MTg_4d12b177-9678-4d70-b824-edfc1a591885">117</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMy0zLTEtMS0xMzE2MTg_446bc6f6-c8ff-442d-b484-b2d78e5f4d91">119</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNC0xLTEtMS0xMzE2MTg_f34d6fff-2ba0-47a0-9b9d-b7014565b79a">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNC0zLTEtMS0xMzE2MTg_9e60961c-a4d4-4846-bf26-70f7a060b5a9">2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value March 31 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNS0xLTEtMS0xMzE2MTg_937a569b-3c02-4cb3-b545-8f46e95255c6">353</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNS0zLTEtMS0xMzE2MTg_f5c083dd-45d4-43c3-8187-91a5c8278e76">572</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At March&nbsp;31, 2023, $<ix:nonfraction unitref="usd" contextref="i8ae2044462124fec8e736b9c160ff048_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQ2ODE_f0029f4c-363a-4329-b0ee-b08014ee1ee9">263</ix:nonfraction> million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of <ix:nonfraction unitref="number" contextref="i8ae2044462124fec8e736b9c160ff048_I20230331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQ4NzI_84ce529a-09f8-40ac-bd31-4ab974671ecd">11.5</ix:nonfraction>% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March&nbsp;31, 2023 includes $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTUxODk_e22e0c6e-3065-42f2-9080-127c8d38a9af">127</ix:nonfraction> million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 16 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i4aa981479cc240b99204444f93effa2b" continuedat="i42f07933ba0a422aa7ce77acefa705ad"><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at March&nbsp;31, 2023, was $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU3NDc_dd08989f-2216-4edb-b796-c503fe479885">28.2</ix:nonfraction> billion compared with a carrying value of $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU3ODQ_4bddb375-cd4d-4b80-8747-ec3b4e5fd365">30.7</ix:nonfraction> billion and at December&nbsp;31, 2022, was $<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU4MDI_fb050a51-0b39-4b7b-aefb-34671fcd6d62">26.7</ix:nonfraction> billion compared with a carrying value of $<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU4Mzk_ca6ef105-6c3d-4d8a-a844-b11cccd7a0b6">30.7</ix:nonfraction> billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&nbsp;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTcxNzI_3b64962b-ba67-4dfa-8d8c-68996b3eee4a">2.4</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="i8fbdfdee6afe4e74be18dd0c62050372_D20220101-20220630" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTcxNzk_3508a104-7358-486a-84b3-3fd5843cf9e9">2.5</ix:nonfraction> billion of accounts receivable as of March&nbsp;31, 2023 and December&nbsp;31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of March&nbsp;31, 2023 and December&nbsp;31, 2022, the Company had collected $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTc3MTE_29b14408-9971-40df-802b-4c63e56ae094">31</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTc3MTg_ab0d93d2-301c-48bb-abea-677752a41a12">67</ix:nonfraction>&nbsp;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in April 2023 and January 2023, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:continuation id="i42f07933ba0a422aa7ce77acefa705ad" continuedat="id92d384b2ecf4ee6b3b13fd8ebaad63d"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg3Njg_d0033a4b-116f-4d9e-afb2-d46a836a0099">13</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg3NzU_3583c354-e49f-4b24-8233-399cd07c5518">66</ix:nonfraction>&nbsp;million at March&nbsp;31, 2023 and December&nbsp;31, 2022, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="id92d384b2ecf4ee6b3b13fd8ebaad63d">. Cash collateral advanced by the Company to various counterparties was $<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODQyNDM0_3a44d50f-65f2-4ace-ae90-ba4fdee12ef2">19</ix:nonfraction>&nbsp;million at December&nbsp;31, 2022.</ix:continuation> </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_52"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfNDE1_4c332579-e324-41dd-9b03-06a4608d6fe6" continuedat="iac5659fedc284494badfce0aad989599" escape="true">Inventories</ix:nonnumeric></span></div><ix:continuation id="iac5659fedc284494badfce0aad989599"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfNDA5_5283fbab-b21a-4cc0-a45c-e64bf59e84a6" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMS0xLTEtMS0xMzE2MTg_e1f6b193-23f4-45f6-a0ff-65afe27b34ec">1,883</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMS0zLTEtMS0xMzE2MTg_dfd8aeb2-f296-41b7-b8be-0329788b9701">1,841</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMi0xLTEtMS0xMzE2MTg_a1fc6eec-983f-49e3-a65d-e8dd0b1f9b93">7,348</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMi0zLTEtMS0xMzE2MTg_63aa8994-a633-4972-934d-ce15a670318a">7,063</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMy0xLTEtMS0xMzE2MTg_8af8aeca-6237-43ab-877f-433e3133ea01">266</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMy0zLTEtMS0xMzE2MTg_5c3f5a84-2d10-46d4-915e-43ab902e6726">238</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNC0xLTEtMS0xMzE2MTg_a885691e-a5f3-49e1-a1ec-dbb2526192e0">9,497</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNC0zLTEtMS0xMzE2MTg_8dc1d0d1-7d74-490c-9e5a-1bcab747bc63">9,142</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNS0xLTEtMS0xMzE2MTg_11a9a970-489b-405e-8b07-ac844e2ad6e9">350</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNS0zLTEtMS0xMzE2MTg_b959ab9b-2ed9-4237-8288-871c069d11d6">293</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNi0xLTEtMS0xMzE2MTg_0f4ba765-458d-4eff-8f69-7ca34c91bf12">9,147</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNi0zLTEtMS0xMzE2MTg_1b4eba78-0003-4fee-9a6a-cb4475c2773d">8,849</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOC0xLTEtMS0xMzE2MTg_59a83081-cdc6-481b-a41d-a5fa08b70c85">5,863</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOC0zLTEtMS0xMzE2MTg_8381d8f5-0cb0-4788-bdf7-520cc25f1f91">5,911</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOS0xLTEtMS0xMzE2MTg_2f636f35-37e8-4a37-9a84-f3e6e0032938">3,284</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOS0zLTEtMS0xMzE2MTg_9a179ab2-4d38-4998-99b4-6e89a5f22c91">2,938</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At March&nbsp;31, 2023 and December&nbsp;31, 2022, these amounts included $<ix:nonfraction unitref="usd" contextref="idf5ff6cbdf22489b9efa70ffb318b8aa_I20230331" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMTky_99619c2c-e46e-4e78-84fe-2645edfe4d6d">2.7</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="ie2fc780817394ba39db27d26c677ae95_I20221231" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMTk5_bc507a30-3a03-4bd0-ad9d-68d00864527a">2.4</ix:nonfraction> billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $<ix:nonfraction unitref="usd" contextref="i49dd486feefe4b749fbe2cca62e80318_I20230331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMzA5_aca92398-3c98-4b83-a9ed-0ee0fac2032e">590</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i3e717c1f26e14e87978e3de102e7c698_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMzE2_b00c67e1-0554-464d-8b73-541b7e4fada9">516</ix:nonfraction> million at March&nbsp;31, 2023 and December&nbsp;31, 2022, respectively, of inventories produced in preparation for product launches.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 17 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_58"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjM4Njk_a2d92dec-e1f1-4934-9a15-0b554c1df578" continuedat="iad3de5c413d84d71a4dabb1b11cbf4d6" escape="true">Contingencies</ix:nonnumeric></span></div><ix:continuation id="iad3de5c413d84d71a4dabb1b11cbf4d6" continuedat="i6254f56b1fa9408da148277f1ce1f8d6"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&nbsp;what claims, if any, will survive dispositive motion practice, (ii)&nbsp;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&nbsp;how the discovery process will affect the litigation, (iv)&nbsp;the settlement posture of the other parties to the litigation and (v)&nbsp;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. <ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjM4ODI_742de232-8515-4d34-814a-a249c63924e4" escape="true">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</ix:nonnumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March&nbsp;31, 2023, approximately <ix:nonfraction unitref="case" contextref="ie81327a316a94b36974954a7e8642bc5_I20230331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNjM4Mg_077e1822-fc37-45b9-a87e-2b9a60f0b7fb">95</ix:nonfraction> cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than <ix:nonfraction unitref="case" contextref="ide0712a78628418ab61bbe9bb313aae7_I20230331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNjk5MQ_66d877f2-2855-4d20-a17d-2356ffed2073">15</ix:nonfraction> product liability cases pending outside the U.S., including <ix:nonfraction unitref="case" contextref="i7358a61460544d15a70b0957807efa73_I20230331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNzA1NA_7d77d8a9-f37b-4c13-845a-debef74650e7">one</ix:nonfraction> purported class action in Colombia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, Merck Sharp &amp; Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of <ix:nonfraction unitref="direct_purchaser" contextref="i674ee2f2e244467391945b56813ef740_I20200831" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfOTE3MQ_27bedc13-deb8-4aff-a0a0-29ea498e6a54">35</ix:nonfraction> direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. In April 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 18 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i6254f56b1fa9408da148277f1ce1f8d6" continuedat="ib3b3a881bb004b039ab4088546d4e89b"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL and remain pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, <ix:nonfraction unitref="claim" contextref="i486acde0965b4e4fa567b783874fdd1b_D20220630-20220630" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMTExNTU_67e7e2c1-fcb5-42eb-8851-48b975b16c89">23</ix:nonfraction> new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 10, 2023, the district court denied the Merck Defendants’ and Glenmark Defendants’ motions for summary judgment. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck will pay $<ix:nonfraction unitref="usd" contextref="i07e39fac74fc4d08a501e1e14a991816_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1OTAwNzMx_80c4d5be-3421-4a0a-b221-69ca44c1f0e1">572.5</ix:nonfraction> million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs’ claims, which was recorded as an expense in the Company’s first quarter 2023 financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 3, 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in <ix:nonfraction unitref="state" contextref="i88f1868d275a4b89ac8e4f956b24ddc5_I20230303" decimals="0" name="mrk:LossContingencyNumberOfStatesInWhichPlaintiffsReside" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjc0ODc3OTE1NjQwNA_7d9cd40d-964c-4f9f-9203-61ffda2d796a">35</ix:nonfraction> states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, trebled, and fees and costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal in February 2022 and issued a decision in April 2022 allowing both parties’ appeals in part. The Court of Appeal amended the class period to start on July 2, 2014, allowed a second plaintiff to serve as a class representative, and modified the list of conditions in the class definition by adding “death” and removing “lack of efficacy.” The Court of Appeal also added to the list of questions to be considered by the trial court the questions of whether the Consumer Protection Act of Quebec applies to the sale of a veterinary product and, if so, whether it was breached. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&nbsp;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&nbsp;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 19 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ib3b3a881bb004b039ab4088546d4e89b" continuedat="id1ac567cfbb14c319494434cb0fe4474"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a <ix:nonnumeric contextref="i4305661e65274f559b5b59766d3c5cc3_D20221219-20221219" name="mrk:LossContingencyTrialPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjc0ODc3OTE1NjQwNw_9663f7fe-ce41-4262-9103-cfb75f192549">one-day</ix:nonnumeric> trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered post-trial briefing on this defense and held closing arguments on February 3, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has settled with <ix:nonfraction unitref="company" contextref="i4bd3fe27e3bf4036897cd39ae0448f14_D20230101-20230331" decimals="INF" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMTU2NDc_e41291d9-fbdc-4ace-adb5-d485d6a1750a">five</ix:nonfraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against <ix:nonfraction unitref="company" contextref="i79aeb0bcc641443b80308ef30bbad1d3_I20230331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMTU5NDE_97198d3d-5fdf-4063-9c7a-e7ddd8204303">two</ix:nonfraction> generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, the FDA granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCI), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held in April 2022. In September 2022, the District Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) appealed to the U.S. Court of Appeals for the Federal Circuit. The parties have now settled the matter, and Mylan has agreed to voluntarily dismiss the appeal following entry of an amended final judgment by the district court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held in August 2022. In September 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In total, the Company has settled with <ix:nonfraction unitref="company" contextref="id8407355ea334e558a58d39cf813e848_D20230101-20230331" decimals="INF" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1ODUzOTg3_58fcfea1-9958-4bb9-8d6b-bc828abcfaed">25</ix:nonfraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus has filed a NDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 20 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="id1ac567cfbb14c319494434cb0fe4474"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the U.S. until May 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until July 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, although another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplementary Protection Certificates (SPCs) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expired between April 7 and 10, 2023, for the majority of European countries. Prior to expiration, generic companies sought revocation of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs in Europe, for which an oral hearing was held on March 8, 2023, and an Advocate General Opinion is expected on July 13, 2023. If the CJEU renders a decision that negatively impacts the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPC.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company filed a complaint against The Johns Hopkins University (JHU) on November 29, 2022, in the District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Merck and JHU partnered to design and conduct a clinical study administering </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract; declaratory judgment of noninfringement; and promissory estoppel. JHU answered the complaint on April 13, 2023, denying Merck’s claims, and counterclaiming for willful infringement of <ix:nonfraction unitref="patent" contextref="i270837c6ca8b41c49574b8b379172454_D20230413-20230413" decimals="0" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1ODU0MDIz_db06a4e7-66fd-4e4a-afcb-a46d2bbdd18b">five</ix:nonfraction> issued U.S. patents, including a demand for damages.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March&nbsp;31, 2023 and December&nbsp;31, 2022 of approximately $<ix:nonfraction unitref="usd" contextref="i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjMyNjg_3cea9046-e2cc-4593-8c4b-44b32a39b73f">225</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="ica1e472338aa4a5298e4b867322ded49_I20221231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1ODU0MjMy_7de2f884-2dc4-4988-9930-4051c329a43b">230</ix:nonfraction> million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_61"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 21 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RleHRyZWdpb246YjZhODViNTUxOGFlNDk3OWEzZTZlYWM5YmY3ZmNkMTlfMjA_a3624188-3689-4101-958b-3de4cf30928e" continuedat="i80bb926a9500493e81dbc0907f32396e" escape="true">Equity</ix:nonnumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i80bb926a9500493e81dbc0907f32396e"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RleHRyZWdpb246YjZhODViNTUxOGFlNDk3OWEzZTZlYWM5YmY3ZmNkMTlfMzA_69ef70d4-a187-4028-b94e-703e168d085e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:29.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other<br>Paid-In<br>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retained<br>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated<br>Other<br>Comprehensive<br>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-<br>controlling<br>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par&nbsp;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ia75c3b66a14446a7b7855544f19742bf_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy0xLTEtMS0xMzE2MTg_00e39d87-4530-4b70-af6d-4051e5b842b3">3,577</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia75c3b66a14446a7b7855544f19742bf_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy0yLTEtMS0xMzE2MTg_4ddc6db0-4b61-43ec-b275-702ca36a6335">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice6bdceaee0c415785e978b1546e824f_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy0zLTEtMS0xMzE2MTg_2bff4825-46c6-4871-8a42-dfdda7ef581f">44,238</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4f9c7cab12f84742bc529ca888140834_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy00LTEtMS0xMzE2MTg_7af0b20a-1f5d-4b8c-8931-e73c20ffc589">53,696</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0c01235f9a47471bbfd246c179b8ec70_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy01LTEtMS0xMzE2MTg_f5edb140-e0b3-4b62-b7f4-dbd1f5ffd6ef">4,429</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ifa0666b9b0854af18214a4de1da949d6_I20211231" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy02LTEtMS0xMzE2MTg_193ab8bd-5208-430b-b226-2f784e403788">1,049</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ifa0666b9b0854af18214a4de1da949d6_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy03LTEtMS0xMzE2MTg_49b4d697-57b2-4a04-b3b7-d90db55b09fc">57,109</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i957a5e7283804544961eeffd229d90ef_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy04LTEtMS0xMzE2MTg_efc21552-1da4-413f-9ca5-fa493bef71c8">73</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy05LTEtMS0xMzE2MTg_479c921e-7b99-4e2a-b26e-3dd32b9624ae">38,257</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieba2932606cf4136b76cf64715d17f5c_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNC00LTEtMS0xMzE2MTg_7ee6c7b2-ac48-495f-b230-f84f45694b37">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNC05LTEtMS0xMzE2MTg_6829220b-b062-4f31-a045-b1a7c53f88e7">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifce529878ee94fbc97ff3cdc8e49ccb4_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNS01LTEtMS0xMzE2MTg_0039b2f6-f0ee-43ca-9820-36979d9df1e7">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNS05LTEtMS0xMzE2MTg_903c0510-1faa-445d-baf6-e24595d17b18">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonfraction unitref="usdPerShare" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNi0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjo4NjIzMzlmYTg1Mjg0YjA5YjU1ZWQwMjNmNDMxYzljNl80NQ_c8eaff0d-d63b-42c3-8300-eea32f0c3040">0.69</ix:nonfraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ieba2932606cf4136b76cf64715d17f5c_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNi00LTEtMS0xMzE2MTg_eef64ab9-ceac-4d12-a773-31a0349ced8a">1,754</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNi05LTEtMS0xMzE2MTg_83146dbb-86de-4d39-a50e-febd3580a5ef">1,754</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i918170e5b2fc416bb5213a74ad72646f_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOC0zLTEtMS0xMzE2MTg_6ec3c77d-efae-4b88-a41b-118c6d8adb57">37</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6faee1c09a204c63baa2f8635ef78da4_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOC03LTEtMS0xMzE2MTg_bf3018f8-1928-4e6d-8489-c663bc3cd424">46</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOC05LTEtMS0xMzE2MTg_434ef5ac-1204-4ce4-a6ac-e84e9e547ee6">83</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4725be788d3c4f1f966fba475c841405_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOS04LTEtMS0xMzE2MTg_db25c73b-064f-4387-997b-18b202361271">3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOS05LTEtMS0xMzE2MTg_1c3da830-c2b5-42ab-b273-eb255e45a8df">3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i6e2497db5f4b4eda93858dd1c188cfb5_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtMS0xLTEtMTMxNjE4_64786792-553d-4c53-925d-d075e2799de7">3,577</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e2497db5f4b4eda93858dd1c188cfb5_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtMi0xLTEtMTMxNjE4_1cbf0e51-20e5-4105-9a31-09794fe159b7">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i08889407a4ca4fa69735b8332945794b_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtMy0xLTEtMTMxNjE4_a79cd451-8411-4f1a-a131-bb354873202b">44,275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idcc9c8d75d064da9855b8d3b37c02b10_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNC0xLTEtMTMxNjE4_6f2b82bd-1d18-4c4f-af22-1e5116bb94ff">56,252</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i42da78b36e31450dab3194041180b0ee_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNS0xLTEtMTMxNjE4_557a9836-7ad8-46a3-935a-00932fd70e16">4,369</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="id895bb14f7154486a761071e11a287ca_I20220331" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNi0xLTEtMTMxNjE4_e8ef6fb9-4bfc-4800-b351-5e04b6d58a25">1,049</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id895bb14f7154486a761071e11a287ca_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNy0xLTEtMTMxNjE4_9006f905-2967-4620-869f-6b10a7badd5f">57,063</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4350e7d8d13e45848709eed82cdba738_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtOC0xLTEtMTMxNjE4_1809f653-65d3-4a1e-b698-943e127d3e2c">70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtOS0xLTEtMTMxNjE4_271ac0f6-c83c-4eb0-8ff9-5f89970b1acd">40,953</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i15d6c8aebc384e4b973cac8799704239_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItMS0xLTEtMTMxNjE4_009c386e-688d-4ce3-830e-210049a2807c">3,577</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i15d6c8aebc384e4b973cac8799704239_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItMi0xLTEtMTMxNjE4_f2bbb453-e234-4bac-8248-772151c439f5">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb5a854388ff4957836b5593bd4f37e4_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItMy0xLTEtMTMxNjE4_8b67cc09-b6eb-4d1e-9398-0fc5705d094d">44,379</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie7b73a7dc82c4055afd7242f0e94f662_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNC0xLTEtMTMxNjE4_4f2ccda2-ed8b-4189-856c-5e26cfd31fa0">61,081</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3b21fb880d134a06abed66e7d998914f_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNS0xLTEtMTMxNjE4_35542f8a-cf77-4c65-a246-c6addc3425d4">4,768</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i796d55aed90341e6a68727c28ffcab70_I20221231" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNi0xLTEtMTMxNjE4_93597b8b-97b0-4928-a347-b7260c51e041">1,039</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i796d55aed90341e6a68727c28ffcab70_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNy0xLTEtMTMxNjE4_81a6fee2-ed67-4c4f-bee6-cb46c6262f1e">56,489</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bc10dff04eb494ba85791126e4db053_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItOC0xLTEtMTMxNjE4_ca799a99-a538-4b54-af0e-7338ccfc3e3b">67</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItOS0xLTEtMTMxNjE4_7cb7a964-11ac-4a10-872b-984fba4248b5">46,058</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i87e04afadbc24d00bf0c906ad452972e_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTMtNC0xLTEtMTMxNjE4_77490c9b-2824-4712-b2dc-a5598ef4cec5">2,821</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTMtOS0xLTEtMTMxNjE4_6b1597ce-de1d-45ae-a2fb-dce203385551">2,821</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibe63a010ec0a40ed91fe4b6b16e51a63_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTQtNS0xLTEtMTMxNjE4_211c4cd3-8f60-4393-bee7-5f1b5240aa14">115</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTQtOS0xLTEtMTMxNjE4_158da7f7-bc51-4522-a2d2-ef6c9564860a">115</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonfraction unitref="usdPerShare" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTUtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246MDIwZjA5OGQxNDVlNDFlMzkyYjViM2VmNDY0MDQzZDZfNDU_93a1a064-af7d-43b4-b1e4-ba0cc5ecd5e2">0.73</ix:nonfraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i87e04afadbc24d00bf0c906ad452972e_D20230101-20230331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTUtNC0xLTEtMTMxNjE4_d097457b-ecdf-45ea-b8d7-fa6140ea494b">1,863</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTUtOS0xLTEtMTMxNjE4_aac68bce-43bc-4ea2-bc21-4d8637534e8a">1,863</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtNi0xLTEtMTM3ODE5_1b9678c8-10a3-47d3-be0b-b983b0909850">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtNy0xLTEtMTM3ODE5_1654c72c-4652-4fd7-bce0-6eb4976632d9">149</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtOS0xLTEtMTM3ODE5_60570ec4-daf6-43d7-948f-b4696c83b26e">149</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ied44c0afd9384c30953e94941daa0cb0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtMy0xLTEtMTMxNjE4_bfb140c9-53be-488c-ae2b-be5a2f37f9c0">88</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtNy0xLTEtMTMxNjE4_a6149862-b2f5-4ff8-a2cf-4b83052e1aff">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtOS0xLTEtMTMxNjE4_b1f25aab-cbf7-4b89-9e81-c5d02327e2c1">149</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i65afee1f42ae486f84514163f3843f68_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTctOC0xLTEtMTMxNjE4_548eff4e-54fc-4857-ac1c-28935f703c7b">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTctOS0xLTEtMTMxNjE4_9ca324f8-7231-43ee-ab3e-53121d69602f">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="id1742aab8c35467db6f531e481322561_I20230331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktMS0xLTEtMTMxNjE4_5e8636c3-f860-4177-8d79-69d9e020965c">3,577</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id1742aab8c35467db6f531e481322561_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktMi0xLTEtMTMxNjE4_3a6cfe71-aa08-4117-b5b6-70c8c954676d">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4b3b6bd9f9044238b1478ab578648204_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktMy0xLTEtMTMxNjE4_835da5bc-b1ed-412c-99b8-6e363da3232f">44,467</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18372378d12a4968ac3f82433fa9ffdd_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNC0xLTEtMTMxNjE4_0cee5ce6-7fa5-4bf0-a945-bd94cbdda1b4">62,039</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i60e7a6142fec4b32aa305b679a0d9a87_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNS0xLTEtMTMxNjE4_0f900243-0722-4d81-8828-c9462d27c4ba">4,883</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ie4437cb5ce2e4c6cb15d052910fc825b_I20230331" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNi0xLTEtMTMxNjE4_96f2ad4c-fd9c-45b4-b596-106d27e47a1c">1,040</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4437cb5ce2e4c6cb15d052910fc825b_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNy0xLTEtMTMxNjE4_b397eb37-0a27-4cd2-84f8-9d320d35eebc">56,577</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8aa514bfad3f4f6883b1d3d93683f530_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktOC0xLTEtMTMxNjE4_d7db5414-8597-4614-b692-73f44d934a00">71</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktOS0xLTEtMTMxNjE4_60259264-e5ec-44d1-aa27-82518ff19967">46,905</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.730%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_64"></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfOQ_0f12f849-f5a4-4846-863e-6737f43a2e6f" continuedat="i2252ca3ead0b4fa2a4febf86edf1aee5" escape="true">Pension and Other Postretirement Benefit Plans</ix:nonnumeric></span></div><ix:continuation id="i2252ca3ead0b4fa2a4febf86edf1aee5" continuedat="ifd50c5804b224d7c822c41c5e8babaab"><ix:nonnumeric contextref="id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfMjM3NA_27e92262-4dcb-446c-83d7-b3bf5dd3bc32" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components:&nbsp;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy0xLTEtMS0xMzE2MTg_bc50d610-0f0e-4ec7-972a-239d01f1578b">76</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy0zLTEtMS0xMzE2MTg_e925becf-d54a-4a3e-9f71-d06d95ef6b0b">49</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy01LTEtMS0xMzE2MTg_bce15ca3-af33-4069-b8ae-cf90a91668a9">99</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy03LTEtMS0xMzE2MTg_360fe79a-ce15-4b0d-9ddf-a36b730563da">75</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC0xLTEtMS0xMzE2MTg_ce68275b-2586-4ad3-98a5-e060e1147a83">133</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC0zLTEtMS0xMzE2MTg_eaefb7de-0edd-454b-a7c9-42dab90ee439">74</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC01LTEtMS0xMzE2MTg_46f55eaa-ff9e-4c24-a5cf-ce02b3dd74f6">103</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC03LTEtMS0xMzE2MTg_85c474bc-135d-4e46-bc7f-220fdbc2acf1">38</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS0xLTEtMS0xMzE2MTg_7f0a9699-e219-4ab9-8d41-929217a8c069">187</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS0zLTEtMS0xMzE2MTg_1bec951e-9ef8-4389-a54f-ac365441058e">128</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS01LTEtMS0xMzE2MTg_f178e151-3c0e-4b7f-8d49-44457f298800">196</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS03LTEtMS0xMzE2MTg_2d032457-09d4-402a-875f-8a2dd780f0d3">101</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi0xLTEtMS0xMzE2MTg_0d92a81f-84cd-411d-a033-71d5121cb9b9">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi0zLTEtMS0xMzE2MTg_0bdda1e1-1499-4eb3-b56d-8e4f9bf0fcd5">3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi01LTEtMS0xMzE2MTg_83365e9f-dfc1-407a-ac75-37d8c7011f50">8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi03LTEtMS0xMzE2MTg_50eec8d2-c0b7-479b-96ab-77ccc96224aa">4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (gain) loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy0xLTEtMS0xMzE2MTg_9c541295-0226-4cb9-86e7-5c2193ac6913">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy0zLTEtMS0xMzE2MTg_041f3f1f-9aae-4e00-99eb-5d47589d6706">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy01LTEtMS0xMzE2MTg_40f055d0-feaa-482a-b292-414119447d2a">56</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy03LTEtMS0xMzE2MTg_291f4111-2046-45e1-afdf-a65cf991e4c6">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS0xLTEtMS0xMzE2MTg_5a9d163e-2113-4feb-9c1a-6a70693bdade">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS0zLTEtMS0xMzE2MTg_88d0d1de-80d6-401d-a96c-8b24230aef7e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS01LTEtMS0xMzE2MTg_3a61c696-8c48-4940-bc29-306a9f1e7d4f">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS03LTEtMS0xMzE2MTg_c4d51d50-96f0-4fdf-8267-35a0eb0f8227">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtMS0xLTEtMTMxNjE4_bb68c941-c06c-44a0-97b7-d1311bfb71be">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtMy0xLTEtMTMxNjE4_5af1743a-1dbe-4e1c-b8a3-9895e6eb73e2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtNS0xLTEtMTMxNjE4_83756ca4-5ec6-4c1d-96fb-cf1d82aa3d9e">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtNy0xLTEtMTMxNjE4_b6f9fee0-967e-4741-a199-e7b1f4da27ff">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtMS0xLTEtMTMxNjE4_d02a4bee-a295-4c96-9430-48656b02422e">45</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtMy0xLTEtMTMxNjE4_9a6d5834-5eab-45f7-ae3a-343937984d65">9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtNS0xLTEtMTMxNjE4_89e75757-00de-4678-8b9a-6d5a91652ef4">58</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtNy0xLTEtMTMxNjE4_3579012d-8762-40f2-9a32-d6765d80f3d3">33</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><ix:nonnumeric contextref="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfMjM3Ng_d22f16e8-c377-4bb7-9a6d-ffb833ba1a39" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&nbsp;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMi0xLTEtMS0xMzE2MTg_29f68b7d-a0e6-4222-b8db-c03b4dbc62e4">8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMi0zLTEtMS0xMzE2MTg_73d10c4f-c0d9-43d0-85c2-b3bc9d15aa44">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMy0xLTEtMS0xMzE2MTg_674b1119-47ff-4351-8d19-21a0f55b9b85">16</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMy0zLTEtMS0xMzE2MTg_1c0ff7b5-0ab1-4bd8-ad72-fd338c79a089">11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNC0xLTEtMS0xMzE2MTg_d12fa7c3-e5c6-4a47-baa2-cb65d0132be4">16</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNC0zLTEtMS0xMzE2MTg_a2d31808-20ba-4d3c-a083-2566a4668cd7">21</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNS0xLTEtMS0xMzE2MTg_4b486b63-924c-4404-9650-39c984ee3c28">12</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNS0zLTEtMS0xMzE2MTg_1e432350-0b2c-47a3-afee-290511ee84c1">14</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNi0xLTEtMS0xMzE2MTg_9b783ab4-019e-4537-8a64-ee3f17e999ea">11</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNi0zLTEtMS0xMzE2MTg_abb38f13-6628-4b0f-b3f6-c614699880fd">11</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfOS0xLTEtMS0xMzE2MTg_afb053dd-c992-46c5-931f-3bd631f868db">15</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfOS0zLTEtMS0xMzE2MTg_e6da31f9-161f-4433-9748-f9b5db3a3923">23</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 22 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ifd50c5804b224d7c822c41c5e8babaab"><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&nbsp;5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">iting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfNTQ5NzU1ODIwNDQz_fec62dca-f4d5-4970-a61a-e106e8a55058">21</ix:nonfraction>&nbsp;million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company’s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March&nbsp;31, 2023, resulted in a net increase of $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfMTU0OQ_8511f4af-951b-4e83-9a3c-07c449cb9124">44</ix:nonfraction>&nbsp;million to net pension liabilities and also resulted in a related adjustment to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note&nbsp;11), with the exception of certain amounts for termination benefits and curtailments which are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits or curtailment is related to restructuring actions.</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_67"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTQz_77d6322f-495b-49a8-abe5-645edbc9682b" continuedat="i0555b90d0ab446f1af73828fd6d69ac1" escape="true">Other (Income) Expense, Net</ix:nonnumeric></span></div><ix:continuation id="i0555b90d0ab446f1af73828fd6d69ac1"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTMy_b340d380-d644-4b04-86a2-e75946091343" continuedat="i2f4bb311276246489f1576f0021f51e1" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:&nbsp;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMi0xLTEtMS0xMzE2MTg_417fcad4-7b2b-41f6-8340-2c6e3a29e34e">112</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMi0zLTEtMS0xMzE2MTg_dd8f0efd-258b-47ee-a5e6-d7c668c3fbf5">7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMy0xLTEtMS0xMzE2MTg_0f7948f9-55b1-4158-93d3-4eb7ae5a810a">242</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMy0zLTEtMS0xMzE2MTg_a440762d-f421-41a8-9e57-736957bf4a0f">243</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNC0xLTEtMS0xMzE2MTg_fe389e9d-6841-45c0-aaff-5db521a10efa">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNC0zLTEtMS0xMzE2MTg_7d48caf1-fdc9-4581-80b8-ef7cf2932001">39</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNS0xLTEtMS0xMzE2MTg_a6e95474-b090-4279-82a8-4ca384d387cb">450</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNS0zLTEtMS0xMzE2MTg_f65933b2-02ac-461e-ae1c-d94d55becdf0">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNi0xLTEtMS0xMzE2MTg_19d0878c-2c26-4d71-bfdf-e13e344c1061">115</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNi0zLTEtMS0xMzE2MTg_a83031d2-9eaa-4ded-bb72-ebfd78c4321b">121</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNy0xLTEtMS0xMzE2MTg_a270fae4-fab0-4298-a8c7-791e19be4d4b">463</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNy0zLTEtMS0xMzE2MTg_318ff1a0-1f99-4c29-84e6-f8d6582406c9">154</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfOC0xLTEtMS0xMzE2MTg_a42a836e-c95a-4390-a982-934bb9261b30">89</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfOC0zLTEtMS0xMzE2MTg_40411eb7-290c-4a99-a4ed-b3c1efe6db04">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"><ix:continuation id="i2f4bb311276246489f1576f0021f51e1" continuedat="i8c7d1597efe84e9c971ff53e030a5a04">(1)&nbsp;&nbsp;&nbsp;&nbsp;</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i8c7d1597efe84e9c971ff53e030a5a04">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net (as reflected in the table above) in the first quarter of 2023 includes a $<ix:nonfraction unitref="usd" contextref="i07e39fac74fc4d08a501e1e14a991816_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTQ5NzU1ODE1MzA2_80c4d5be-3421-4a0a-b221-69ca44c1f0e1">572.5</ix:nonfraction>&nbsp;million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note&nbsp;8).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid for the three months ended March&nbsp;31, 2023 and 2022 was $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTA5_3f9fe702-c913-446d-aac7-906079c5f2a9">208</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTE2_073f6b7d-7d2b-4bad-9e07-a8cd40c69667">211</ix:nonfraction> million, respectively.</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_70"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfMTcyNA_b561dd59-fd06-4f46-abf2-b8bae80c0c1e" continuedat="i5f9a6462f59e4d29a559e26f10fff701" escape="true">Taxes on Income</ix:nonnumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i5f9a6462f59e4d29a559e26f10fff701">The effective income tax rates were <ix:nonfraction unitref="number" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfNzY_4f83916f-7825-4290-9b6e-3241daa35023">22.6</ix:nonfraction>% and <ix:nonfraction unitref="number" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfODM_8e518908-0a2f-4b5d-9662-4c93fb2d26fc">11.4</ix:nonfraction>% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which <ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="0" name="mrk:TaxBenefitResultingFromAcquisitionCharge" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfMjc0ODc3OTA3NTc0OA_d609f97d-72fd-428b-a143-99ff04b22871">no</ix:nonfraction> tax benefit was recognized, as well as higher foreign taxes, the impact of the R&amp;D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company’s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate.</ix:continuation> </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_73"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfNDQ5_15ab1976-79a2-4368-a526-5e8b16739d87" continuedat="id7bdd4ddb51e4cbc8e99c42132b2607b" escape="true">Earnings Per Share</ix:nonnumeric></span></div><ix:continuation id="id7bdd4ddb51e4cbc8e99c42132b2607b" continuedat="ied25165a21e34e2d9fbc0d9f93759d7d"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfNDYx_78002e68-a337-4efc-967c-d79086e29177" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:81.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.236%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0xLTEtMS0xMzE2MTg_83d23b6a-af3a-441b-a01d-dc74e3c73fd3"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0xLTEtMS0xMzE2MTg_bf7181b2-d549-480f-8afb-653e35103a42">2,821</ix:nonfraction></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0zLTEtMS0xMzE2MTg_648701dc-ed48-46bf-8e67-e2c62d4ed953"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0zLTEtMS0xMzE2MTg_7e7c14f8-226a-4f08-bd98-2e83b3a39731">4,310</ix:nonfraction></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNS0xLTEtMS0xMzE2MTg_615ef519-aa4a-49c3-a94f-efebfc5aafce">2,538</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNS0zLTEtMS0xMzE2MTg_d076aaf5-53ab-4897-b20b-e76cf27118de">2,528</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNi0xLTEtMS0xMzE2MTg_40b45c6c-53d6-485e-a9c9-ac5d349900d8">13</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNi0zLTEtMS0xMzE2MTg_a5404a0a-54c8-4549-bf26-9631509c4344">9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNy0xLTEtMS0xMzE2MTg_af551db3-0e9a-4d33-8b9f-c988c9ae2b7b">2,551</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNy0zLTEtMS0xMzE2MTg_7db26e1d-bd26-4f41-b587-f8ab48a0c996">2,537</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTEtMS0xLTEtMTMxNjE4_f16f05ec-d3f7-4a8d-895b-fba44d7e42bb">1.11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTEtMy0xLTEtMTMxNjE4_2dfe0dfd-0e6a-455d-92ee-ca8926c301c4">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTUtMS0xLTEtMTMxNjE4_16f50926-d120-46fc-bc50-68cd6f7b308a">1.11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTUtMy0xLTEtMTMxNjE4_cfab628f-6e32-4deb-8ae3-a2f9342604bc">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;Issuable primarily under share-based compensation plans.</span></div></ix:nonnumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ied25165a21e34e2d9fbc0d9f93759d7d">For the first quarter of 2023 and 2022, <ix:nonfraction unitref="shares" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfMTYw_c557fab6-60e1-44aa-9ae4-80a542395262">1</ix:nonfraction> million and <ix:nonfraction unitref="shares" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfMTY3_4ff01dad-53bb-492d-9c5e-5f0bf55ce9c4">7</ix:nonfraction> million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 23 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_76"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RleHRyZWdpb246Njc5OWNmZTk5MmM4NDc1MWFmMDZhMTU3OGNjZjM4MDRfMzMz_b15db8b0-2371-4e6f-a81d-7feb1e9577cc" continuedat="iaebf7ec259554eecabb3f99e0c60dfb4" escape="true">Other Comprehensive Income (Loss)</ix:nonnumeric></span></div><ix:continuation id="iaebf7ec259554eecabb3f99e0c60dfb4"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RleHRyZWdpb246Njc5OWNmZTk5MmM4NDc1MWFmMDZhMTU3OGNjZjM4MDRfMzQ2_d99aa86d-93d7-40a8-b05d-693303caf62b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee<br>Benefit<br>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign Currency<br>Translation<br>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Other<br>Comprehensive<br>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i041db7ac9be74d218c0c23a960fc9a27_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi0xLTEtMS0xMzE2MTg_44810d6b-12bb-4ebb-8780-dffbe96bc17e">144</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i33af4ad78921440a981af5aa4715c88a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi0zLTEtMS0xMzE2MTg_fde501ed-d121-4679-b37c-d87cf6ff2b15">2,743</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iad527aecfb724bf3b4777b628fefa6b2_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi01LTEtMS0xMzE2MTg_5602d1b7-f946-476a-8997-6eb898f303a7">1,830</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0c01235f9a47471bbfd246c179b8ec70_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi03LTEtMS0xMzE2MTg_86f111b7-a84a-4ec2-8fa0-8d4c7aecc3d7">4,429</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy0xLTEtMS0xMzE2MTg_f2fc2a50-705d-4181-8e01-d40afc780aab">148</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy0zLTEtMS0xMzE2MTg_3807828e-c921-43fb-a2e4-420df6bc9e02">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy01LTEtMS0xMzE2MTg_49165ab9-5dc3-491c-93b5-6c6dca697ead">18</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy03LTEtMS0xMzE2MTg_c753905e-3607-400f-ab2b-98429325ca82">131</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC0xLTEtMS0xMzE2MTg_04ff338a-2b90-4ed6-bd79-ff2bdb702b7b">31</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC0zLTEtMS0xMzE2MTg_25df2b21-d481-4186-9aba-138314bfc60e">2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC01LTEtMS0xMzE2MTg_44893c5d-f0cd-4c9f-b3ae-7391902ee51e">17</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC03LTEtMS0xMzE2MTg_57c55961-6700-4334-a0a0-ccc8a40d8554">50</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS0xLTEtMS0xMzE2MTg_67a46a52-066d-4c51-a37c-449d8572b4a9">117</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS0zLTEtMS0xMzE2MTg_20bb398a-30a0-4cc7-957b-ca1b82e0250f">1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS01LTEtMS0xMzE2MTg_0385cb5f-45ba-48d6-a250-801c15473624">35</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS03LTEtMS0xMzE2MTg_d0370e0b-025a-4978-a6cd-57946ac7a4ae">81</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi0xLTEtMS0xMzE2MTg_f1d504c7-965c-498c-ad7a-6b46731d82f7">68</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi0zLTEtMS0xMzE2MTg_66e937a9-6b49-46e9-b62a-f533e2db84a3">45</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi01LTEtMS0xMzE2MTg_ef33b7e4-9433-46b9-838b-e5ea08fa1518">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi03LTEtMS0xMzE2MTg_cbba4b1b-94c1-4c62-8d93-af7c5579c4bd">23</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy0xLTEtMS0xMzE2MTg_c25c89a8-5c00-459e-b1ff-6f88ec6b5e90">14</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy0zLTEtMS0xMzE2MTg_a4f92724-44d0-4daf-8b05-4729e90d9fc7">12</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy01LTEtMS0xMzE2MTg_9c4c0598-222b-437f-8ea6-25de9ddb3994">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy03LTEtMS0xMzE2MTg_33ec11d8-bc14-4b4c-bc6d-85e941a4568c">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC0xLTEtMS0xMzE2MTg_c3dfe168-cd5a-4f39-9c20-eb02a0955b31">54</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC0zLTEtMS0xMzE2MTg_c44ae61e-5e89-4caf-bee2-ffbd9054338f">33</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC01LTEtMS0xMzE2MTg_6c6779ea-a1ab-485a-aed7-a460e5b997a2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC03LTEtMS0xMzE2MTg_51d07f75-ab80-4ccc-9d39-4c6e3b953679">21</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS0xLTEtMS0xMzE2MTg_cc363569-8c98-4432-a380-783b8897dd6e">63</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS0zLTEtMS0xMzE2MTg_76bc7884-3d22-4bfd-86e4-8eea8b88704b">32</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS01LTEtMS0xMzE2MTg_5c4d85cf-db10-4870-bb0a-baeac0608b62">35</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS03LTEtMS0xMzE2MTg_1333dd8e-1dd4-4fd0-aa63-aaee814d686f">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2319d946cd342759a8f984524b58ad8_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtMS0xLTEtMTMxNjE4_c2753a79-c7f8-4191-b5bf-b15be4baa965">207</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i95a7d6e4f3b642ac849cb5b1af84aca1_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtMy0xLTEtMTMxNjE4_c706ce6c-c0f4-4619-8b4e-68a78f04c417">2,711</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic8a93158890945a9aa15c60a05506723_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtNS0xLTEtMTMxNjE4_b9c63d63-f143-4dd5-bff7-18bb4a37200e">1,865</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i42da78b36e31450dab3194041180b0ee_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtNy0xLTEtMTMxNjE4_54b20997-795c-4b88-8a83-b4e674de0736">4,369</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i31f76fe0b880480684d05d01c6f398ff_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtMS0xLTEtMTMxNjE4_0c887a02-21c7-4164-8bf5-2436f00cf930">73</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8b83eed87b2d41c1a8c610f98765bba3_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtMy0xLTEtMTMxNjE4_8cc9cd45-d572-480f-9303-8093278de5d6">2,408</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6d63d8c8b08843008160820a9757c059_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtNS0xLTEtMTMxNjE4_abac9ac0-2b80-4356-955e-c4ff9861b4b1">2,433</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3b21fb880d134a06abed66e7d998914f_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtNy0xLTEtMTMxNjE4_65f6608a-8bb6-4134-ba6d-0fd93184f36a">4,768</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItMS0xLTEtMTMxNjE4_dd84de2f-d242-43bb-bfc8-d3bfc2b1f317">66</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItMy0xLTEtMTMxNjE4_ba64b2ae-e33b-4ac2-9008-af2eab88bf17">47</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItNS0xLTEtMTMxNjE4_49703699-5a0b-4652-b159-d9582b6e1bd4">79</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItNy0xLTEtMTMxNjE4_04560a5c-3dfc-4d30-a247-8f4b359633b2">34</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtMS0xLTEtMTMxNjE4_50ed424b-af09-43d9-8c57-614acbe8fc3c">14</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtMy0xLTEtMTMxNjE4_e7ed1079-0111-47da-b167-d28477d37c03">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtNS0xLTEtMTMxNjE4_d80d2519-6c46-40d3-aa2c-6a8694a40e6f">20</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtNy0xLTEtMTMxNjE4_46b07516-ed3d-4dab-8bb0-d8c42dff25d3">4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtMS0xLTEtMTMxNjE4_022d8ce9-b8e4-4661-8a14-9303534f5856">52</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtMy0xLTEtMTMxNjE4_bfbb089e-3f91-402d-b77f-5adb5e3ea779">45</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtNS0xLTEtMTMxNjE4_1a5f7e54-b3e8-41ee-967d-d1c54eaf2691">59</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtNy0xLTEtMTMxNjE4_62892b5a-89a4-4b87-96f6-9a5f03c5d2ad">38</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtMS0xLTEtMTMxNjE4_293f7994-d602-466b-935c-f543c7e00401">102</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtMy0xLTEtMTMxNjE4_95bc1f2f-6e9d-47ed-a883-b9253a1e702e">7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtNS0xLTEtMTMxNjE4_74113e62-de86-43ee-9b17-91a562957a47">9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtNy0xLTEtMTMxNjE4_cc32a334-3561-4a30-8ebb-aff6c9524b91">100</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtMS0xLTEtMTMxNjE4_86bbacad-7c71-4512-b74c-b4ba1c7ada8a">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtMy0xLTEtMTMxNjE4_592cef05-3b2d-4d8f-adb8-efd416df6083">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtNS0xLTEtMTMxNjE4_6575f2c5-b139-4798-a59e-f0e68418f78e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtNy0xLTEtMTMxNjE4_0f37f855-e7ed-48b0-a551-4e9c3a0dd067">23</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctMS0xLTEtMTMxNjE4_c5281d00-1799-4705-8807-e57fe3d60973">81</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctMy0xLTEtMTMxNjE4_c003d93a-807f-4383-a9fc-338e9c7f152a">5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctNS0xLTEtMTMxNjE4_44e31216-07b2-4f62-8efc-09d529966ff3">9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctNy0xLTEtMTMxNjE4_df0d3458-7957-4239-a78a-85082040b024">77</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtMS0xLTEtMTMxNjE4_36bdebc4-d9a8-4f3a-bdfc-df10e562783b">133</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtMy0xLTEtMTMxNjE4_a83f2f5e-7ff0-4639-86b7-f9a9bc1f22aa">50</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtNS0xLTEtMTMxNjE4_66b67526-37cc-452f-92c5-8ba4ee1fc1cc">68</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtNy0xLTEtMTMxNjE4_3c343a9e-abab-4fc7-8b65-6d2ffa3d911f">115</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7af996fcfb0942ebab3aa1e8cea2e1a4_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktMS0xLTEtMTMxNjE4_775755c5-b1e3-42c5-987c-45e712d0bc7c">60</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8e5c54f51e5440dd9db7d51479f49629_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktMy0xLTEtMTMxNjE4_e7a84c46-8fc0-498f-84eb-0dd64cdde26a">2,458</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i44331becfc824debbd8e96c96c590f56_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktNS0xLTEtMTMxNjE4_5a930cdf-1510-45e2-bae6-314e19b2f150">2,365</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i60e7a6142fec4b32aa305b679a0d9a87_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktNy0xLTEtMTMxNjE4_58b4c4dd-a9fc-4a7b-b764-001bc601d98b">4,883</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&nbsp;10).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.339%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br></span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_79"></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ3Mw_8877f9a1-419b-4a94-a407-cc796264c2c3" continuedat="i79eca66fbd23468eb11ae08138ccd36f" escape="true">Segment Reporting</ix:nonnumeric></span></div><ix:continuation id="i79eca66fbd23468eb11ae08138ccd36f" continuedat="i74bb392a12e842148b0779ee79ecd6be"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s operations are principally managed on a product basis and include <ix:nonfraction unitref="segment" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfOTM_92d0a8f5-7ea6-4292-a1d9-a4cf9e489335">two</ix:nonfraction> operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&nbsp;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 24 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i74bb392a12e842148b0779ee79ecd6be" continuedat="if966040dffa94db3a20e72cb255d69b1"><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTUwNQ_05fdad2b-f964-4b65-a6aa-55463b2bfa68" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.631%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&nbsp;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8df183ec48194fc4a2c6f8e8d986193f_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS0xLTEtMS0xMzE2MTg_ef2b120d-82cf-425c-bf17-0d8b4328bf97">3,485</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf2b65d0efcd4588b8eaf74e00590ea7_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS0zLTEtMS0xMzE2MTg_15002e29-bc96-473e-b310-574b29a87c4d">2,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie772b761081d4a3f88dd5b139a18cde5_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS01LTEtMS0xMzE2MTg_91234f17-3414-4369-8991-7bb8006a9ad8">5,795</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id23605aa21764c15b522d6ea781638b6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS03LTEtMS0xMzE2MTg_044f057b-9ed0-4726-8254-cc91383def5f">2,779</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8b1fe39c7ec246f0a53097e0b00b0803_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS05LTEtMS0xMzE2MTg_e64bb3b1-06cb-4484-aeb3-b34f27343f26">2,030</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7caeaf606112447a8aa0d87b20c8f163_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS0xMS0xLTEtMTMxNjE4_2e409739-686b-48f2-8fab-a534ed940485">4,809</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if193ecf6603e436e9bc55f3e4f86a576_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi0xLTEtMS0xMzE2MTg_94ed05c5-b448-447e-a261-e3ae0e338382">142</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4b3b69956cc9411da3f54f428aeeeb42_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi0zLTEtMS0xMzE2MTg_3890109d-7d86-4663-ab06-325348a981e7">133</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4ef00ecad3374cfaa1259915898dc915_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi01LTEtMS0xMzE2MTg_81acfbca-54ce-459b-a4a9-7a228af04df4">275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id0d6b8513dcd4021a200090641fe0bff_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi03LTEtMS0xMzE2MTg_2d4fdf33-6355-4938-81b0-59a862f9decd">141</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0666b87a008d48918f71fa4e40a3259d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi05LTEtMS0xMzE2MTg_6a4dfb95-4059-4e70-bac1-52736254fad7">125</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ied5a517f75814ffdacb6613032349a19_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi0xMS0xLTEtMTMxNjE4_ce2b4fb0-4458-4df5-b9f9-262c161c6911">266</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bdd7b02457a4826aeec0e25dbfa4df0_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy0xLTEtMS0xMzE2MTg_790133c1-4058-4f19-b508-bc9bc557581f">153</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i373f00d87cd7457d9b079c9415e0c4ad_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy0zLTEtMS0xMzE2MTg_9f347d7a-9176-4027-9b86-4f7b621ad47a">79</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic416d710ef924adc9df8131effd1c200_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy01LTEtMS0xMzE2MTg_5eecc9b5-6917-4325-bbef-8d586cf33296">232</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i421974800c0844798343dd8cfc3f3a20_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy03LTEtMS0xMzE2MTg_0e5c0569-f11f-47c5-b2c1-bd7635281d6c">156</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i26f185cbe1da4f4e89a1e2093171e27b_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy05LTEtMS0xMzE2MTg_2c60a0aa-f6b9-488c-8055-0108620030f1">71</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7706e3163ae4d58a5f8660cb640d5ba_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy0xMS0xLTEtMTMxNjE4_aa3611ea-2e5f-44d0-94e4-2e9cb44b77f4">227</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf21fc9f03d342bbbd66be0123de6225_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC0xLTEtMS0xMzE2MTg_ba66b2ec-a0bf-45fe-afb1-9dc52dcb8eb7">30</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i943ebcf31d20440ea90b753cb238fe02_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC0zLTEtMS0xMzE2MTg_34b8ac87-3d93-491d-bc80-5e62ced6a1f9">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i245cacaf455e42329f9ae587d1a10cad_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC01LTEtMS0xMzE2MTg_5ac0347c-c6aa-4452-b4ea-1238bcadc98f">43</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia13e94e1a90043bcaea2ffba6d27061a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC03LTEtMS0xMzE2MTg_d6fa372a-29db-4d93-95ec-373ad653729e">27</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f73d3370a5348dda651da8166f72bfc_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC05LTEtMS0xMzE2MTg_254485a1-b420-4ddb-9070-730a8d7af23d">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2dba74425a51433497fa7e5529627e25_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC0xMS0xLTEtMTMxNjE4_d2de489b-6e5b-416d-916d-149a5274be6e">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie40a08ab45e2491eaad9788d31bc031d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS0xLTEtMS0xMzc0NDA_1adb609a-9bce-4383-888e-7e300a6c7e79">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i98d5687c5bca4aa0ae8be180444502a5_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS0zLTEtMS0xMzc0NDA_ec4c6f90-c108-4860-81c2-091efdc43173">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i148665041c5d4969a1b7468fc0b3306f_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS01LTEtMS0xMzc0NDA_93b9bbaa-586a-49b0-8a26-b18af9af0238">42</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i245f27c3d3884d16886e2a02a3bea2be_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS03LTEtMS0xMzc0NDA_9eca8a7a-0ddb-4fe0-8ff9-0956abb9f30c">18</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i683c95eda6cc4e83a3f200cd8c1ae979_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS05LTEtMS0xMzc0NDA_a4b6e895-f779-4b5d-bf36-1df737ecc25c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabc5de1d9ad9496abbed9093f2560c7e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS0xMS0xLTEtMTM3NDQw_6254b731-d2a1-4cdd-aeaa-054c8deeb219">18</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d15bac232384d3d9b567829ed8b4e4c_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtMS0xLTEtMTMxNjE4_f9bed54c-4a2f-4ae3-afa7-37e2080b714e">416</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0eb110c2888a401a99ce08584a59ae29_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtMy0xLTEtMTMxNjE4_6d44ab5a-ef76-43cf-96e2-f5cb3e63075b">1,556</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0622fda057824fe2acccd535fdedb1c4_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtNS0xLTEtMTMxNjE4_752bbfd3-712e-4866-a1ec-3c2c19d4af3a">1,972</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1317f96f8242416cb217168b296ac180_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtNy0xLTEtMTMxNjE4_d5569185-a478-4ce6-9edd-eebb5f7b0ed5">418</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i15590b4a502a4441b2031cb5e67c164c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtOS0xLTEtMTMxNjE4_0176a57a-43a0-417f-82c1-6ef19d14c304">1,042</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0272e13e3911432484c3574c4d88dea4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtMTEtMS0xLTEzMTYxOA_27e46f8e-652a-4297-b949-a2c714973d97">1,460</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie1dd61290d2e4c28bdc142b28449b630_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtMS0xLTEtMTMxNjE4_df881402-b4dd-42bc-bdb9-ca896f30bb73">421</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0676bda79d3444beb30669ea1761cefa_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtMy0xLTEtMTMxNjE4_771f5bf0-476b-4f0b-a74d-eb96033d23c6">107</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92cf8249b51045fc9f74f556cbb77945_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtNS0xLTEtMTMxNjE4_7525428d-e657-4a74-9c6b-ce730da27cd1">528</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd868d1665e843e8ba8e68820863660a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtNy0xLTEtMTMxNjE4_340fe18e-f036-43be-a7cd-607a0c021571">371</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i85dada8cd49f441ca2211b4790538075_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtOS0xLTEtMTMxNjE4_9fb82f91-48f4-40c2-8966-74fb8360589b">99</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9e7b43ab9aca461cbd07c3408576229d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtMTEtMS0xLTEzMTYxOA_1e49a012-3af6-49c5-84d2-c2517239dff5">470</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i502537b5bd3244cba8148fdcded195c1_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItMS0xLTEtMTMxNjE4_9e2ced00-99ed-4dfc-8db1-e55a286f0405">180</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd1279562a9049789bcf67e36e1345e6_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItMy0xLTEtMTMxNjE4_46cacb43-eb46-476d-ac6e-22f3a4566e80">117</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if12d006ccf6947e59b7e26e27405537e_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItNS0xLTEtMTMxNjE4_392ae0ce-1b6c-487a-b804-9d84727fe8b5">297</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2caa7eb6734e47f694c35387f0b24c5e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItNy0xLTEtMTMxNjE4_9a44aaaa-f945-43cc-b00d-e80c2f15b178">175</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iefe80ade170b452d810ea857bfb36486_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItOS0xLTEtMTMxNjE4_042a94b0-50cd-43f1-a354-450f88805877">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i168a16270ba04bf5bd0a98c57f6e7453_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItMTEtMS0xLTEzMTYxOA_b7b7d7d7-8539-4fe0-ac52-89f511647ca5">216</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i38f3c51ed3c142088d512d3cf86a4e85_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMS0xLTEtMTQwNzkz_fc2a3e1a-08d8-49b5-afe3-55dc744da2ae">94</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5facb3a2afd54e37a08fcb30616f2d40_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMy0xLTEtMTQwNzkz_8781e8e5-aa49-4852-a335-1835e13b37ed">13</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i71c307b84c814567af562b778b4c1b53_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNS0xLTEtMTQwNzkz_b62c2169-ae8e-45f4-829f-f7fbdccaeb49">106</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie8a9542dc59a4777a668cd31211b6c7a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNy0xLTEtMTQwNzkz_fa20673d-0873-435f-a672-e41474cdc1c3">5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaa6e384e748d4e74833d7c8bd58e5051_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtOS0xLTEtMTQwNzkz_8d2ad58d-1417-45e4-9671-0cfc84a0d7ed">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a9cd1b2796b45cd823635c3a4ca1ec1_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMTEtMS0xLTE0MDc5Mw_636c85f0-b166-4bf3-ab44-efdc270ecfa3">5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc1f221331e847f78e9890ad89af8d80_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtMS0xLTEtMTMxNjE4_624b7c58-4c09-42ba-9447-131afd4d1d2c">40</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iced6646c844d4419a1591abce5241bc1_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtMy0xLTEtMTMxNjE4_4fbabf03-716b-4068-8111-4078d3877b7a">56</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d46a1bed5b64222a563d18e9091ab03_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtNS0xLTEtMTMxNjE4_32f352ba-63ba-44a6-96f7-a420dc4101d7">96</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iee7d83d494044d17ac974c40323b8bfa_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtNy0xLTEtMTMxNjE4_b6a38190-85ca-435a-aa28-090efeb5cf60">118</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf3bf82a5181435e9e26d6dfe9ccb7a1_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtOS0xLTEtMTMxNjE4_5452738d-004d-4b75-bd3b-7b66f362051e">55</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83f5ca79492e42dba088722bf7ae9575_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtMTEtMS0xLTEzMTYxOA_c77eb623-e028-4786-bf10-3dde2d6851fc">173</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i556f1c52ae734ae6910cf6d6b9d26d16_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMS0xLTEtMTMxNjE4_a39766a8-ac1e-4069-8f30-14db5ac60474">30</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie70b1f6ac9824c5c9604f2e6cda7b721_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMy0xLTEtMTMxNjE4_a07d1e82-aa60-406d-96a2-a927daf3aede">10</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i13c7df0a730141689941ffc740882c67_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNS0xLTEtMTMxNjE4_b2136ab7-b707-40b2-8c01-c9840620503f">40</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie19b5dd8e1da4e7ca8d5114cd25d465e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNy0xLTEtMTMxNjE4_725ba813-1e18-4fa5-bc5a-b79c6aa50921">29</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8845bbae207945c29f58ed0faa7c916d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtOS0xLTEtMTMxNjE4_c7648a55-100c-43ae-85e7-44e046e71261">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ce84ce5bc4d4fd09f2f2edef567c63f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMTEtMS0xLTEzMTYxOA_2879c2b0-801a-41d2-98b6-ae9386bd854b">36</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id3307d951777433f9183e38cea7b0eee_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtMS0xLTEtMTMxNjE4_69b43d5d-2874-4f77-b3df-8d67ccb08c83">276</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie514f725ab204576a9d82e520a0747cc_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtMy0xLTEtMTMxNjE4_3dc80213-b2be-4a0f-8a14-060d68004459">210</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic3c351d397e549f08a5550b64c7bd217_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtNS0xLTEtMTMxNjE4_165198a2-3775-4392-a7fd-6eb73797b0cf">487</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia85cef5855f74b3aa28b80d7e773c5e5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtNy0xLTEtMTMxNjE4_4008ef98-0426-480a-9ffa-f5529d725532">195</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7d745b43d42740a2a636f93305a10162_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtOS0xLTEtMTMxNjE4_e370ffbd-5012-4819-8941-96cb8a65a5c7">199</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idffa9ebb25b04dc3ab346d0e2525d0f5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtMTEtMS0xLTEzMTYxOA_ca912eb9-d99e-45fc-93fb-1b421f68dc9c">395</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i81842dbc49284aeb8c307b130fc51daf_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctMS0xLTEtMTMxNjE4_cde0af28-b4bb-4b65-8ac5-e34587a7e814">54</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ae5e82b75cb428f864e7695e7ca9c03_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctMy0xLTEtMTMxNjE4_34051f84-3cdc-403f-85ce-cb9aaa6d3f3f">75</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c5c36e08c35436d890e3cc5e49a26b5_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctNS0xLTEtMTMxNjE4_2052c7b7-1767-4ac3-9bd0-83b9c61560e8">129</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i63dd5e6b38074752a8397afebca2f449_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctNy0xLTEtMTMxNjE4_c3c1de80-0c8b-4c8f-beb3-94c3a07d008b">40</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id6a6d9596af343fe9fbfaadc1d8d3d34_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctOS0xLTEtMTMxNjE4_e67d7ccd-e0af-4148-a301-b0c15a434335">54</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6cb822f6f0d24e56b21b1ba8cf3c5144_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctMTEtMS0xLTEzMTYxOA_17c8f864-f3e0-430e-a0e3-fa97a9934af7">94</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie1a2a61f6cc34473ab9936b7066ad51b_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMS0xLTEtMTQwNzgw_e2db4b26-2581-47a5-8c63-4455c67ca5b6">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6b9400d903e47749af467e683ebf4b8_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMy0xLTEtMTQwNzgw_82bedd10-76e6-4d7d-bf2a-cdc4ced4bb8d">76</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e28d66cb4d143f5b15da4ce16a7ff80_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNS0xLTEtMTQwNzgw_460a5fb3-cfd5-4122-a8f0-3eaa52f20421">80</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83dc7aa4430a4932893b4dc1505dc632_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNy0xLTEtMTQwNzgw_131401d6-6a0e-4418-ae95-b1f812dcfaa5">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd11a9dea94b46ed9112ffcc77e533a5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtOS0xLTEtMTQwNzgw_307d7b22-1799-402a-8b68-cf1e17fd113d">58</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifa49ff54d4904fb783f4f755bf9c4739_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMTEtMS0xLTE0MDc4MA_a68309f8-de33-4763-8109-cc42f11af76b">58</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i16385f11510546058467040c76602eda_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtMS0xLTEtMTMxNjE4_f6048126-f496-4593-8a4f-23f8a614720d">62</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i97cacd287b274b7283ca51aef88bed26_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtMy0xLTEtMTMxNjE4_00af82de-c4cf-4e2a-9289-bafcf93b0132">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ied566206459a4f21bda9d764fbd67597_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtNS0xLTEtMTMxNjE4_940cb2d9-3fe8-4cc7-9fb4-b581c42f6421">65</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8c13b48a7232487dade4344d3bd6fef4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtNy0xLTEtMTMxNjE4_43d7bb5c-962f-4e34-baf6-7d986541fbf4">49</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i36f1883cf7ee41de9a38e097ff1eebdc_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtOS0xLTEtMTMxNjE4_2f141819-9699-4a22-99b6-892e9f2623aa">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id1f696b0a7e848ffa8cd28bc5f62be74_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtMTEtMS0xLTEzMTYxOA_eb9b2e43-4811-4a67-a118-35d137ecfe7a">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i33013fc5c1544b508c1f023d7e114799_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMS0xLTEtMTMxNjE4_a655c2cd-de64-49f3-8391-fc00e85d4f43">14</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8189ab3ff1aa4b3fac07ab4d084ef309_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMy0xLTEtMTMxNjE4_b91ed4a7-918b-4d10-9ea5-8c6c09eeec57">46</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0934dfe57f25400aabf7629e013bf2d9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNS0xLTEtMTMxNjE4_82d8444d-4060-4c3a-80ab-6a3dd1b0e618">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia482068e1c6841608dd3a6fc8530cff5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNy0xLTEtMTMxNjE4_4764bde1-b2f7-4ff4-816f-d5b4ddfcc733">10</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i36f337569e6e4b90b6c49162eccc9245_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtOS0xLTEtMTMxNjE4_0b46e29e-a5cf-4454-b391-96b7caa9011a">48</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i370790356a1f4d0f910d0150c46829ba_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMTEtMS0xLTEzMTYxOA_292325fc-1429-4db9-936f-1d5917f6ff71">57</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic3ad548049e7437392c37716ac4a83fb_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtMS0xLTEtMTMxNjE4_e0c48a8f-2572-4686-ba40-7085bc440f90">27</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3025f3862fa34281bb1ddc0c23288056_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtMy0xLTEtMTMxNjE4_fc6e5ef3-d88c-4071-8f8e-81e20bd96439">23</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iadcf254d19a94241a8a193b57dc553f7_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtNS0xLTEtMTMxNjE4_b5873064-3610-414f-a44e-06e93d18ac4f">50</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1be1a7ec6a2548d4861b2e925582acb3_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtNy0xLTEtMTMxNjE4_8adaf06a-1d02-44d4-a2f7-68457466bff4">18</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ece7f9fc39047fbaf47a27cce6b32ab_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtOS0xLTEtMTMxNjE4_7eb9b714-2767-4c28-9362-8fa73debc790">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c4d7a0899854fe795ccaec1a0161a84_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtMTEtMS0xLTEzMTYxOA_3709754b-3cbf-463d-ba03-8137f05831a3">30</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i01970431619244f9a83fb73990c5cf14_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtMS0xLTEtMTMxNjE4_8362f82e-1c98-49c0-a1e4-13b640813631">83</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i958da05d9055499a88d25a539d74f6b9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtMy0xLTEtMTMxNjE4_0e5c4fa6-ed5c-4b86-9379-14336022f583">16</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a61880f039405d9d8e1832fd26a2d0_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtNS0xLTEtMTMxNjE4_7702f13b-b60f-41ec-8bbb-9b36eba7021e">99</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i06d3dc01e4cd4880b999376bd99d6191_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtNy0xLTEtMTMxNjE4_7d306b7f-4787-4bf0-9467-a33f85c6ee55">71</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7414168e369644d7a58d58414fbde705_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtOS0xLTEtMTMxNjE4_ff53446a-30e3-4375-b4ec-cf72de9b587a">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8d7e8ff816e241f199e0011935427e7a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtMTEtMS0xLTEzMTYxOA_b1b33d9e-cd4d-4c8a-9e05-96f96049c279">72</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iad4d2d0ea13747a1b99b669cf7ce5f36_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtMS0xLTEtMTMxNjE4_009088eb-775e-4a93-83e0-7a0dba8d40a2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i01c8b28beea44e9998a1034bce51e508_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtMy0xLTEtMTMxNjE4_f93d0d7a-77a7-4d32-ac0d-1bd53ffb54b4">59</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifc25085e4f3246fcbff1828176d06cb2_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtNS0xLTEtMTMxNjE4_b42464fc-f701-469a-a8e1-cf7dbccff949">59</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i42b4b84e15304e879f573aebe7198888_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtNy0xLTEtMTMxNjE4_d44cc367-4687-4822-83ad-dfef01970e0f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1abbf56d966442aea56ac371531ef7d4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtOS0xLTEtMTMxNjE4_26ad746c-5c90-4465-81df-ba7138dab08f">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46444b1898a945a692f90d2a907898a2_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtMTEtMS0xLTEzMTYxOA_8a605ae1-6bdc-4d94-880c-ac5663de8009">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i745ba7617eb74e15ad18bf9b1bb5709e_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtMS0xLTEtMTMxNjE4_d2e02649-10c3-4966-94b2-8a5438a5b354">2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2d35a8760f2f49e89952d761b1399baf_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtMy0xLTEtMTMxNjE4_c3078931-c03e-4b6b-be9e-1fdb050615d1">394</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i185e17abc9a24ea38c9ca4921fa60212_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtNS0xLTEtMTMxNjE4_c45526d4-afc9-4353-9af9-e2372ab0ab98">392</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i69279d4f3a814a78996b4c54c84aba07_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtNy0xLTEtMTMxNjE4_272525b6-f820-45e5-ab38-eae0f0127194">1,523</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if658e80c557842d4a20c5570140db4b6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtOS0xLTEtMTMxNjE4_b9724a28-b5ad-461f-a863-3d5234b58db9">1,723</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if0feca83d79141c7aa9f2bbb6f89ece9_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtMTEtMS0xLTEzMTYxOA_59e90e64-dd82-4bb7-9f1d-e938906902bf">3,247</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id9ab213a9fd74c98afcb44eb19dbc18a_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktMS0xLTEtMTMxNjE4_ebbc4ea9-5fd8-485b-b3ff-8a2383782f29">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b3ad2cd408f4af38f724dabed4a97ef_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktMy0xLTEtMTMxNjE4_cd5ae235-c1eb-46c3-a30b-34c6eb8de73a">71</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d330794d9a24933add16f9c3e14c0e6_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktNS0xLTEtMTMxNjE4_0434947b-2e95-4df9-a1a0-2d22279ae247">123</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i90f3bbf8132048e7a806ef1c700bcb02_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktNy0xLTEtMTMxNjE4_5c844838-6108-4091-ad9a-852e9fd0d85d">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c033c7782a84654914962664067c0b5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktOS0xLTEtMTMxNjE4_4d36f132-0cf7-4f4c-9c52-6ab9c1a3841c">97</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic44db3f3e64b400fbb66bf36b4d59948_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktMTEtMS0xLTEzMTYxOA_df855e64-6908-494b-b24d-89bb704193df">158</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia0f47191ae984e44a0ea39f24de59ca8_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtMS0xLTEtMTMxNjE4_ed3dc208-fdef-436e-ab28-b29584635cab">16</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ica88e8e09cf5471f8ec81237bf2424e8_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtMy0xLTEtMTMxNjE4_901d919a-c006-419f-981f-a9a04c94fc8a">40</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icf3db16464a242348f5f5ec6b303e8e8_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtNS0xLTEtMTMxNjE4_f1b96916-cd2f-476b-b304-3f0431533b6c">56</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic5dcef3812b24f21b01ed1f074b5e48e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtNy0xLTEtMTMxNjE4_c58ebf9a-c33e-453d-bf47-b0d1a528cabc">20</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie078fe8aa4b049019f87a49fe7163a94_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtOS0xLTEtMTMxNjE4_6f5f230c-e941-434c-849c-f530228ecacb">48</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic81d4335a8564f6893a52c09eee896bb_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtMTEtMS0xLTEzMTYxOA_fcc29d89-cf9e-4f7d-a2a2-c686323c34bb">69</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i38f8338e607f4961b4e06e5ad59f06d1_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtMS0xLTEtMTMxNjE4_06586f62-37aa-4215-a57c-bc3b32fbf8db">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i481c25e1dc4042e583fd9ae56af1ea83_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtMy0xLTEtMTMxNjE4_a43a37bf-cae2-4b71-a63a-064ec2f0ba6e">180</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ab42425f0e84d0fa9cc1faa24e50ad9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtNS0xLTEtMTMxNjE4_d39446ea-dae2-4f8a-9c46-7c0895ffcb9f">180</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f1f69903f024330aa3cd5f89dfe4aef_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtNy0xLTEtMTMxNjE4_a44eb7cb-344e-47fd-bf4d-41a9d3faa265">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4f18afff1f924a87aca15181db888f45_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtOS0xLTEtMTMxNjE4_71baa138-34ee-4828-9898-5e30552159cb">186</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7f2b65669412421487fc5a293c2d0226_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtMTEtMS0xLTEzMTYxOA_21e54091-77a9-4e76-ac29-67c14dd4e092">186</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i252bf97a988d4ca089b4880ef38b9f6f_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtMS0xLTEtMTMxNjE4_2dce8da4-7855-4324-9b0b-ef2a881bf53a">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8ac3b496e9b7497bbd0a8568c2c05058_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtMy0xLTEtMTMxNjE4_b35356f6-7be8-4495-82ef-69c3b0e3f9db">51</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ba905ef97ef4ea2a2b74f044e828215_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtNS0xLTEtMTMxNjE4_323184cb-6ee3-4bb3-999b-22fb850bd3ba">51</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i341c1828f974489ca631fd2f6fd5de33_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtNy0xLTEtMTMxNjE4_2d64884c-59bc-4cde-a8fb-e6294649db9e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i91767bfb04eb4bad8b4c74cc699c4f11_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtOS0xLTEtMTMxNjE4_6df05aec-8419-4a1b-a946-7149a51584dc">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i078db72152b7433b892f65578b578811_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtMTEtMS0xLTEzMTYxOA_dec801b9-74bc-47a9-89c8-fb0995af45b0">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d3ed97dcb1048b9b00df266e47fef85_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtMS0xLTEtMTMxNjE4_42abdd8d-d8a7-46eb-878b-f611b122ae16">271</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idf7f29b275f343aeb93a10d0bc96a43a_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtMy0xLTEtMTMxNjE4_efa28396-43f0-4f4e-a554-dd19047b69cb">280</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1c5a4e651d8048d0bb7be915788d3451_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtNS0xLTEtMTMxNjE4_7bfa03f7-8536-4454-9aa0-75d5b9978061">551</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idfe3cd40147f4e2bbdcc6daea5c4f648_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtNy0xLTEtMTMxNjE4_93f7770b-9c4f-4460-abda-cee60e110b9a">325</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idc375c5fb83442ce960061c4c1e7d3d2_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtOS0xLTEtMTMxNjE4_eda8d58e-a5b4-4bed-9fe5-a754b0e43797">454</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1068453fd58a43ed853c52e49d369635_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtMTEtMS0xLTEzMTYxOA_85db9919-9c69-4015-9a49-43423005b538">779</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2a170523e4784bd68826594b94740470_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctMS0xLTEtMTMxNjE4_9a8f0c4f-f5e9-4d59-8500-869cc42f442a">56</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icd460b0376004e6c9a2f91d187784dc9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctMy0xLTEtMTMxNjE4_796f7198-0fe6-4f0c-9a95-6bf417495824">272</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib5c0d77138754544a2110eafaf9ef1de_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctNS0xLTEtMTMxNjE4_1c6001ef-90d8-404e-8e2f-529c0f165852">329</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie30c6b82c81544b2a213a66f88a666e6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctNy0xLTEtMTMxNjE4_fa47f488-9d24-47b5-91a1-916fdd657552">63</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i944297bc97294b85b64026a5234105db_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctOS0xLTEtMTMxNjE4_39b78dcc-d7f3-4ffa-9641-18af1df42b3a">391</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6714caf41ce2406282b4c22d36869265_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctMTEtMS0xLTEzMTYxOA_06efb935-6747-493c-aed9-a854a591d8c0">454</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib880b79c41404a7f9ccb683284f4a657_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtMS0xLTEtMTMxNjE4_c90feffd-32e6-4616-b76a-a71541b516ed">172</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7242924d01844781882444c559d8edd7_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtMy0xLTEtMTMxNjE4_b54c44ca-13db-41b8-b587-e4d6cd1205e3">414</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0b5149a7a9724ba099430ae94f3eb7f9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtNS0xLTEtMTMxNjE4_243f0539-7b6a-4534-b610-52a29988e70d">584</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f44546bfba04d3182b566c995d1d6a5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtNy0xLTEtMTMxNjE4_4b5acf86-2bdf-4361-ab00-713955542104">160</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea28f75c29f9495d97b2490ad495e473_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtOS0xLTEtMTMxNjE4_98e25f04-1ba2-4e87-bb96-468b98dda3f2">443</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1c30e990884c453a8e86bf31356441ab_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtMTEtMS0xLTEzMTYxOA_5eecc931-c9fe-4033-a930-f31aabe63709">602</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1de53f2d14549978ff86137b26acfdf_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktMS0xLTEtMTMxNjE4_464bca47-180b-4995-ae73-5430c55e334a">6,117</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea0edbdebc194dbda6f583be24a5f5be_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktMy0xLTEtMTMxNjE4_a1642759-028f-4ab1-b5e0-b83e9a525c7a">6,604</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iff180f6730404c2fb6244e53cad88916_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktNS0xLTEtMTMxNjE4_49ed9b4e-a36f-44ed-8ada-c3f29974cc8f">12,721</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idc67e8a229ad434b9d2759887e18dcff_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktNy0xLTEtMTMxNjE4_50228069-c141-4870-8dea-ec78d994cde3">6,773</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3ecc10254bda49bf803e6b76575554b2_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktOS0xLTEtMTMxNjE4_e9848f28-e5a8-4f0a-9bce-565597bed367">7,334</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia58fab4c69fb453394fb53a0a9cb3d93_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktMTEtMS0xLTEzMTYxOA_819143ad-b68a-4e33-833a-826bc508a5ca">14,107</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i08f54d2fb7c74345a43dd8eb5652ccb9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtMS0xLTEtMTMxNjE4_43d124bd-db25-4181-8e18-8bf953c34b32">174</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia99f107296c340309c3405bc2810419c_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtMy0xLTEtMTMxNjE4_2dd1f72f-3611-4256-ae55-0cbb477ce99f">676</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ied991033c3cc4ae8b1774bcbdfbc6a61_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtNS0xLTEtMTMxNjE4_c3ca8c54-26b5-4b9e-9105-4bd209bcb0a3">849</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i48ac0207dbb24fba961de45411f8f863_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtNy0xLTEtMTMxNjE4_43d77804-b7e3-4a3e-8501-a4a3248a094b">171</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83d344caa1af4fadaeddfdde40462eb2_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtOS0xLTEtMTMxNjE4_45770cb1-fe8f-4ddd-926e-ac9acf8b58b9">661</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8c73bc1480c5460787fa096cbca3e186_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtMTEtMS0xLTEzMTYxOA_18e494e8-8760-40ef-a709-0ec4834fb2b0">832</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4136a4c6588c473b8dbc29bd43446a8c_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItMS0xLTEtMTMxNjE4_8f160c29-8390-4d1f-8c10-48edc7fe4fc0">308</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if77a7432ec784877b792884b4331e9ee_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItMy0xLTEtMTMxNjE4_9551723d-4994-42b3-b696-31c42fe8280e">334</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id486cc4b73964a048598ee4145a36f51_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItNS0xLTEtMTMxNjE4_2f231c72-adca-4969-9d92-dc2512e75e9d">642</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i260d3e7cbd5a4346b6de45c5013de1eb_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItNy0xLTEtMTMxNjE4_9d295a3c-76b9-4c1c-b1d0-f4f41aca9362">302</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2913a3930e88428aacc1ff729877e753_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItOS0xLTEtMTMxNjE4_103c718c-a7ed-48ff-bb15-8a1c71265ddf">348</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if553fafbad26405cad25ce4550638d3f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItMTEtMS0xLTEzMTYxOA_22fcbfa2-f551-423a-a4f1-505f6939cc41">650</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i660405fd34d447fbac3495f01c37c868_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtMS0xLTEtMTMxNjE4_c9a2c592-3dd8-4252-a381-4877e061c9b3">482</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic90971f816384ed793878fbed1daf9b9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtMy0xLTEtMTMxNjE4_63bee262-7be2-4492-8ebb-928b3fc2a1e4">1,010</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i904e8e179a1a49698833ce1b0110d5b4_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtNS0xLTEtMTMxNjE4_787cdef4-0937-4cd8-9959-d62cbc8ece21">1,491</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0a26625eb0434b3aa7c78f6443da31d6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtNy0xLTEtMTMxNjE4_92ccec34-9d1f-4be5-9427-06903dd8c13a">473</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib7dcf8dd27b941e6a6224761d29aa39d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtOS0xLTEtMTMxNjE4_b889ca21-8e1f-4102-9a6f-42eb9b83d401">1,009</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83fa1e7afed046c4a90965eb45e55ef4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtMTEtMS0xLTEzMTYxOA_2ef2246b-6c21-471d-a5d9-5058c75f6b4a">1,482</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i296f4d5ae9ac48818a1c814d83edd6c5_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtMS0xLTEtMTMxNjE4_5feb8fa3-515c-44b8-a057-7beb9b1aa868">6,599</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i541f7bde3cb144d6a1a06f324c128077_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtMy0xLTEtMTMxNjE4_84ac04c5-039c-4583-aa02-a6b0077cd1c5">7,614</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtNS0xLTEtMTMxNjE4_ae37c227-14ed-4741-a155-a31b659ec67c">14,212</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2171622cc8164fae9f90806cca105ee4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtNy0xLTEtMTMxNjE4_d672ec05-7276-450b-9914-34d058f42b75">7,246</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0201d118d8574b6db54cf6f7f5bb5c3e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtOS0xLTEtMTMxNjE4_a63e5363-8419-459c-a2fb-39864fd958ca">8,343</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc177dc034fa4f9ca0cad6e36eb33f5d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtMTEtMS0xLTEzMTYxOA_ec4af8fa-e539-4a8e-abe3-fb15cb243fb9">15,589</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfa83b7726804a0da22e28fcde9c5ed2_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtMS0xLTEtMTMxNjE4_64b6e335-bef7-4f7a-bd55-506876f02edd">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i70a11b67918c44d3bfc01126c08b9fc2_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtMy0xLTEtMTMxNjE4_9deb4a1a-ad98-43e0-96c3-604cafb07109">214</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icf8c3545f0134eebae2941403b2e022b_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtNS0xLTEtMTMxNjE4_f1712555-79c6-4dc2-b6f3-1aa090f88bc1">275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f24746bebef41f9a462c02b830d6110_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtNy0xLTEtMTMxNjE4_a3b98f10-18b0-43e1-878f-f51f7cc352c3">93</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i307318101eaf48d785d4b776c386341a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtOS0xLTEtMTMxNjE4_d2c21f26-4598-4b74-a022-6a0acaae81cc">220</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if69fe081e83e44b89e1642cb41b84015_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtMTEtMS0xLTEzMTYxOA_ecfa1695-f3e6-4910-bb2a-a7b31d8b1404">312</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e9cb136461a4e8aa85239cb391d845b_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtMS0xLTEtMTMxNjE4_32d6a6fa-9829-49dc-ae00-7544dae524f8">6,659</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a97503f4be84d46bdeff57349e01c23_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtMy0xLTEtMTMxNjE4_0ebaf935-cd67-4312-afd6-c22068f8f875">7,828</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtNS0xLTEtMTMxNjE4_caa70205-c25a-4785-b056-9ed26b521571">14,487</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i809f9ceab45b4cc88ceaa644a4ed41d8_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtNy0xLTEtMTMxNjE4_a3d3fc3f-e336-4c7e-8ce8-58f6034c877c">7,339</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic58118074eba4189a105e403b1233b58_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtOS0xLTEtMTMxNjE4_b31c0435-9612-4186-a2cf-2f2b4cd99a36">8,563</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtMTEtMS0xLTEzMTYxOA_f82df2d4-7ac0-4665-899e-343f53d34937">15,901</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&nbsp;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note&nbsp;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&nbsp;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="mrk:IncreaseDecreaseInHedgeRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ5NzU1ODIwNzc5_627192b8-5092-4f99-b82d-e675cc6c2a03">99</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="mrk:IncreaseDecreaseInHedgeRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ5NzU1ODIwNzg3_6e7eca59-4393-451f-9bff-d822ae6b6c49">69</ix:nonfraction>&nbsp;million for the three months ended March&nbsp;31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March&nbsp;31, 2023 and 2022 also includes $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMjgxMA_c41639be-76e7-4717-b6ce-90797ecc2923">51</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMjgxNw_06d0af1b-4675-4859-ba6e-576293ec3c38">114</ix:nonfraction>&nbsp;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</span></div></ix:nonnumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 25 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="if966040dffa94db3a20e72cb255d69b1"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $<ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMzQ2MQ_1b0585f9-763e-42aa-80ad-e4740e0504b5">3.1</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMzQ2OA_a8953536-8d80-4270-8c7f-08a18bbbcaef">2.9</ix:nonfraction> billion for the three months ended March&nbsp;31, 2023 and 2022, respectively. </span></div><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ4NA_024fa4e0-421d-4f84-b58b-b8dd4c7c6dc7" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.674%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e9cb136461a4e8aa85239cb391d845b_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMi0xLTEtMS0xMzE2MTg_8acfbe8a-4750-4cde-a751-509b9b1eb504">6,659</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i809f9ceab45b4cc88ceaa644a4ed41d8_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMi0zLTEtMS0xMzE2MTg_db062b2a-335b-4968-b37a-b2150da16643">7,339</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i679d69340bf54bb4a090a15b7ce9076e_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMy0xLTEtMS0xMzE2MTg_420ef679-9547-4710-9c21-f01436be7491">3,303</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4067fe86262c405cb2919284c7e1f31c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMy0zLTEtMS0xMzE2MTg_75c92b69-79d2-499a-a8ac-856ae32e665b">4,359</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib86ae90471ee4ab18226e2683b749444_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNC0xLTEtMS0xMzE2MTg_f7f0799b-6755-4818-b812-430b4d78156c">1,715</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b6b67a7073245c79ad8b17846729383_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNC0zLTEtMS0xMzE2MTg_0678dfe1-7865-4389-bbb4-a3509289d339">1,143</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iee1279d9656246229165b6071a908fe4_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0xLTEtMS0xNDQ0OTM_bd13176d-2d50-423b-a924-c122f38f11db">846</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie1eaefd10a6d4f75bc5b01e6fd6e7612_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0zLTEtMS0xNDQ0OTM_419bff35-b60d-426b-967f-6d40bf428195">930</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice769ebe11cd4873b0e7fae638d4de55_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0xLTEtMS0xMzE2MTg_af0989cb-f3b3-4a2b-b90e-596cae6763e3">758</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i77d9b85158ec4e37be193731477b820f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0zLTEtMS0xMzE2MTg_212e8a97-0d62-4365-a0c5-008ea6205e0f">989</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83848e68f3b04891aad523922cca52c7_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNy0xLTEtMS0xMzE2MTg_16895df7-1630-48a7-bbb7-6051b41df14b">661</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic9bae06748084a678545ae2a472fc025_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNy0zLTEtMS0xMzE2MTg_69feecdc-cfde-4be8-8467-f14c6d88b417">607</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i49396c3fa3284569b4be0611825c2214_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOC0xLTEtMS0xMzE2MTg_0c43bbc3-ad75-4e76-a4b1-d88a82af73e2">545</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i492a23d281624d04895b84c347c42464_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOC0zLTEtMS0xMzE2MTg_14d13378-92e4-4e44-b0e2-abf3ba81de9b">534</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOS0xLTEtMS0xMzE2MTg_9a32c585-90c8-4774-8e80-2891c0f92fe4">14,487</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOS0zLTEtMS0xMzE2MTg_58dcbd93-aa7c-442f-8864-d21733a8306c">15,901</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><ix:nonnumeric contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ3Nw_271793ba-f9b9-491b-bb6c-038502f74f6f" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iff180f6730404c2fb6244e53cad88916_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMy0xLTEtMS0xMzE2MTg_db560a57-eb51-4c7c-8620-c1e229fc8122">9,140</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia58fab4c69fb453394fb53a0a9cb3d93_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMy0zLTEtMS0xMzE2MTg_4563d745-d4b6-4773-914b-99b8875bb0a7">9,501</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i904e8e179a1a49698833ce1b0110d5b4_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNC0xLTEtMS0xMzE2MTg_25406fb4-7cb7-42f5-87dd-0de77af4d93c">566</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83fa1e7afed046c4a90965eb45e55ef4_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNC0zLTEtMS0xMzE2MTg_7aa88ea1-e238-4033-b889-1b0ab25b8897">585</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNS0xLTEtMS0xMzE2MTg_2128dfa3-e31a-46e6-bd91-7748d93123f5">9,706</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc177dc034fa4f9ca0cad6e36eb33f5d_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNS0zLTEtMS0xMzE2MTg_93d39df7-ee23-45bc-a1b7-dc2f71ca2e32">10,086</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icf8c3545f0134eebae2941403b2e022b_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNi0xLTEtMS0xMzE2MTg_fd5b5857-916f-4978-b7c1-626225946bfa">164</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if69fe081e83e44b89e1642cb41b84015_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNi0zLTEtMS0xMzE2MTg_7a6bf9c1-77d4-4df5-b32e-3bbd30d79cf7">194</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOC0xLTEtMS0xMzE2MTg_55627434-dec2-4436-a779-6573f08f0ec0">112</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOC0zLTEtMS0xMzE2MTg_eb0d237c-8981-4b04-8370-95c4ed45f849">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOS0xLTEtMS0xMzE2MTg_f99e5cd7-ab3b-4ddb-a1f4-f42f80028599">242</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOS0zLTEtMS0xMzE2MTg_cfe94af6-c88b-4446-956c-258a0eb24f5d">243</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTAtMS0xLTEtMTMxNjE4_c1e92fd2-fbe5-43cd-864a-430d251cdee1">543</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTAtMy0xLTEtMTMxNjE4_6a62b77f-d8fb-4884-b6d6-b562bcf8961e">699</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTEtMS0xLTEtMTMxNjE4_33f222f5-9e60-4f0b-a385-a98bf01fc58e">398</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTEtMy0xLTEtMTMxNjE4_86811367-cac3-44d1-9e87-2b9614469684">378</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTItMS0xLTEtMTMxNjE4_da141c0a-bf31-44ee-be5f-8677d0402bea">4,147</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTItMy0xLTEtMTMxNjE4_46891065-8529-4e23-b938-853fee2538b7">2,446</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTMtMS0xLTEtMTMxNjE4_d580a05c-b9a3-46b3-9f33-e43ee7694fce">67</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTMtMy0xLTEtMTMxNjE4_67754d23-a072-4bb8-bbd7-f729d89f6637">53</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMS0xLTEtMTQ0MTUw_4626e948-711d-48d0-8395-d4398490d415">573</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMy0xLTEtMTQ0MTUw_a90df1b5-4a33-4f81-87ee-b6711bbefeec">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMS0xLTEtMTMxNjE4_9e832d62-b9eb-46a8-9804-da7ad83ecf3b">362</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMy0xLTEtMTMxNjE4_6bafc467-d4f6-4298-a10a-cc89692c24d4">1,607</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTUtMS0xLTEtMTMxNjE4_b3c84d4c-c521-4439-9afb-f564a0d7abd1">3,650</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTUtMy0xLTEtMTMxNjE4_7eedbb30-3c6e-4dc9-8db5-844f77725fd7">4,861</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 26 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_82"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:15pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&nbsp;2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_85"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Business Developments</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of significant business development activity thus far in 2023. See Note&nbsp;2 to the condensed consolidated financial statements for additional information.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus’ lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $10.3&nbsp;billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses or approximately $4.00 per share. Additionally, Merck anticipates earnings per share (EPS) will be negatively affected by approximately $0.25 in the first 12 months following the closing of the transaction resulting from investments to advance the related pipeline assets, as well as the cost of financing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments and tiered royalties on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech’s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60&nbsp;million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $219 million, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.2 billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_88"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Pricing</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in the first three months of 2023 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In 2022, the U.S. Congress passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs (starting in 2026) and Medicare Part B drugs (starting in 2028). In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Supply Chain</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of global macroeconomic conditions, the Company is experiencing some minor disruption and volatility in its global supply chain network. These disruptions could increase in the future and cause delays in shipments of raw materials and packaging, as well as related cost inflation.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_91"></div><div style="margin-top:12pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 27 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Sales</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,659&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,828&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,563&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,487&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,901&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales declined 9% to $14.5 billion in the first quarter of 2023 primarily due to lower sales in the virology franchise, largely attributable to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), which had sales of $392 million in the first quarter of 2023 compared with $3.2 billion in the first quarter of 2022. Also contributing to the revenue decline in the first quarter of 2023 were lower sales in the diabetes franchise due to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl), as well as lower sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23 (pneumococcal vaccine polyvalent). The sales decline in the first quarter of 2023 was partially offset by higher sales in the oncology franchise, largely driven by strong growth of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab), higher sales in the vaccines franchise, primarily attributable to growth of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and the ongoing launch of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Pneumococcal 15-valent Conjugate Vaccine) for pediatric use, as well as higher sales of hospital acute care products, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note&nbsp;15 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,795&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,809&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue - Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">- </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* &gt; 100%</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&nbsp;3 to the condensed consolidated financial statements).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note&nbsp;3 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, MSI-H/dMMR advanced endometrial carcinoma, primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma including non-muscle invasive bladder cancer. Additionally, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved as monotherapy for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence and for certain patients with completely resected stage IIB, IIC or III melanoma, and for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage 1B (T2a ≥4 cm), II, or IIIA NSCLC. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is also approved for certain patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy with or without bevacizumab for advanced cervical cancer, in combination with chemotherapy for esophageal cancer, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with chemotherapy for HNSCC, in combination with chemotherapy for locally recurrent unresectable or metastatic TNBC, in combination with axitinib for advanced RCC, in combination with Lenvima for certain patients with advanced endometrial carcinoma or advanced RCC, and in combination with enfortumab vedotin for certain patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy. The </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> clinical development program includes studies across a broad range of cancer types. See “Research and Development Update” below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> grew 20% in the first quarter of 2023. Sales growth was primarily driven by higher demand as the Company continues to launch </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> with multiple new indications globally. Sales growth in the U.S. reflects increased </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 28 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">uptake across earlier-stage indications including in high-risk early stage TNBC, as well as certain types of RCC and melanoma, and higher demand across the multiple approved metastatic indications, in particular for the treatment of certain types of RCC, NSCLC, TNBC, and HNSCC cancers. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales growth in international markets reflects higher demand for the HNSCC and RCC metastatic indications, as well as uptake in earlier-stage indications, particularly in Europe and Latin America. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> received the following regulatory approvals thus far in 2023.</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approval</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on results from the Phase 2 KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on data from the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas. </span></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lynparza (olaparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note&nbsp;3 to the condensed consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers. Alliance revenue related to Lynparza increased 3% in the first quarter of 2023 largely driven by higher demand, particularly in Europe in certain patients with ovarian cancer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note&nbsp;3 to the condensed consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for certain patients with advanced endometrial carcinoma or advanced RCC. Alliance revenue related to Lenvima grew 2% in the first quarter of 2023 reflecting uptake in the advanced RCC indication in Europe, partially offset by lower volumes in China. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (see Note&nbsp;3 to the condensed consolidated financial statements). Reblozyl is approved for the treatment of anemia in certain rare blood disorders. Merck recorded alliance revenue related to this collaboration of $43 million in the first quarter of 2023 (consisting of royalties) compared with $52 million in the first quarter of 2022 (consisting of royalties of $32&nbsp;million and the receipt of a regulatory approval milestone payment of $20&nbsp;million).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Welireg </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(belzutifan), for the treatment of adult patients with certain von Hippel-Lindau disease-associated tumors, were $42 million in the first quarter of 2023 compared with $18 million in the first quarter of 2022 due to continued uptake in the U.S. following launch in 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,972&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,460&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ProQuad</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">II</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax 23</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* &gt; 100%</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Combined worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 35% in the first quarter of 2023 driven primarily by strong demand outside of the U.S., particularly in China, which also benefited from the timing of shipments and increased supply. Sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 in the U.S. were essentially flat in the first quarter of 2023 as lower sales due to public sector buying patterns were offset by higher pricing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, increased 17% in the first quarter of 2023 primarily reflecting higher demand and pricing in the U.S. and higher demand in Europe.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 29 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, declined 1% in the first quarter of 2023 primarily due to lower tenders in Latin America, largely offset by higher pricing and demand in the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), grew 15% in the first quarter of 2023 primarily attributable to higher demand and pricing in the U.S. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children, grew 38% in the first quarter of 2023 primarily due to inventory stocking in China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a vaccine to help prevent invasive pneumococcal disease, increased to $106 million in the first quarter of 2023 primarily due to continued uptake in the pediatric indication in the U.S. following launch in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23, a vaccine to help prevent pneumococcal disease, declined 44% in the first quarter of 2023 primarily reflecting lower demand in the U.S. as the market continues to shift toward newer adult pneumococcal conjugate vaccines following changes in the recommendations of the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices in 2021. The Company expects the decline in U.S. sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23 to continue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 23% in the first quarter of 2023 primarily due to higher demand, particularly in the U.S., reflecting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">’s growing share among neuromuscular blockade reversal agents. The patent that provides market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the European Union (EU) will expire in July 2023; the Company anticipates sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in these markets will decline thereafter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prevymis </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(letermovir), a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 38% in the first quarter of 2023 due to higher demand in the U.S. and Europe, as well as uptake from the 2022 launch in China. In February 2023, the FDA granted priority review for a supplemental New Drug Application (NDA) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (D+/R-); the Prescription Drug User Fee Act (PDUFA), or target action, date is June 5, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue - Adempas/Verquvo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&nbsp;3 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note&nbsp;3 to the condensed consolidated financial statements). Adempas is approved for the treatment of certain types of pulmonary arterial hypertension and chronic pulmonary hypertension. Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Alliance revenue from the collaboration grew 38% in the first quarter of 2023 primarily due to higher profit sharing reflecting increased demand in Bayer’s marketing territories. Revenue also includes sales of Adempas and Verquvo in Merck’s marketing territories. Sales of Adempas in Merck’s marketing territories were nearly flat in the first quarter of 2023 compared with the prior year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Virology</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 30 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback (see Note&nbsp;3 to the condensed consolidated financial statements). Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide. Sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> declined 88% in the first quarter of 2023 largely attributable to sales in the U.S. and UK markets in the first quarter of 2022 that did not recur in the first quarter of 2023. The </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales decline was also attributable to lower sales in Japan and Australia. The Company expects full-year 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales to be approximately $1.0 billion. In April 2023, Japan’s Ministry of Health, Labor and Welfare granted full approval for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was previously granted Special Approval for Emergency in Japan in December 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global combined sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 23% in the first quarter of 2023 primarily due to lower global demand, reflecting in part competitive pressure particularly in Europe and the U.S. The Company expects competitive pressure for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to continue.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The patent that provides market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the EU will expire in July 2023; the Company anticipates sales declines of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in these markets will accelerate thereafter.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Diabetes</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,233&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide combined sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 29% in the first quarter of 2023 primarily reflecting the loss of exclusivity in several markets in Europe and the Asia Pacific region, as well as in Canada, coupled with lower demand and pricing in the U.S. due to competitive pressures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the key U.S. patent for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products (see Note&nbsp;8 to the condensed consolidated financial statements), the Company expects that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until May 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until July 2026, although </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. As a result of competitive pressures, the Company anticipates pricing and volume declines for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the U.S. for the remainder of 2023 and thereafter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company lost market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in all of the EU and for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in some European countries in September 2022. Exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was lost in other European countries in April 2023. While the Company lost market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in China in 2022 with the launch of a generic equivalent product, the impact on sales in 2023 is expected to be modest. Although several generic equivalents of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> have been approved in China, none have launched, and the Company expects it is unlikely that any will launch prior to December 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Combined sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in Europe, China and the U.S. represented 11%, 13% and 37%, respectively, of total combined </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales for the first quarter of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In response to a request from a regulatory authority, Merck evaluated its sitagliptin-containing products for the presence of nitrosamines. Nitrosamines are organic compounds found at trace levels in water and food. Nitrosamines can also result from chemical reactions and can form in drugs either due to the drug’s manufacturing process, chemical structure, or the conditions in which the drugs are stored or packaged. The Company detected a nitrosamine identified as Nitroso-STG-19 (NTTP) in some batches of its sitagliptin-containing medicines. The Company has engaged with major health authorities around the world and has implemented additional quality controls to ensure its portfolio of sitagliptin-containing products meet health authorities’ interim acceptable NTTP limits for continuing distribution of product to the market. The Company is making progress in its efforts to reduce the level of nitrosamines in its sitagliptin-containing medicines. However, difficulties in reducing those levels, or achieving timely regulatory approvals for required changes, could result in product shortages. </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Animal Health Segment</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">849&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of livestock products grew 2% in the first quarter of 2023 primarily reflecting strong demand in the ruminant and poultry product portfolio, which includes technology solution products, as well as higher pricing. Sales of companion animal products declined 1% in the first quarter of 2023. Excluding the unfavorable effect of foreign exchange, companion animal sales performance primarily reflects higher pricing. Sales of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fluralaner) parasiticide line of products were $314 million in both the first quarter of 2023 and the first quarter of 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 31 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_100"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Costs, Expenses and Other</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,926&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,380&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,479&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,323&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,276&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,576&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,837&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,040&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales decreased 27% in the first quarter of 2023. Cost of sales includes $221 million and $1.7 billion in the first quarter of 2023 and 2022, respectively, related to sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which is being developed in a collaboration with Ridgeback</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(see Note&nbsp;3 to the condensed consolidated financial statements). Cost of sales also includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $532 million and $683 million in the first quarter of 2023 and 2022, respectively. Amortization expense in the first quarter of 2023 and 2022 includes $72&nbsp;million and $250&nbsp;million, respectively, of cumulative catch-up amortization related to Merck’s collaborations with Eisai and AstraZeneca, respectively, (see Note&nbsp;3 to the condensed consolidated financial statements). Also included in cost of sales are expenses associated with restructuring activities, which amounted to $29 million and $46 million in the first quarter of 2023 and 2022, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross margin was 72.9% in the first quarter of 2023 compared with 66.2% in the first quarter of 2022. The gross margin improvement primarily reflects the favorable impacts of lower </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales (which have a low gross margin), product mix and lower amortization of intangible assets (noted above).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses increased 7% in the first quarter of 2023 primarily due to higher administrative costs and increased promotional spending, partially offset by the favorable effect of foreign exchange. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses increased 66% to $4.3 billion in the first quarter of 2023 primarily due to a $1.2 billion charge for the acquisition of Imago, as well as higher upfront charges related to collaborations and licensing arrangements. Also contributing to the increase in R&amp;D expenses were higher compensation and benefit costs, reflecting in part increased headcount to support clinical development activity, higher investments in discovery research and early drug development, as well as increased clinical development spending. The increase in R&amp;D expenses was partially offset by the favorable effect of foreign exchange.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $2.1 billion and $1.8 billion for the first quarter of 2023 and 2022, respectively. Also included in R&amp;D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&amp;D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $2.2 billion and $750 million for the first quarter of 2023 and 2022, respectively. The increase in these expenses in the first quarter of 2023 was largely attributable to a $1.2 billion charge for the acquisition of Imago (as noted above) and a $175 million charge for a license and collaboration agreement with Kelun-Biotech. See Note&nbsp;2 for additional information related to business development activity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, Merck&nbsp;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint.&nbsp;The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. Merck expects to record charges of approximately $400 million for the full year of 2023 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in cumulative annual net cost savings of approximately $900 million by the end of 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $67 million and $53 million for the first quarter of 2023 and 2022, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 32 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional costs associated with the Company’s restructuring activities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs. The Company recorded aggregate pretax costs of $97 million and $127 million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities (see Note&nbsp;5 to the condensed consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, was $89 million of expense in the first quarter of 2023 compared with $708 million of expense in the first quarter of 2022. The change was primarily due to net unrealized gains from investments in equity securities recorded in the first quarter of 2023 compared with net unrealized losses recorded in the first quarter of 2022, as well as higher interest income in the first quarter of 2023. The favorability was partially offset by a $572.5 million charge in the first quarter of 2023 related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note&nbsp;8 to the consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For details on the components of Other (income) expense, net, see Note&nbsp;11 to the condensed consolidated financial statements. </span></div><div style="margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment Profits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment profits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,140&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,501&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment profits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,056)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,861&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&amp;A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&amp;A and R&amp;D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&amp;D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition- and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits declined 4% in the first quarter of 2023 reflecting lower sales, largely attributable to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, as well as higher administrative and promotional costs, and the unfavorable effect of foreign exchange. Animal Health segment profits declined 3% in the first quarter of 2023 reflecting higher administrative and promotional costs, as well as increased research and development expenses. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Taxes on Income</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effective income tax rates were 22.6% and 11.4% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as higher foreign taxes, the impact of the R&amp;D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company’s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-GAAP Income and Non-GAAP EPS</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&nbsp;EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 33 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&nbsp;EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP&nbsp;EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP&nbsp;EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP&nbsp;EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:83.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.212%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before taxes as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,861&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition- and divestiture-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">590&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">573&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,481&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,309&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes on income as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated tax benefit on excluded items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP taxes on income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">883&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,568&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,426&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income (loss) attributable to noncontrolling interests as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,564&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,429&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS assuming dilution as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11&nbsp;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70&nbsp;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.29&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.44&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP EPS assuming dilution</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.14&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisition- and Divestiture-Related Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&nbsp;EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures of businesses. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&nbsp;EPS exclude costs related to restructuring actions (see Note&nbsp;5 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income and Losses from Investments in Equity Securities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&nbsp;EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Items</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2023 is a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note&nbsp;8 to the condensed consolidated financial statements). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 34 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_103"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and Development Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the U.S. and internationally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-4482, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in collaboration with Ridgeback. The FDA granted Emergency Use Authorization for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in December 2021; last issued in February 2023, to authorize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for the treatment of adults with a current diagnosis of mild to moderate COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. In November 2021, the European Medicines Agency (EMA) issued a positive scientific opinion for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which is intended to support national decision-making on the possible use of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> prior to marketing authorization. In October 2021, the EMA initiated a rolling review for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for the treatment of COVID-19 in adults. In February 2023, Merck and Ridgeback announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended the refusal of the marketing authorization application (MAA) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Merck and Ridgeback have appealed the decision and requested a re-examination of the MAA. Applications to other regulatory bodies are underway. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA and the EMA. The marketing applications for gefapixant are based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck’s NDA for gefapixant. In the CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. The CRL was not related to the safety of gefapixant. The Company is performing additional analyses and anticipates submitting this information to the FDA in the second quarter of 2023 in response to the CRL. The review period in the EU was extended pending the receipt of additional information, which Merck submitted to the EMA in the first quarter of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-3475, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently encompasses more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review by the FDA for the treatment of patients with previously treated advanced HCC. This submission is based on data from the Phase 3 KEYNOTE-394 trial along with supportive data from the KEYNOTE-240 and KEYNOTE-224 trials. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for this indication in the U.S. under the FDA’s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. This submission is based on data from the Phase 3 KEYNOTE-913 trial. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for this indication in the U.S. under the FDA’s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is also under review by the FDA in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. The submission is based on data from the KEYNOTE-859 trial, in which </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus chemotherapy demonstrated a statistically significant improvement in overall survival versus chemotherapy alone, regardless of PD-L1 expression, in patients who were HER2 negative. The FDA set a PDUFA date of December 16, 2023. KEYNOTE-859 is also under review in the EU.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review by the FDA as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB NSCLC based on the KEYNOTE-671 study. A perioperative treatment regimen includes treatment before surgery (neoadjuvant) and continued after surgery (adjuvant). The FDA set a PDUFA date of October 16, 2023. KEYNOTE-671 is also under review in the EU.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review in the EU for the adjuvant treatment of patients with stage IB (≥4 cm), II or IIIA NSCLC following complete surgical resection. The submission is based on data from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review in Japan for the treatment of patients with relapsed or refractory PMBCL. This submission is based on data from the Phase 2 KEYNOTE-170 study and the Phase 1 KEYNOTE-A33 study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck announced it was discontinuing the Phase 3 KEYNOTE-641 trial evaluating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in combination with enzalutamide and androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) based on the recommendation of an independent Data Monitoring Committee. At an interim analysis, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in combination with enzalutamide and ADT did not demonstrate an improvement in radiographic progression-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 35 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">free survival or overall survival, the trial’s dual primary endpoints, compared to placebo plus enzalutamide and ADT, and crossed a pre-specified futility boundary for overall survival.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2023, Merck provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe-002 is evaluating MK-7684A, a coformulation of vibostolimab, an anti-TIGIT therapy, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, with or without docetaxel for the treatment of patients with metastatic NSCLC with progressive disease after treatment with immunotherapy and platinum-doublet chemotherapy. KeyVibe-002, a partially blinded study, was designed with two primary objectives: 1) to evaluate the efficacy of MK-7684A alone compared with docetaxel, a standard of care; and 2) in a blinded assessment, evaluate the efficacy of adding MK-7684A to docetaxel compared with docetaxel alone. Results from the open-label arm of the study evaluating MK-7684A alone showed that the coformulation did not reach statistical significance for the primary endpoint of progression-free survival and was numerically less effective compared with docetaxel. The blinded arms of the study will continue to further evaluate MK-7684A with docetaxel versus docetaxel alone. Results will be presented at an upcoming medical meeting once further data from the blinded study arms are available.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7339, Lynparza, is an oral PARP inhibitor currently approved for the treatment of several cancers being co-developed for additional cancer types as part of a collaboration with AstraZeneca (see Note&nbsp;3 to the condensed consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, the FDA convened its </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Oncologic Drugs Advisory Committee (ODAC) to discuss the supplemental NDA for use of Lynparza in combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of adult patients with mCRPC, based on the results of the Phase 3 PROpel trial. By a vote of 11 to 1 with one abstention, the OADC supported FDA approval of Lynparza plus abi/pred for the first-line treatment of adult patients with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">-mutated (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m) mCRPC. The committee voted that the FDA should restrict use of Lynparza plus abi/pred to these </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m mCRPC patients, recommending against approval beyond this patient population. The ODAC provides the FDA with independent, expert advice and recommendations on marketed and investigational medicines for use in the treatment of cancer. The FDA is not bound by the committee’s guidance but takes its advice into consideration. AstraZeneca and Merck will continue to work with the FDA as the agency completes its review of the application. Lynparza is also under review in Japan for the treatment of certain patients with mCRPC based on the PROpel trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7902, Lenvima, is an oral receptor tyrosine kinase inhibitor currently approved for the treatment of several cancers being developed as part of a collaboration with Eisai. Merck and Eisai are studying the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, Merck and Eisai announced the discontinuation of the Phase 3 LEAP-003 trial evaluating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma based on the recommendation of an independent Data Monitoring Committee, which reviewed data from a planned interim analysis and determined </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus Lenvima did not demonstrate an improvement in overall survival, one of the study’s dual primary endpoints, versus </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> alone. Merck and Eisai also provided an update on the Phase 3 LEAP-017 trial evaluating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus Lenvima for the treatment of patients with unresectable and metastatic colorectal cancer that is mismatch repair proficient or not MSI-H who experienced disease progression on, or became intolerant to, prior therapy. The trial did not meet statistical significance for its primary endpoint of overall survival in the final pre-specified analysis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The charts below reflect the Company’s research pipeline as of May 3, 2023. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 36 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Phase 2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-0482</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1308 (quavonlimab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular </span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-2140 (zilovertamab vedotin)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Bladder</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-2870</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(3)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Neoplasm Malignant</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3543 (bomedemstat)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Myeloproliferative Disorders</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4280 (favezelimab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Baldder     </span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung        </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4830</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Esophageal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Melanoma</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5890 (boserolimab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Small-Cell Lung</span></div><div style="text-indent:9pt"><span><br></span></div><div style="text-indent:9pt"><span><br></span></div><div style="text-indent:9pt"><span><br></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">MK-6440 (ladiratuzumab vedotin)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">MK-6482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Rare cancers</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Von Hippel-Lindau Disease-Associated Tumors (EU)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Bladder</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Cervical</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Bladder</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Cervical</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span><br></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">V940</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Dengue Fever Virus Vaccine</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">V181</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8591B (islatravir+MK-8507)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8591D (islatravir+lenacapavir)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(5)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Hypercholesterolemia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-0616</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Nonalcoholic Steatohepatitis (NASH)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-6024 (efinopegdutide)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-5475</span></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pulmonary Hypertension Due To Left Heart Disease</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7962 (sotatercept)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Schizophrenia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8189</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Thrombosis</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-2060</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Treatment Resistant Depression</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1942</span></div><div style="text-indent:9pt"><span><br></span></div></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 37 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Phase 3 (Phase 3 entry date)</span></td><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Under Review</span></td></tr><tr style="height:236pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> (U.S.) (May 2021)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(7)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1026 (nemtabrutinib)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hematological Malignancies (March 2023)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell (April 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary (September 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular (May 2016) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Mesothelioma (May 2018)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian (December 2018)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung (May 2017)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 (pembrolizumab subcutaneous) </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (August 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475A (pembrolizumab+hyaluronidase subcutaneous) </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (February 2023)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal (November 2021)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hematological Malignancies (October 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-6482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell (February 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast (October 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal (August 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (June 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung (December 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma (January 2023)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (April 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung (March 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal (July 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric (December 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Head and Neck (February 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (March 2019)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8591A (doravirine+islatravir) (February 2020)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">V116 (July 2022)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7962 (sotatercept) (January 2021)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Respiratory Syncytial Virus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1654 (clesrovimab) (November 2021)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">New Molecular Entities</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> (EU)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(8)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cough</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7264 (gefapixant) (U.S.)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> (EU)</span></div><div><span><br></span></div><div><span><br></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Certain Supplemental Filings</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">•    Second-Line Hepatocellular Carcinoma</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-394) (U.S.) </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">•    Locally Advanced or Metastatic Merkel Cell Carcinoma </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-913) (U.S.)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">•    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-859) (U.S.) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">•    Resectable Stage II, IIIA or IIIB NSCLC</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-671) (U.S.) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">•    Adjuvant Non-Small-Cell Lung Cancer</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-091) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">•    Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-170/KEYNOTE-A33) (JPN)</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span><br></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">•    First-Line Metastatic Prostate Cancer </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(PROpel) (U.S.) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span><br></span></div><div><span><br></span></div></td></tr><tr style="height:180pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Footnotes:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Being developed in a collaboration.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Being developed in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Being developed as monotherapy and/or in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Keytruda.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  On FDA clinical hold.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  On FDA partial clinical hold for higher doses than those used in current clinical trials.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Phase 2b development costs are being co-funded.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Available in the U.S. under Emergency Use Authorization.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Requested re-examination of EU MAA following CHMP recommendation for the refusal of the marketing authorization.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the second quarter of 2023.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br></span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br></span></div></td></tr></tbody></table></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_106"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,677&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,207&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,271&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,483&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt to total liabilities and equity</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.5&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash provided by operating activities was $1.3 billion in the first three months of 2023 compared with $4.8 billion in the first three months of 2022 primarily reflecting the impact of lower </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales. Cash provided by operating activities was reduced by milestone payments related to certain collaborations of $115 million and $1.2 billion in the first three months of 2023 and 2022, respectively. Cash provided by operating activities continues to be the Company’s primary source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance business development transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash used in investing activities was $2.4 billion in the first three months of 2023 compared with $1.2 billion in the first three months of 2022. The higher use of cash in investing activities was primarily due to the acquisition of Imago and higher purchases of securities and other investments, partially offset by higher proceeds from sales of securities and other investments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash used in financing activities was $2.1 billion in the first three months of 2023 compared with $3.1 billion in the first three months of 2022. The decrease in cash used in financing activities was primarily due to lower payments on long-term debt, partially offset by treasury stock purchases and higher dividends paid to shareholders. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures totaled $1.0 billion in the first three months of 2023 compared with $984 million in the first three months of 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 38 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.4 billion and $2.5 billion of accounts receivable at March&nbsp;31, 2023 and December&nbsp;31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividends paid to stockholders were $1.9 billion and $1.7 billion for the first three months of 2023 and 2022, respectively.&nbsp;In January 2023, the Board of Directors declared a quarterly dividend of $0.73 per share on the Company’s outstanding common stock for the first quarter that was paid in April 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As discussed above, in April 2023, Merck announced an agreement to acquire Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2022, the Company’s $1.25 billion, 2.35% notes matured in accordance with their terms and were repaid. In September 2022, the Company’s $1.0&nbsp;billion, 2.40% notes matured in accordance with their terms and were repaid. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The Company anticipates making modest share repurchases under this program in 2023. During the first three months of 2023, the Company purchased $149 million (1 million shares) of its common stock for its treasury under this program. As of March&nbsp;31, 2023, the Company’s remaining share repurchase authorization was $4.9&nbsp;billion. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note&nbsp;2 to the consolidated financial statements for the year ended December&nbsp;31, 2022 included in Merck’s Form 10‑K filed on February&nbsp;24, 2023. See Note&nbsp;1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2023. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K. There have been no significant changes in the Company’s critical accounting estimates since December&nbsp;31, 2022. </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For a discussion of recently issued accounting standards, see Note&nbsp;1 to the condensed consolidated financial statements.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&nbsp;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Company’s 2022 Form 10-K filed on February&nbsp;24, 2023. </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_118"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&nbsp;4. Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of March&nbsp;31, 2023, the Company’s disclosure controls and procedures are effective. During the quarter, the Company upgraded its financial consolidation system to the latest software version and moved it to an externally hosted cloud-based environment. The Company completed testing of this system prior to its launch, continues to monitor impacted financial and business processes and believes that an effective control environment has been maintained post-implementation.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 39 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">other words of similar meaning, or negative variations of any of the foregoing. One can&nbsp;also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item&nbsp;1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended December&nbsp;31, 2022, filed on February&nbsp;24, 2023, the Company discusses in&nbsp;more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list&nbsp;to be a&nbsp;complete statement of all potential risks or uncertainties.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_124"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">PART II - Other Information</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_127"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&nbsp;1. Legal Proceedings</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information called for by this Item is incorporated herein by reference to Note&nbsp;8 included in Part I, Item&nbsp;1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_133"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuer purchases of equity securities for the three months ended March&nbsp;31, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:27.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($&nbsp;in&nbsp;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total&nbsp;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average&nbsp;Price<br>Paid Per<br>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Approximate&nbsp;Dollar&nbsp;Value&nbsp;of&nbsp;Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">That May Yet Be Purchased</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under the Plans or Programs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1 - January 31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1 - February 28</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328,800&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$108.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328,800&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5,012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1 - March 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,066,937&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$106.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,066,937&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4,898</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,395,737&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$107.00</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,395,737&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 40 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br></span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_136"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&nbsp;6. Exhibits</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex31.htm">Restated Certificate of Incorporation of Merck &amp; Co., Inc. (November 3, 2009) – Incorporated by reference to Merck &amp; Co., Inc.'s Current Report on Form 8-K filed on November&nbsp;4, 2009 (No. 1-6571)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm">By-Laws of Merck &amp; Co., Inc. (effective March 22, 2022) – Incorporated by reference to Merck &amp; Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-rule13ax14a15dx.htm">Rule 13a – 14(a)/15d – 14(a) Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-rule13ax14a15dx.htm">Rule 13a – 14(a)/15d – 14(a) Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-section1350cert.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-section1350cert.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 41 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_139"></div><div style="margin-top:6pt;text-align:center"><span><br></span></div><div style="margin-top:6pt;text-align:center"><span><br></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Signatures</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MERCK &amp; CO., INC.</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date:  May 5, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President and General Counsel</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date:  May 5, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Rita A. Karachun</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RITA A. KARACHUN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Vice President Finance - Global Controller</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 42 -</span></div></div></div>
</div>


	</div>

	<div id="form-information-modal" data-test="form-information-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="form-information-modal-title" data-test="form-information-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">
				<i id="form-information-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="14"></i>

				<i id="dialog-box-copy-content" title="Click to Copy all Dialog Box Content." class="reboot fas fa-copy m-1 click" tabindex="14"></i>

				<i id="dialog-box-close" data-name="Form Information Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="14"></i>

			</div>
		</div>
		<div class="reboot dialog-content">
			<div id="form-information-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="dialog-content-copy-content" class="reboot float-right click color-inherit" tabindex="14">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="14"></textarea>
			</div>
			<div id="form-information-modal-carousel" class="reboot carousel pointer-event" data-interval="false" data-ride="carousel">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-1" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-2" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-3" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-4" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button id="form-information-prev" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="prev" tabindex="14">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="form-information-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button id="form-information-next" data-test="form-information-next" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="next" tabindex="14">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="settings-modal" data-test="settings-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="settings-modal-title" data-test="settings-modal-title" class="reboot lead mb-0">Settings</p>
			<div class="reboot dialog-header-actions">
				<i id="settings-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="15"></i>

				<i id="settings-modal-close" data-name="Settings Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="15"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<form class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Hover
						over Fact for quick information.</label>
					<select id="hover-option-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="true">On</option>
						<option class="reboot" value="false">Off</option>
					</select>
				</div>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Auto
						Scrolling Position</label>
					<select id="scroll-position-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="start">Top</option>
						<option class="reboot" value="center">Center</option>
					</select>
					<small class="reboot form-text text-muted col-sm-12" tabindex="15">Selecting
						a fact from the Sections Menu or the Fact Menu will automatically
						scroll that element to the (Top, or Middle) of the viewer window.
						This setting will have no use on IE 10, or Safari.</small>
				</div>
				<hr class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tagged-data-example-1">Tagged Data</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tagged-data-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 6.66667%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 102, 0); color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 102, 0), rgba(255, 102, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 102, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot search-results-example-1">Search
							Results</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="search-results-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 14.0523%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 215, 0); color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 215, 0), rgba(255, 215, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 215, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot selected-fact-example-1">Selected Fact</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="selected-fact-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tag-shading-exmple-1">Tag Shading
							(hover)</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tag-shading-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 0%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 0, 0); color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 0, 0), rgba(255, 0, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 70%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgba(255, 0, 0, 0.3);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot text-block-exmple-1">Text Block Indicators</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="text-block-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
			</form>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around"></div>
	</div>

	<div id="taxonomy-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="taxonomy-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">

				<i id="taxonomy-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="16"></i>

				<i id="taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="16"></i>
				<i id="taxonomy-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="16"></i>

				<i id="taxonomy-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-close" class="reboot fas fa-times m-1 click" tabindex="16"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<p id="taxonomy-modal-subtitle" class="reboot text-center font-weight-bold"></p>
			<div id="taxonomy-copy-paste" class="reboot form-group d-none">
				<label>Copy and Paste Below Content.</label>
				<a id="taxonomy-copy-content" class="reboot float-right click color-inherit" tabindex="16">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="16"></textarea>
			</div>
			<div id="taxonomy-modal-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-1" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-2" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-3" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-4" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="prev" tabindex="16">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="next" tabindex="16">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="taxonomy-nested-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p class="reboot lead mb-0">
				Nested Facts
				<span class="reboot" id="nested-page"></span>
				<span class="reboot">/</span>
				<span class="reboot" id="nested-count"></span>
			</p>
			<div class="reboot dialog-header-actions">
				<i id="taxonomy-nested-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="17"></i>

				<i id="nested-taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-close" class="reboot fas fa-times m-1 click" tabindex="17"></i>
			</div>
		</div>
		<div class="reboot dialog-content pt-0">
			<div id="modal-nested-fact-labels" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot d-flex">
					<button data-test="modal-taxonomy-nested-prev" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="prev" tabindex="17">
						<i class="reboot fas fa-chevron-left" title="Previous"></i>
						<span class="reboot sr-only">Previous</span>
					</button>
					<div id="modal-taxonomy-nested-label-carousel" class="reboot carousel-inner">
						<!-- Below is populated dynamically VIA JS -->
					</div>
					<button data-test="modal-taxonomy-nested-next" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="next" tabindex="17">
						<i class="reboot fas fa-chevron-right" title="Next"></i>
						<span class="reboot sr-only">Next</span>
					</button>
				</div>
			</div>
			<div id="taxonomy-nested-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="taxonomy-nested-copy-content" class="reboot float-right click color-inherit" tabindex="17">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="17"></textarea>
			</div>
			<div id="modal-taxonomy-nested-content-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-1" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-2" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-3" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-4" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div id="taxonomy-nested-nav-controls" class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="prev" tabindex="17">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-nested-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
				<!-- Below is populated dynamically VIA JS -->
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="next" tabindex="17">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>



</body></html>